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Summary 
 
Buruli ulcer (BU) caused by Mycobacterium ulcerans is a chronic necrotizing skin 
disease with the highest prevalence in West-African countries. The current WHO 
treatment recommendation is a combination of the two antibiotics rifampicin, given 
orally and streptomycin, requiring daily injections. Although antibiotic treatment 
reduced recurrence rates below 2% and circumvents surgical excision in part of the 
patients, toxic side effects, immunopathological adverse events and other wound 
healing disorders may occur. In this thesis we conducted detailed histopathological 
studies to better characterize responses to antibiotic treatment and the nature of 
paradoxical reactions.  
In the case of non-ulcerative plaque lesions, we observed in half of all patients either 
an enlargement or ulceration of lesions during antibiotic therapy. Histopathological 
analysis after completion of antibiotic treatment revealed the persistence of extensive 
necrotic areas besides hallmarks of successfully treated BU lesions, like infiltration, 
granuloma formation and loss of solid staining of the mycobacteria. Where removal 
of the necrotic tissue by the immune system is not efficient enough, lesions are 
ulcerating, leading to the discharge of necrotic tissue. Based on the clinical and 
histopathological data it is suggested to support healing of such plaque lesions by 
surgical débridement. While our data demonstrate that the antibiotic therapy 
efficiently destroys M. ulcerans infection foci, they also indicate that proper wound 
management during and after chemotherapy is for advanced BU lesions as important 
as the antibiotic treatment itself.  
Secondary lesions may occur at distant body sites during and after chemotherapy. 
Our analysis of such secondary lesions revealed hallmarks of inactive M. ulcerans 
infection. Emergence of secondary lesions during antibiotic treatment may thus be 
the result of immune-mediated paradoxical reactions driven by mycobacterial 
antigens and immunostimulators at sites of clinically inconspicuous infection foci. 
These lesions may, however, also have arisen from new infections or mycobacteria 
that have survived chemotherapy. In this case our histopathological findings would 
indicate that after priming during the successful treatment of the initial lesion, the 
immune system is capable of eliminating new infection foci. Our results demonstrate 
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that no additional antibiotic treatment is necessary, when such secondary lesions 
appear. 
To reduce the danger of toxic side effects and to obviate the need for daily injections, 
an entirely oral treatment without streptomycin would be preferable. In the framework 
of this thesis we analyzed tissue samples from a first clinical treatment trial using 
clarithromycin instead of streptomycin. Histopathological findings and efficacy were 
comparable to the current treatment, leading to the planning of a WHO-sponsored 
large multi-center trial comparing the efficacy of eight weeks treatment with 
clarithromycin and rifampicin versus streptomycin and rifampicin.  
To gain deeper insights into the histopathological changes in the very early phase of 
M. ulcerans infection, we conducted in parallel to the analysis of clinical samples, 
longitudinal histopathological studies in experimentally infected mice. Many features 
found in the mouse model, such as an early wave of infiltrating neutrophils, as well as 
the formation of B-cell clusters and the loss of solid Ziehl-Neelsen staining of 
mycobacteria during chemotherapy, have correlates in human BU lesions. The 
mouse infection model thus appears to be suitable for the preclinical evaluation of 
new drug treatments and of candidate vaccines.  
Taken together the results described in this thesis demonstrate that histopathology is 
an important tool to strengthen diagnosis of BU, to evaluate new treatment regimens 
and to come to a better understanding of paradoxical reactions emerging during 
antibiotic treatment of BU. 
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Zusammenfassung 
 
Das Buruli-Ulkus (BU) ist eine nekrotisierende Hauterkrankung, die von 
Mycobacterium ulcerans hervorgerufen wird und vor allem in den tropischen 
Regionen West-Afrikas auftritt. Gegenwärtig empfiehlt die Weltgesundheits-
organisation (WHO) eine systemische Chemotherapie mit dem oral verabreichten 
Antibiotikum Rifampicin kombiniert mit einer täglichen Injektion von Streptomycin. 
Nach dieser Therapie treten bei weniger als 2% der Patienten Rückfälle auf und eine 
chirurgische Zusatzbehandlung der Läsion ist bei vielen Patienten nicht erforderlich. 
Allerdings können toxische Nebenwirkungen sowie immunpathologische Reaktionen 
und andere Wundheilungsstörungen auftreten. In der vorliegenden Arbeit wurden 
detaillierte histopathologische Studien durchgeführt, um die therapeutische 
Wirksamkeit der Chemotherapie des BU besser zu verstehen und die Natur von 
paradoxen Reaktionen zu charakterisieren. 
Bei vielen Patienten mit zunächst geschlossenen BU Plaques kommt es während der 
Chemotherapie zur Ulzeration. Unsere histopathologischen Analysen zeigten, dass 
auch nach Beendigung der vollständigen Antibiotika-Behandlung noch grosse 
nekrotische Gewebebereiche zurückbleiben können. Daneben sind andererseits 
auch typische Merkmale einer behandelten BU-Läsion wie Infiltration, Granulom-
Bildung und Verlust der vollständigen Anfärbbarkeit der Mycobakterien zu 
beobachten. Unvollständige Resorption des nekrotischen Gewebes durch das 
Immunsystem führt jedoch häufig zur Ulzeration und Abstossung des nekrotischen 
Gewebes. Basierend auf unseren histopathologischen und klinischen Daten 
erscheint es angezeigt, die vollständige Ausheilung von Plaques durch chirurgisches 
Debridement zu beschleunigen. Die Befunde zeigen, dass M. ulcerans Bakterien 
durch die Chemotherapie mit Rifampicin und Streptomycin zwar effektiv abgetötet 
werden, dass aber vor allem im fortgeschrittenen Stadium eine gute 
Wundversorgung für den Heilungserfolg beim BU ebenso wichtig ist. 
Bei einem Teil der BU Patienten entwickeln sich während oder nach Abschluss der 
Chemotherapie sekundäre Läsionen. Bei der Analyse solcher Läsionen haben wir 
charakteristische Merkmale einer inaktiven M. ulcerans Infektion gefunden. Der 
Auslöser für die Entwicklung von Sekundärläsionen könnte daher eine paradoxe 
Immunreaktion gegen noch im Gewebe vorhandene mykobakterielle Antigene bei 
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klinisch zuvor nicht auffälligen Infektionsherden sein. Möglich wäre allerdings auch, 
dass sich nach der Chemotherapie durch überlebende Mycobakterien oder durch 
Neuinfektion neue Läsionen gebildet haben. In diesem Fall würden unsere 
Ergebnisse darauf hindeuten, dass die neuen Infektionsherde durch eine während 
der Erstinfektion gebildete protektive Immunantwort zerstört worden sind. Insgesamt 
zeigen unsere Untersuchungen, dass eine erneute Antibiotikagabe beim Auftreten 
von sekundären Läsionen nicht erforderlich ist. 
Zur Reduzierung der Gefahr toxischer Nebenwirkungen und zur Vermeidung der 
täglich erforderlichen Injektionen, wäre eine vollständig orale Chemotherapie ohne 
Streptomycin anstrebenswert. Bei einer ersten klinischen Studie, bei der 
Streptomycin durch Clarithromycin ersetzt wurde, waren Wirksamkeit und 
histopathologische Beobachtungen vergleichbar zu den Ergebnissen mit der 
gegenwärtigen Standardtherapie. Basierend auf diesen Ergebnissen plant die 
Weltgesundheitsorganisation eine multizentrische klinische Studie, bei der 8 Wochen 
Rifampicin/Clarithromycin mit 8 Wochen Rifampicin/Streptomycin verglichen werden 
soll. 
Um einen tieferen Einblick in die frühen Phasen der M. ulcerans Infektion zu 
bekommen, wurden longitudinale histopathologische Untersuchungen mit 
experimentell infizierten Mäusen durchgeführt. Viele histopathologische Befunde, wie 
das Auftreten einer ersten Infiltration mit Neutrophilen in der Frühphase der Infektion 
und die Entwicklung von B-Zell-Anhäufungen und der Verlust der gleichmässigen 
Anfärbbarkeit der Mycobakterien während der Chemotherapie haben 
Entsprechungen bei der BU Erkrankung beim Menschen. Das Mausmodell scheint 
daher geeignet zu sein, neue Therapien und Kandidaten-Impfstoffe präklinisch zu 
testen. 
Insgesamt zeigen unsere Ergebnisse, dass die Histopathologie nicht nur ein sehr 
aussagekräftiges Diagnosewerkzeug ist, sondern dass sie auch einen wichtigen 
Beitrag zur Beurteilung neuer Behandlungsmethoden und zur Erforschung paradoxer 
Reaktion während der Antibiotika Behandlung leisten kann. 
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AFB    Acid Fast Bacilli 
BALB/c   mouse strain 
BCG    Bacillus Calmette-Guèrin 
BU    Buruli ulcer 
CFU    Colony forming units 
CTUB    Centre de dépistage et de Traitement de l’Ulcere de Buruli 
DCs    Dendritic cells 
HE    Haematoxylin- Eosin staining 
IFN    Interferon 
Ig    Immunglobulin 
IHC    Immunohistochemistry 
IS    Insertion sequence 
mAb    monoclonal antibody 
MU    Mycobacterium ulcerans 
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qPCR    quantitative PCR 
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R/S    Rifampicin and Streptomycin 
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WHO    World Health organization 
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The neglected tropical necrotizing skin disease Buruli ulcer (BU) is the third most 
common mycobacterial disease after tuberculosis and leprosy and is caused by an 
infection with Mycobacterium ulcerans1. The main burden falls on children below the 
age of 15 in rural West-African countries but in general people of all ages, races and 
socioeconomic classes are susceptible 2. 
 
1.1 History and Epidemiology 
The disease was first discovered and described as “the presence of large ulcers” in 
1897 by Sir Robert Cook in Uganda and later by Kleinschmidt in northeast Congo 
during the 1920s 3. The definitive description of BU and the isolation of the causative 
agent Mycobacterium ulcerans was first published in 1948 by Mac Callum and 
colleagues. They described six Australian patients with unusual skin lesions caused 
by a mycobacterium which only grew at a lower temperature than usually used for 
cultivating Mycobacterium tuberculosis 4. 
Between the 1960s and 1980, several African countries reported about focal areas 
endemic for BU including Congo, Uganda, Gabon, Nigeria, Cameroon and Ghana 5. 
Because the first reported cases came from the Buruli region of Uganda near Lake 
Kyoga the Uganda Buruli group introduced the name “Buruli”6. Dramatic increases in 
the reported incidence of BU have been reported since 1980, especially in West-
African countries, and more than 30 countries worldwide are affected today (Figure 
1) 7,8. In some countries reported detection rates were higher than those for leprosy 
and tuberculosis 9. New foci are still today constantly reported. Some of these may 
have developed because of man-made environmental alterations (dammed lakes, 
water irrigation systems, deforestation) 10. In remote areas of developing countries 
case detection and surveillance is difficult which might lead to an under-reporting. 
In 1998, the Yamoussoukro declaration on Buruli ulcer recognized BU as a re-
emerging infectious disease with a significant public health impact and called on the 
international community to support control and research efforts11. Last reports of the 
WHO indicated that more than 5000 people annually are diagnosed with BU 7. 
Chapter 1. Introduction 
 
3
 
Figure 1: Distribution of BU by country, 2010. Relative endemicity is denoted as high 
(red), moderate (yellow), and low (green). Asterisks denote countries with suspected 
cases. (Source: Walsh DS et al, Dermatol Clin. 2011) 
 
1.2 Causative organism 
Traditionally, M. ulcerans was thought to belong to the large group of environmental 
or so called “occasional pathogens” which can cause disease in humans and 
animals. Usually those bacteria have an environmental reservoir and infect their host 
accidentally 12. However, for M. ulcerans an environmental reservoir has not been 
identified so far. Isolation from the environment is a major challenge, since M. 
ulcerans is a slow growing bacterium which grows best at 30°C on Löwenstein-
Jensen medium. Primary cultures from BU lesions are difficult to obtain often taking 
several months to grow 13. 
 
1.2.1 Genome and genetic diversity of M. ulcerans 
Phylogenetic studies indicate that M. ulcerans has evolved from a common M. 
marinum progenitor. Despite their contrasting phenotypes, M. ulcerans and M. 
marinum have almost identical genome sequences. Acquisition of a virulence 
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plasmid, incorporation of multiple copies of two insertion sequences (IS2404 and 
IS2606) into the genome and genome reduction by gene deletion are hallmarks of 
the development of M. ulcerans 14-17. M. ulcerans strains can be either assigned to 
the ancestral lineage (strains from Asia and South America) which is closer related to 
M. marinum or to the classical lineage (strains from Africa and Australia) which seem 
to be more virulent 18. M. ulcerans strains from Africa reveal a high clonality making 
genetic fingerprinting and molecular epidemiological analysis extremely demanding.  
 
1.2.2 Mycolactone 
Much of the pathology and virulence of M. ulcerans seems to be attributed to the 
polyketide macrolide toxin mycolactone which is the major component of the 
acetone-soluble lipid extract of an M. ulcerans culture 19. Different forms, named 
Mycolactone A to F, are found in M. ulcerans strains from different countries or in 
other mycolactone producing mycobacteria. Extracted as well as synthetically 
produced mycolactone exhibits cytotoxic and immunosuppressive features in vitro as 
well as in vivo. When added to fibroblasts and macrophages, effects on the 
cytoskeleton, cell growth arrest, necrosis and apoptosis are observed. Injection of 
purified mycolactone into the skin of guinea pigs induces ulceration comparable to 
BU lesions 20. Mycolactone extracted from human infected tissue shows chemical 
and biological properties of mycolactone A/B 21. It is assumed that mycolactone is the 
cause of the limited immune response inside the necrotic core of BU lesions, 
although large clusters of extracellular bacteria and extensive tissue damage are 
observed 20. In particular, T-cell responses seem to be suppressed 22. In mice, 
destruction of nerves by mycolactone can be observed and might explain the 
painlessness of BU lesions in humans 23,24.  
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Figure 2: Mycolactone A/B. (Source: Stinear et al, Natural Product Reports, 2008) 
 
1.3 Reservoir and Transmission 
Both, transmission as well as the environmental reservoir of M. ulcerans still remain a 
mystery 25. Endemic foci are associated with slow flowing or stagnant water with hot 
and humid climate (except for the temperate region of southern Australia) indicating 
water as a risk factor. Also men made environmental modifications such as dams, 
irrigation systems or deforestation are thought to increase the risk of acquiring BU 
1,10,26,27. Trauma is probably the most frequent means by which M. ulcerans might be 
introduced into the skin from environmental sources 27,28. 
M. ulcerans was first detected in the environment with the help of the Polymerase 
Chain Reaction (PCR) targeting a M. ulcerans specific Insertion sequence element 
(IS2404) 29,30. DNA of M. ulcerans was also found in aquatic insects obtained from 
BU endemic areas leading to the hypothesis that bites of water insects might transmit 
the disease. Experimentally infected water insects, Naucoridae, were able to transmit 
M. ulcerans to laboratory mice leading to the formation of typical ulcers 31,32. 
Additionally, M. ulcerans DNA was detected in water, biofilms, plants and snails 33-36. 
Until today only one culture of an environmental M. ulcerans strain could be isolated 
from a water strider supporting the concept that the agent of BU is a human 
pathogen with an environmental niche 37.  
Studies in Australia revealed a strong correlation between the incidence of BU and 
the incidence of vector borne infections (Ross River Virus). Mosquitoes captured 
during an outbreak of BU in a highly endemic area in southern Australia (Point 
Lonesdale) identified 4.3/1000 IS2404 positive mosquitoes 38. Recently Fyfe et al 
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discovered that up to 38% of possums, small terrestrial marsupials, captured at Point 
Lonesdale had laboratory confirmed M. ulcerans skin lesions and/or PCR positive 
faeces 25,39. 
 
1.4 Pathogenesis 
1.4.1 Clinical presentation 
BU is characterized by a spectrum of clinical forms, either as a non-ulcerative lesion 
or as an open ulcer. A papule, nodule or oedema is usually a sign of an early BU 
lesion which can progress to ulcers with undermined edges and cotton wool-like 
discharge. Most ulcers are painless unless secondary infections with other bacteria 
occur 7,40. Any part of the body can be affected but lesions mostly occur at the 
extremities 41. The incubation time is assumed to range between a few weeks up to 
years. Patients usually present late at the hospital when large ulcers are already 
established, leading to long hospital stays, disabling contractures, scarring or even 
amputation 9,42. Approximately 10% of the patients develop bone involvement 
subjacent to skin lesions or metastatic osteomyelitis from lymphohematogenous 
spread 7,43. 
 
 
Figure 3: Various stages of BU (Source: WHO) 
 
1.4.2 Histopathology 
Typical histopathological features found in tissue sections from untreated BU patients 
include coagulative subcutaneous necrosis of the adipose and deep dermal 
connective tissue including destruction of vessels, nerves and epidermis. Other 
hallmarks of the disease are fat cell ghosts and epidermal hyperplasia. Inside the 
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large necrotic areas clusters of extracellular bacteria are usually focally distributed. 
Inflammatory responses inside the necrotic core are minimal to absent, especially in 
oedema and plaque lesions 40,44-46. 
 
 
Figure 4: Histopathological characteristics associated with untreated BU lesions. 
(Source: Schütte et al, 2007, Plos Negl Trop Dis.) 
 
Eventually, in late chronic stages of the disease, leukocyte infiltration and granuloma 
formation can be observed. The immunosuppressive effect of the toxin might be 
overcome by the host in late stages then allowing immunity to develop and healing to 
commence 47,48. 
Although M. ulcerans is found primarily extracellular, clinical data as well as mouse 
studies indicate a transient intracellular stage during early infection 49,50. Antibiotic 
therapy abolishes the characteristic immunosuppresion and leads to strong local 
inflammatory responses with the development of granulomas, ectopic lymphoid 
structures and the destruction of bacteria 45,51-53. 
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Figure 5: Histopathology of a BU lesion after rifampicin/streptomycin combination 
therapy. (Source: Schütte et al, 2007, Plos Negl Trop Dis.) 
 
1.5 Immune response 
Currently, only limited data on specific immune response and immune protection 
against Mycobacterium ulcerans are available. Usually, M. ulcerans and M. bovis 
purified protein (PPD) skin tests are negative in early stage BU patients 54,55. Over 
time it may switch to a positive reaction suggesting the development of a systemic 
response56,55. New observations indicate that besides being mainly located 
extracellular, M. ulcerans proceeds through a transient intracellular phase49,50 which 
may lead to the induction of a Th-1 response. Because cellular Th-1 responses with 
high levels of IFN-γ are regarded as crucial 57 for the hosts defence against 
mycobacteria several studies on T-helper subset responses were carried out, 
yielding controversial results. Most studies showed a predominance of Th-2 response 
with production of IL-10 during the early phases of the disease and a predominant 
Th-1 response with high secretion of IFN- γ in advanced phases as well as during 
healing 58-63. In addition to the cytotoxic effects, mycolactone is also 
immunomodulatory in lower concentrations 64. Demangel et al showed that 
mycolactone down regulates the TCR expression and alters the IL-2 production of T-
cells 22.  
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During the extracellular stage of the disease antibodies could play a role in 
immunoprophylaxis and spontaneous healing. Sera from infected individuals and 
household contacts showed high antibody titres against different M. ulcerans 
antigens 55,65.  
BCG vaccination seems to be protective in mice against low dose inoculation and in 
humans it seems at least to prevent the severe stage of osteomyelitis 66,67. Repeated 
BCG vaccinations, attenuated M. ulcerans vaccine strains, and subunit vaccines 
incorporating protective protein antigens or the mycolactone toxin are currently under 
pre-clinical investigation as options for immunoprophylaxis against M. ulcerans 
disease 68. 
 
1.6 Diagnosis 
In the rural African BU endemic regions diagnosis of BU is often based alone on 
clinical evidence. When performed by experienced clinicians, this can be relatively 
reliable in particular for ulcerated lesions 54,69. However, several other diseases can 
present with symptoms similar to BU. Pre-ulcerative BU lesions can be confused with 
lymphadenitis, mycosis, lipoma or psoriasis and ulcerative lesions with cutaneous 
leishmaniasis or squamous cell carcinoma 42. Therefore, laboratory tests should be 
performed to confirm the diagnosis. Available tests are (1) direct smear examination 
by microscopy, (2) cultivation of M. ulcerans (3) histopathological evaluation and (4) 
detection of M. ulcerans DNA by polymerase chain reaction 40.  
 
1.6.1 Direct smear examination  
Direct smear examination is an easy, cheap and fast method to detect Ziehl-Neelsen 
stained AFBs under the microscope after counter-staining with methylene blue. It 
does not require sophisticated equipment which makes it suitable for endemic 
regions with poor infrastructure. However, specificity is low because several other 
mycobacteria positive upon staining by Ziehl-Neelsen can cause skin lesions. 
Therefore detection of AFB alone does not prove M. ulcerans to be the cause of the 
disease. Due to the low sensitivity (below 60%), presence of only a few bacteria 
might remain undetected giving a false negative result. Additionally, trained 
laboratory personal is needed to assure quality of the results 40,70,71. 
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1.6.2 Culture 
Isolation of the causative agent is the final proof laboratory diagnostic method. 
However, cultivation of M. ulcerans is difficult and time- consuming. Usually, it takes 
between 6 weeks and 5 months to obtain a primary M. ulcerans culture. Besides, 
samples sent for cultivation are often contaminated with faster growing 
microorganism making a harsh decontamination necessary 13. Sensitivity ranges 
between 20-60 % depending on the laboratory performing the assay 72.  
 
1.6.3 Histopathological analysis 
Samples for histopathological analysis are either small punch biopsies or surgical 
excisions and help to establish the differential diagnosis. There are typical 
histopathological features which are associated with M. ulcerans disease: necrosis of 
the subcutaneous fat tissue and formation of fat cell ghosts, oedema, epidermal 
hyperplasia, minimal infiltration and clusters of extracellular bacteria 44-47. But 
depending on the age of a lesion or the location of the sample taken, not all 
hallmarks typical for BU might be present. Since bacteria are located in focal clusters 
in the deep subcutaneous layers, not all histopathological specimens might contain 
AFB. An additional challenge in the histopathological diagnosis of this disease is 
having adequate tissue samples, consisting of all thee skin layers (epidermis, dermis 
and subcutis) 40,44,70 available. When performed by well-trained personal, detection of 
histopathological changes is a reliable diagnostic method with a sensitivity which can 
be >90%. 
 
1.6.4 Detection of M. ulcerans DNA by PCR 
Today, PCR of M. ulcerans DNA, based on the amplification of the insertion 
sequences IS2404, IS2606 and the ketoreductase genes, is a widely used standard 
tool performed in national and international reference laboratories. It is a rapid, highly 
sensitive and specific method but requires technical expertise and is prone to 
contaminations. In addition to the standard PCR, real time PCR, using the TaqMan 
system allows to quantify M. ulcerans DNA providing a measure of mycobacterial 
burden in clinical and environmental samples 16,73-75. Since no sufficiently sensitive 
point-of-care diagnostic test for BU is currently available, the WHO technical advisory 
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group for BU has identified development of a simple, cheap and rapid diagnostic test 
with high sensitivity and specificity as one of the most important research goals.  
 
1.7 Treatment 
Until 2004 the recommended treatment for BU was wide surgical excision followed by 
subsequent skin grafting, if necessary. Relapses occurred in 15% to 47% of the 
cases due to incomplete removal of the pathogen 76,77. Studies in M. ulcerans 
infected mice revealed the combination of rifampicin and amikacin administered for 
12 weeks to be active against the disease 78. Efficacy of a combination of rifampicin 
and streptomycin in a clinical trial with early BU lesions led to publication of a 
provisional guidance by the WHO for the use of these drugs 79,80. An observational 
study in Pobe, Benin in which 310 BU patients were treated, showed that nearly 50% 
of all lesions healed with antibiotics alone whereas others still required surgical 
excision and skin grafting. Altogether, the recurrence rates were as low as 1.4% 81. 
These results were confirmed by several follow-up trials 82,83. Since streptomycin has 
to be administered daily intramuscularly, and since there is risk of toxic side effects, 
especially in children, an exclusive oral treatment would be favourable. A first clinical 
trial conducted to compare 8 weeks of rifampicin/streptomycin with 4 weeks 
rifampicin/streptomycin followed by 4 weeks of rifampicin/clarithromycin showed 
similar efficacy 84. In Australia BU patients treated with an all-oral chemotherapy 
showed healing and no recurrence 85. More studies are needed to confirm these 
results and novel drugs effective against M. ulcerans are urgently needed because 
rifampicin is also one of the frontline drugs for M. tuberculosis. 
An alternative treatment was introduced in the mid-seventies when a small trial was 
conducted by Meyers et al. 86. He referred to the fact that M. ulcerans usually grows 
best between 30-32°C and therefore applied higher temperatures to the lesions. 
Results were encouraging but electricity requirements and complicated devices 
made it impossible for use in rural areas. In 2009, Junghanss et al. accomplished a 
first trial based on the application of heat by using a bag filled with a cheap and non-
toxic phase change material which emits constant heat over hours. First results were 
promising, all lesions healed and no relapse was observed 87. Currently, a large 
thermotherapy trial is ongoing. 
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Figure 6: Mounting of the PCM-based heat application system and temperature 
monitoring device. (Source: Junghanss et al. 2009, Plos Negl Trop Dis.) 
 
1.8 Wound management 
Since antibiotic treatment instead of surgical excision is the primary treatment for BU, 
wound care and wound management becomes more and more important. Usually, 
patients present late with extensive ulcers and after completion of antibiotic 
treatment, large open wounds persist. Often skin grafting and prolonged hospital 
stays with intensive wound care are necessary. Delayed wound healing may be due 
to secondary infections or an arrest of the wound in the chronic stage. Noninfected 
wounds that do not progress towards closure at a consistent rate (about 10-15% 
wound volume per week) have to be considered as chronic wounds and need special 
attention and care88 . By using limited surgical débridement to remove the dead 
tissue, transformation into an acute wound and initiation of the normal healing stages 
(inflammation, proliferation and maturation) are possible88-91.  
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2.1 Goal 
 
The aim of this thesis was to investigate chemotherapy- associated responses, 
paradoxical reactions and efficacy of a new treatment regimen by histopathology, in 
order to gain a better insight into the host immune response and to improve 
treatment of M.ulcerans infected patients. 
 
2.2 Objectives 
 
1. To analyze the early local immune response and the histopathological 
changes during antibiotic treatment in mice experimentally infected with 
Mycobacterium ulcerans. 
2. To analyze local immunological and histopathological changes during 
antibiotic therapy of Buruli ulcer plaque lesions and to determine the cause of 
ulceration during treatment. 
3. To histopathologically examine and evaluate secondary lesions which occur 
after completion of antibiotic treatment. 
4. To analyze histopathological changes in BU lesions during antibiotic therapy 
with two oral drugs (RIF/CLR). 
5. To analyze a worldwide collection of M. ulcerans strains for the presence of 
the highly immunogenic proteins EsxA, EsxB, and HspX. 
6. To develop and optimize a method to extract M.ulcerans DNA in a high yield 
and purity. 
7. To develop a highly discriminatory fine-typing method for M.ulcerans and to 
perform microepidemiological studies in an endemic area in Ghana. 
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Abstract  
 
Combination chemotherapy with rifampicin and streptomycin (RIF-STR) for eight 
weeks is currently recommended by WHO as first line treatment in Mycobacterium 
ulcerans infection (Buruli ulcer). To gain better insight into the mode of action of 
these antibiotics against established M. ulcerans infection foci and to characterize 
recovery of local immune responses during chemotherapy, we conducted a detailed 
histopathological study in M. ulcerans infected and RIF-STR treated mice. Mice were 
inoculated with M. ulcerans in the footpad and eleven weeks later treated with RIF-
STR. Development of lesions during the first eleven weeks after infection and 
subsequent differences in disease progression between RIF-STR treated and 
untreated mice were studied. Changes in histopathological features, footpad swelling 
and number of colony forming units were analyzed. After inoculation with M. ulcerans 
massive infiltrates dominated by polymorphonuclear leukocytes developed at the 
inoculation site, but did not prevent bacterial multiplication. Huge clusters of 
extracellular bacteria located in large necrotic areas and surrounded by dead 
leukocytes developed in the untreated mice. Chemotherapy with RIF-STR led to a 
rapid drop in colony forming units associated with loss of solid Ziehl-Neelsen staining 
of acid-fast bacilli. Development of B-lymphocyte clusters and of macrophage 
accumulations surrounding the mycobacteria demonstrated the resolution of local 
immune suppression. Results demonstrate that the experimental M. ulcerans mouse 
infection model will be a valuable tool to investigate efficacy of new treatment 
regimens and of candidate vaccines.  
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Introduction 
 
Buruli ulcer (BU) caused by Mycobacterium ulcerans is the third most common 
human mycobacterial disease of immunocompetent hosts after tuberculosis and 
leprosy (19, 38, 41, 42). It is a neglected emerging disease present in tropical and 
subtropical regions with the highest prevalence in West-African countries (2, 6). 
Occurrence of BU is associated with swampy areas, stagnant water bodies or slow 
flowing rivers. However, the mode of transmission and the natural reservoir of M. 
ulcerans are still not known. Contamination of wounds from environmental reservoirs, 
such as bio films on aquatic vegetation or soil, but also transmission via insect bites 
have been implicated (10, 24–27, 29, 30). An animal reservoir, possums, has been 
identified in a BU endemic region of Southern Australia (11), but so far not in Africa 
(9, 43). 
 
Clinical presentation of BU starts with a painless subcutaneous nodule, papule, 
plaque or edema which can later develop into ulcers with extensive necrosis and 
undermined edges (44). The disease is primarily affecting the limbs but also other 
body parts can be involved. Spontaneous healing may occur often leaving extensive 
scarring and deformities behind (6, 38, 42). While surgery has traditionally been the 
only recommended treatment for BU, the current WHO treatment recommendation is 
a combination chemotherapy with Rifampicin and Streptomycin (RIF–STR) for 8 
weeks for all forms of the active disease (3, 20, 28, 33, 45). Drawbacks of this 
combination are potential long term side effects and the daily intramuscular injections 
required for Streptomycin (37). Therefore alternative treatment regimens are being 
evaluated (4).  
Clumps of extracellular acid fast bacilli surrounded by large areas of necrosis of the 
deep dermal and adipose tissue associated with only minimal inflammation are 
characteristic histopathological features of BU (12–14, 35). Immune responses to 
mycobacterial infections are normally characterized by an early, acute, predominantly 
neutrophilic response, whereas in the chronic stage mononuclear and granulomatous 
patterns develop (35). While M. ulcerans cells may be taken up in the early stages of 
infection by phagocytes, they seem to persist only transiently inside these host cells 
(5, 34, 36). Killing of the phagocytes by the macrolide cytotoxin mycolactone of M. 
ulcerans leads to the release of the bacteria. Subsequent extracellular multiplication 
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results in the development of extracellular clusters of acid-fast bacilli (AFB) inside 
large necrotic areas (35). 
Here we have studied bacterial killing and recovery of local immune responses in a 
mouse model for M. ulcerans disease and compared these findings to features 
observed in human BU lesions.  
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Materials and Methods 
 
Ethics statement 
In conducting the experiments, the Laboratoire de Bactériologie-Hygiène followed the 
official instructions for the appropriate use of animals (issued by the Direction 
Départementale des Services Vétérinaires de Paris and the Préfecture de Police de 
Paris).  
 
Infection of mice with M. ulcerans  
The M. ulcerans strain CU001 isolated from a BU patient from Côte d’Ivoire was 
maintained through regular passage in mouse footpads. This isolate has been used 
in other studies evaluating the in vivo activity of various antimicrobial agents against 
M. ulcerans.(15–18, 23). Minimum inhibitory concentrations (MICs) of RIF and STR 
for strain CU001 on 7H11 agar medium are 2 and 0.25µg/ml (18). 98 female BALB/c 
mice, 4-week-old, were purchased from the Janvier Breeding Center, Le Genest-
Saint-Isle, France. Both hind footpads of mice were inoculated subcutaneously with 
0.03 ml of a freshly prepared M. ulcerans suspension each. The inoculum size was 
8.1x103 colony forming units (CFU) per footpad.  
 
Antibiotic treatment of mice 
Rifampicin (RIF; Aventis, Paris, France) was suspended in 0.05% agar-distilled water 
and given by oral gavage (10mg/kg body weight). Streptomycin (STR, Panpharma, 
Fougeres, France) was diluted with normal saline and administered by subcutaneous 
injection (150mg/kg body weight). Both antimicrobial agents were given once daily 
during weekdays, i.e., 5 times weekly. (15–18, 23) 
 
Study design 
Until week eleven after inoculation, every second week three mice were sacrificed 
(Figure 1). The right footpad was used for histopathological analysis whereas the left 
hind footpad was used to determine the CFU per footpad. After 11 weeks mice were 
randomized and allocated among two groups: untreated control and RIF/STR treated 
group. Treatment with RIF/STR was started immediately after randomization and 
lasted for 12 weeks. The first 4 weeks after randomization 5 mice of the treated and 
untreated group were sacrificed each week for histopathological analysis and 
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determination of CFU. Afterwards samples were taken every second week. For the 
untreated group two more time points (week 6 and week 8 after commencement of 
treatment) and for the treatment group four more time points (week 6, 8, 10 and week 
12 after commencement of treatment) were evaluated (Figure 1).  
 
Scoring of lesion index 
Footpads were examined for determination of the lesion index directly before mice 
were sacrificed. The lesion index was scored from 0 to 4 as follows: 0, the footpad 
appeared normal; 1, the footpad showed slight swelling 2, swelling limited to the 
inoculated footpad; 3, swelling extended to the whole hind foot; 4, swelling extended 
to the whole limb (Figure 2). 
 
Enumeration of colony forming units (CFU) in footpads 
 To enumerate CFU, the tissues of the inoculated footpads were removed aseptically 
and homogenized in Hanks' solution in a final volume of 2 ml. For the untreated 
control mice, the tissue suspensions were serially diluted in 10-fold steps, and 0.1 ml 
of each of three appropriate dilutions was plated in triplicate on Löwenstein-Jensen 
medium. For the RIF/STR treated mice, the entire volume (2 ml) of the undiluted 
tissue suspension from each inoculated footpad was plated on 10 tubes of 
Löwenstein-Jensen medium. CFU were enumerated after incubation at 30°C for 90 
days. 
 
Histopathological analyses 
After mice were sacrificed, footpads were removed above the ankle and immediately 
fixed in neutral buffered 4 % paraformaldehyde for 24 hours. Afterwards they were 
incubated in decalcification solution, consisting of 0.6 M EDTA and 0.25 M citric acid, 
for 10 days at 37°C under shaking conditions. After decalcification of bones footpads 
were embedded in paraffin, cut into 5 µm sections using a HM 335 E rotary 
microtome (MICROM International GmbH) and retrieved on Superfrost Plus (Thermo 
scientific) slides. Staining with Haematoxylin/Eosin (HE) and Ziehl Neelsen (ZN) was 
performed according to standard WHO protocols (44). 
For immunohistochemistry sections were deparaffinized and rehydrated, endogenous 
peroxidase was blocked with 3 % H2O2 for 10 minutes and unspecific binding 
prevented by incubating with blocking serum matching the secondary antibody host. 
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Subsequently slides were pre-treated with the hot Borate antigen retrieval method 
(0.02 M, ph 7) (21) and incubated at room temperature with (i) monoclonal antibodies 
against CD45R (B-cells, Serotec, Clone RA3-6B2), Mo-Ma 
(Monocytes/macrophages, Serotec, Clone MOMA-2), CD3 (T-cells, Serotec, Clone 
CD3-12), Neutrophils (Abcam, Clone NIMP-R14), KI67 (proliferation marker, Thermo 
Scientific, Clone SP6) or (ii) polyclonal rabbit serum against mycobacterial (M. 
leprae) antigens (pAbLep; Colorado State University, CO, USA). Afterwards sections 
were incubated for 30 min with a corresponding biotinylated secondary antibody 
(Vector Laboratories) and for additional 30 min with streptavidin horseradish 
peroxidase conjugate (Vectastain ABC Kit, Vector Laboratories). Staining was 
performed using Vector NovaRed (Vector Laboratories) and Meyer’s haematoxylin as 
counter stain (Sigma). Sections were mounted with Eukitt® mounting medium (Fluka). 
Pictures were taken with a Leica® DM5000B microscope.  
Based on the analysis of numerous tissue samples from lesions of Buruli ulcer 
patients, taken before, during or after treatment we selected characteristic pictures 
shown in Figure 8. 
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Results 
 
Multiplication of M. ulcerans and tissue destruction in inoculated footpads 
Eleven weeks after footpad inoculation with M. ulcerans, lesion indices of infected 
mouse footpads had increased from zero to “1” (Figure 2) and mice were randomized 
into a control group receiving no antibiotic therapy and a treatment group receiving 5 
times weekly antibiotics (Figure 1). Thereafter the lesion indices of the group without 
antibiotic treatment proceeded fast to “3” or “4” (Figure 2). At week 19 all remaining 
untreated mice had to be sacrificed because first signs of severe pathology 
developed. These macroscopic observations correlated well with the 
histopathological features. Results of the histopathological analyses are shown for 
representative samples and for selected time points in Figure 3.  
One week after inoculation, when the lesion index was still zero, only minor 
histopathological changes could be observed (Figure 3A1-A3). Between the muscle 
fibers small clusters of infiltrating cells, mainly polymorphnuclear leucocytes (PMNs) 
co-localizing with the AFB were observed. AFB were found both intra- and 
extracellularly during this early stage of infection. Animals receiving no treatment 
showed a swelling of the whole footpad 14 weeks after inoculation associated with 
large numbers of AFB, localized in accumulations of killed leucocytes (Figure 3A4-6). 
Infiltration in untreated footpads consisted mainly of neutrophils (Figure 4B),and 
monocytes/macrophages (Figure 4C), T-cells (Figure 4D) and B-cells (Figure 4E) 
were rarely found at this time-point of the infection the majority of bacteria were found 
extracellularly between the dead leucocytes. Globi-like intracellular AFB clusters 
(Figure 5A1, A2) may represent precursors of extracellular microcolonies (5). Without 
antibiotic treatment, 17 weeks after infection macroscopic swelling of footpads had 
extended to the ankle and the lower part of the leg (Figure 3A7-A9). Histopathology 
revealed large necrotic areas where connective tissue, muscles and glands were 
completely destroyed. Neutrophilic infiltrates present earlier during the infection had 
largely disappeared (Figure 3A7). Huge clusters of extracellular bacteria were 
primarily located in the middle of this necrotic area (Figure 3A8, A9). At the periphery 
of the extended necrotic areas containing this enormous bacterial burden, new foci 
were developing from spreading mycobacteria (Figure 5A1). Here interactions 
between bacterial cells and phagocytes attracted to the site of infection could be 
observed (Figure 5A2). In contrast, to the AFBs forming the large extracellular 
Chapter 3. Buruli ulcer histopathology in mice 
 
29
conglomerations in the main necrotic infection focus (Figure 5B1, B2), more than 
50% of the mycobacteria forming the new foci exhibited no longer a uniform solid ZN 
staining, but had a ‘beaded’ appearance (Figure 5A3,A4).  
The epidermis above the infection foci remained intact for extended periods of time 
after infection, covering the necrotic dermal layer. Ulceration therefore occurred 
much later than footpad swelling (data not shown). Proliferation of keratinocytes in 
the epidermal layer was demonstrated by specific staining for the proliferation marker 
Ki67 (Figure 5C1, C2). Compared to tissue from uninfected mice this staining tended 
to be stronger, but due to heterogeneity within the dermis, a quantitative assessment 
of differences was not possible. 
 
Response to chemotherapy  
Footpad lesion indices of mice receiving antibiotic treatment from week eleven 
onwards, increased transiently to “2”  in 35% of the mice or to “3” in 5% of the mice, 
but from week 21 onwards all footpads returned to “1” (Figure 2). While the right hind 
footpads were used for histopathological analysis, the left hind footpads were used 
for enumeration of CFUs. Chemotherapy caused a rapid decline in the number of 
CFUs (Figure 6). Already after three weeks of treatment four of five footpads were 
culture negative. However, single culture positive footpads were still found after 6 
and 8 weeks of treatment and only after 10 and 12 weeks all (5/5) footpads were 
culture negative (Figure 6). CFU counts in untreated footpads increased further 
(Figure 6) until 17 weeks after inoculation when mice had to be sacrificed. 
Already three weeks after start of chemotherapy, over 50% of the AFB were either 
internalized or associated with macrophages and neutrophils and showed no longer 
a uniform solid ZN staining but appeared as beaded rods (Figure 3B2, B3,). After 8 
weeks of chemotherapy none of both the intracellular (Figure 7A1) as well as the 
extracellular AFBs (Figure 7A2) showed solid ZN staining.  
Three weeks after initiation of chemotherapy, footpads showed no longer major 
swelling or edema, although chronic infiltrates had developed (Figure 3B1). 
Immunohistochemical staining revealed the formation of leukocyte accumulations 
mainly composed of an outer macrophage belt (Figure 7B1, B2) and an inner belt 
consisting of neutrophils (Figure 7B3) surrounding residual AFBs (Figure 7B4). 
Limited numbers of T-cells and individual B-cells were interspersed in these clusters 
(data not shown). While three weeks later the overall extent of the leukocyte 
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infiltration had decreased, very densely packed lymphocyte clusters (Figure 3B4) 
appeared in addition to the still persisting beaded AFBs immersed in accumulations 
of macrophage/neutrophils. These lymphocyte clusters (Figure 7C1) consisted 
mainly of CD45R positive B-cells (Figure 7C2), no macrophages (Figure 7C4) or 
PMNs (Figure 7C5) and only scattered T cells. More T cells were found in the areas 
surrounding the tightly packed clusters (Figure 7C3).  
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Discussion 
 
Since 2004 WHO recommends a dual antibiotic therapy with oral rifampicin (10 
mg/kg) and i. m. streptomycin (15 mg/kg) administered daily for at least eight weeks 
(45). While early BU lesions can usually be effectively managed by this antimicrobial 
treatment alone, more advanced lesions may require surgical débridement and/or 
skin grafting (3, 20, 28, 33). To contribute to a better understanding of the local 
responses in BU lesions, here, we performed a longitudinal histopathological study in 
mice experimentally infected with M. ulcerans. Changes in macroscopic appearance, 
mycobacterial load, tissue destruction and local immune responses before and 
during chemotherapy were assessed.  
 
During the establishment of infection intracellular bacilli were observed and 
intracellular accumulation of AFB led to the development of globi-like structures. After 
killing of host cells by the macrolide toxin mycolactone these may be efficient seeds 
for the large extracellular clusters of AFB that developed at later stages of the 
infection. Evidence for a transient intracellular stage of M. ulcerans and the ability to 
subsequently destroy the infected phagocytes has also been obtained in vitro studies 
(5, 40). However, early immune responses may also have protective potential, since 
only a small proportion of individuals exposed to M. ulcerans seem to develop clinical 
disease (8). Immune status, as well as the size of the initial inoculums and the site of 
the initial infection may influence the outcome.  
 
Animal studies have yielded conflicting results regarding the nature of leukocytic 
infiltrates in early stages of the infection. While it has been reported that neither wild 
type nor mycolactone negative M. ulcerans strains were strong neutrophilic 
attractants (1), in agreement with results reported by Coutanceau et al. (5) we 
observed substantial neutrophilic infiltrates during the first weeks after infection. At 
later stages, no viable neutrophils were left in the necrotic centre of the established 
BU lesions, but remains of the killed neutrophils could still be detected by 
immunohistochemical staining. In humans the very early stages of M. ulcerans 
infection are not associated with significant clinical signs and symptoms and have 
therefore never been examined histopathologically. However, massive neutrophilic 
infiltrates observed during the first weeks after experimental infection of mice seem to 
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have correlates in early human disease, since remains of neutrophils are commonly 
found in the necrotic areas of human BU lesions (Figure 8A-D) (32, 35). 
 
In the mice, the epidermis above the infection foci stayed for extended periods of 
time after inoculation intact, covering the progressively necrotizing dermal layer. In 
human BU disease epidermal hyperplasia is a characteristic feature and elevated 
proliferation of keratinocytes is typically observed (Figure 8E, F). Also in the mice the 
epidermis above the infection foci showed strong staining with the proliferation 
marker Ki67 (Figure 5C). Other hallmarks of human BU lesions, such as extensive 
coagulative necrosis and edema formation (35) developed slowly in the mouse 
footpads and became only apparent in untreated mouse footpads about 14 weeks 
after inoculation. Since the mode of transmission of M. ulcerans is not clear, the 
incubation time in humans cannot be reliably estimated.  
 
While the necrotic core of advanced BU lesions is typically free of viable leucocytes, 
accumulations of immune cells are found both in the mouse model and in human 
lesions (Figure 5A, B and Figure 8G) at the rim between the necrotic and the healthy 
tissue. Also in untreated lesions these seem to be sites where adaptive immune 
responses are initiated. These may be of importance for spontaneous healing 
occasionally observed both in early and advanced BU disease (7, 42).  
 
After start of antibiotic treatment, local infiltrates switched from a predominantly 
unorganized neutrophilic to a more organized chronic infiltration type. Macrophages 
and neutrophils formed tight clusters around AFBs and dense lymphocyte clusters 
mainly consisting of CD45R positive B-cells developed nearby. Also in human BU 
lesions structured accumulations of immune cells including large CD20 positive B-cell 
clusters (Figure 8H) are developing in the course of chemotherapy (35). However, 
contrary to what is observed during antibiotic treatment of human BU lesions, we 
found no granuloma formation in the mouse footpads. Whether this lack of 
granuloma formation is related to the mouse strain used remains to be elucidated.  
 
Already one week after start of the antibiotic treatment, incomplete ZN staining of the 
mycobacteria was observed giving them a beaded appearance. In M. tuberculosis 
and M. leprae beading seems to be an indicator of a loss of viability (22). In M. leprae 
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the morphological index (MI) is therefore used to determine the effectiveness of the 
antibiotic treatment. Ultrastructural visualization of M. leprae showed that in untreated 
patient samples the majority of the bacilli showed a solid staining and that cell bodies 
were filled homogenously with cytoplasm. In contrast irregular ZN stained bacilli from 
treated patients showed an intact cell wall but a cytoplasm which was detached from 
the cell wall and in later stages a complete degeneration of all structures (22). 
Beading was also detected in samples from untreated mice at the periphery of the 
lesions, where bacteria were found intracellularly or in close contact with phagocytes. 
This and similar findings in human lesions suggests that the immune system has the 
capacity to kill dispersed M. ulcerans bacteria and that development of microcolonies 
surrounded by a protective cloud of mycolactone is a critical step in the 
establishment of a chronic M. ulcerans infection.  After completion of treatment, AFB 
throughout the whole footpad revealed a beaded structure, and cultures went 
negative supporting the hypothesis of beading as a marker for loss of viability. 
Osteomyelitis is a major severe complication  occurring in >10% of all BU patients 
(31, 39). We observed in 15 % of all examined mouse footpads bacterial infiltration in 
the bone marrow (data not shown), but with antibiotic treatment also these bacteria 
revealed a beaded appearance indicating effective treatment.  
 
Single culture positive footpads were still found after six and eight weeks of 
chemotherapy and only after 10 and 12 weeks all footpads were culture negative. 
Although also clinical trials indicate that some bacilli may survive the recommended 
eight week course of antibiotic treatment (28, 33), recurrence rates after RIF-STR 
treatment are as low as 1-2%. This indicates that immune responses primed by 
antigens and immunostimulators released during chemotherapy by killed bacilli are 
strong enough to eliminate residual dispersed bacilli (32)   
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Figure 1: Study design 
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Figure 2:  Evolution of the lesion index over time after infection 
(A) Evolution among untreated (●) and RIF-STR treated (∆) mice. (B) Representative 
presentations of footpads associated with different scores of the lesion index. 
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Figure 3: Overview of histopathological features of treated and untreated 
lesions  
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Histological sections stained with HE (A1, A4, A7, B1, B4) and ZN (A2, A3, A5, A6, 
A8, A9, B2, B3, B5, B6); counterstaining with methylenblue. Footpads from mice 
without chemotherapy (A) and with RIF-STR treatment (B). (A1-A3) footpad one 
week after inoculation, showing slight infiltration and small numbers of intra- and 
extracellular bacteria. (A4-A6) footpad 14 weeks after inoculation, showing a large 
infiltrated area mainly composed of destroyed PMNs surrounding large numbers of 
extracellular AFBs. (A7-A9) footpad 17 weeks after inoculation without treatment, 
showing a large edematous necrotic area, with extracellular bacterial clusters. (B1-3) 
footpad three weeks after start of treatment with RIF-STR, showing mild infiltration 
and AFBs with beaded appearance. (B4-B6) footpad six weeks after start of 
treatment, showing dense lymphocyte clusters and AFBs with beaded appearance. 
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Figure 4: Neutrophilic infiltration in untreated mouse footpads early after 
inoculation 
Histological sections of a footpad from an untreated mouse 3 weeks after inoculation 
stained either with haematoxylin-eosin (A) or with antibodies against cell surface or 
cytoplasmic markers and counterstained with haematoxylin (B-E). Haematoxylin-
eosin staining revealed a large band of infiltrating leucocytes, mainly composed of 
neutrophils (B) and monocytes/macrophages (C). Only few CD3 positive T- cells (D) 
and few CD45R positive B-cells (E) were found. 
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Figure 5: Appearance of mycobacteria at different times after inoculation 
Histological sections of the footpad from an untreated mouse 19 weeks after 
inoculation (stained with ZN, counterstained with methylene blue (A, B) or with an 
antibody-based staining, counterstained with haematoxylin (C). The main infection 
focus and a more peripheral accumulation of AFBs are boxed (A). Low magnification 
picture of a peripheral AFB accumulation, showing interactions between the 
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mycobacteria and phagocytes (A1). Globi-like structures representing numerous 
intracellular AFB residing in macrophages (A2). ZN staining of peripheral AFB 
reveals the presence of beaded bacteria (A3, A4). The main infection focus 
containing no viable phagocytes, but large extracellular clusters of AFB (B1) 
exhibiting solid ZN staining (B2). Staining with the proliferation marker Ki67 revealed 
a strong proliferative activity of epidermal kerationocytes (C1, C2).  
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Figure 6: Changes in CFU counts after inoculation and during RIF-STR 
treatment 
Mice footpads were inoculated with 8.1x103 CFU M. ulcerans at week 0. The control 
group (●) received no treatment; in the treatment group (Δ), chemotherapy with RIF-
STR started at week 11. 
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Figure 7: Inflammatory responses and development of B-cell clusters in RIF-
STR treated mice  
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Histological sections were either stained with ZN-methylenblue (A1,A2), antibodies 
against cell surface or cytoplasmic markers, counterstained with haematoxylin (B1-
B4, C2-C5) or sections were stained with Haematoxylin/Eosin (C1). After 8 weeks of 
antibiotic therapy all intracellular (A1) as well as extracellular (A2) AFB appeared as 
beaded rods. Immunostaining of mouse footpads three weeks after commencement 
of antibiotic therapy revealed a strong clustering of monocytes/macrophages (Mo-
Ma) (B1, B2), neutrophils (B3) and M. ulcerans bacteria (B4), as well as the formation 
of large lymphocyte accumulations six weeks after commencement of antibiotic 
therapy (C) which were mainly composed of CD45 positive B-cells (C2), only a few 
CD3 positive T-cells C3) and basically no macrophages (C4) or neutrophils (C5). 
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Figure 8: Features of human BU lesion with correlates in the mouse infection 
model 
Histological sections of human tissue were either stained with haematoxylin-eosin 
(E,G) or with antibodies against cell surface or cytoplasmic markers and 
counterstained with haematoxylin (A-D, F, H-J). A belt of intact macrophages 
surrounded the necrotic core (A) with neutrophilic debris from the initial wave of 
infiltration still being detectable (C). Appendices of macrophages reaching into the 
necrotic core (B). Inside the necrotic area no intact neutrophils could be detected (D). 
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Epidermal hyperplasia typically observed in human BU lesions (E) associated with an 
elevated proliferation of the keratinocytes, indicated by staining with the Ki67 
proliferation marker (F). In the neighborhood of the necrotic core of the lesion, 
accumulations of viable leucocytes can be observed in untreated patients (G). 
Cluster of CD20 positive B-cells (H), partially highly proliferating (I) and interspersed 
with few CD3 positive T-cells (J) are typically developing in the lesions of BU patients 
during and after completion of chemotherapy. 
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Abstract  
 
Background: Buruli ulcer (BU) caused by Mycobacterium ulcerans is a necrotizing 
skin disease usually starting with a subcutaneous nodule or plaque which may 
ulcerate and progress, if untreated, over months and years. During the currently 
recommended antibiotic treatment with rifampicin/streptomycin plaque lesions tend to 
ulcerate, often associated with retarded wound healing and prolonged hospital stays. 
 
Methodology/Principal findings: Included in this study were twelve laboratory 
reconfirmed, HIV negative BU patients presenting with plaque lesions at the CDTUB 
in Allada, Benin. Punch biopsies for histopathological and immunohistochemical 
analysis were taken before start of treatment and after four to five weeks of 
treatment. Where excision or wound débridement was clinically indicated, the 
removed tissue was also analyzed. Based on clinical judgment, nine of the twelve 
patients enrolled in this study received limited surgical excision seven to 39 days after 
completion of chemotherapy, followed by skin grafting. Lesions of three patients 
healed without further intervention. Before treatment, plaque lesions were 
characterized by a destroyed subcutis with extensive necrosis without major signs of 
infiltration. After completion of antibiotic treatment partial infiltration of the affected 
tissue was observed, but large necrotic areas remained unchanged.  
 
Conclusion/Significance: Our histopathological analyses show that ulceration of 
plaque lesions during antibiotic treatment do not represent a failure to respond on 
antimycobacterial treatment. Based on our results we suggest formal testing in a 
controlled clinical trial setting, whether limited surgical excision of necrotic tissue 
favours wound healing and can reduce the duration of hospital stays.  
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Author Summary 
 
The tropical necrotizing skin disease Buruli ulcer (BU) caused by Mycobacterium 
ulcerans is associated with extensive tissue destruction and local 
immunosuppression caused by the macrolide exotoxin mycolactone. Chemotherapy 
with a combination of rifampicin and streptomycin for 8 weeks is the currently 
recommended treatment for all types of BU lesions, including both ulcerative and 
non-ulcerative stages (plaques, nodules and oedema). Our histopathological analysis 
of twelve BU plaque lesions revealed extensive destruction of sub-cutaneous tissue. 
This frequently led to ulceration during antibiotic treatment. This should not be 
mistaken as a failure of the antimycobacterial chemotherapy, since we found no 
evidence for the persistence of active infection foci. Large necrotic areas were found 
to persist even after completion of antibiotic treatment. These may disturb wound 
healing and the role of wound débridement should therefore be formally tested in a 
clinical trial setting. 
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Introduction  
 
Buruli ulcer (BU), the third most common human mycobacterial disease, is caused by 
M. ulcerans [1,2]. While the disease is present in around 30 countries worldwide the 
main focus with the highest prevalence is found in West African countries like Benin, 
Ghana, Cameroon and the Ivory Coast [3,4]. Three categories of pre-ulcerative 
lesions, painless movable subcutaneous nodules or papules, oedema and plaques 
are distinguished. All three forms of pre-ulcerative lesions may progress to ulcerative 
lesions, when destruction of the subcutis is leading to the collapse of the overlying 
epidermis and dermis [1,5,6]. 
  
In 2004 WHO treatment recommendations for BU changed from a purely surgical 
treatment to a dual antibiotic therapy with rifampicin and streptomycin for eight weeks 
[7]. Recurrence rates after antibiotic treatment are low, but a proportion of antibiotic 
treated patients, in particular those with extensively ulcerated wounds, requires 
excisions and skin grafting [8-13]. During and after completion of antibiotic treatment 
paradoxical reactions associated with the enhancement of local immune responses 
and increases in size of lesions may be mistaken as disease progression [14,15]. 
Observational studies have shown that while nodules usually heal after antibiotic 
treatment without further intervention, ulceration and an increase in the size of the 
lesion is often observed in the case of plaque lesions. These paradoxical reactions 
may occur after initial improvement and often require extensive medical care, 
causing long hospital stays. To elucidate the underlying mechanisms and to gain a 
better insight into the histopathological features of plaque lesions we conducted 
detailed histopathological and immunohistochemical analyses of tissue specimen 
from 12 plaque patients treated with rifampicin and streptomycin. 
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Materials and Methods 
 
Ethics statement 
Ethical approval (clearance N° 011, 12/10/2010) for analyzing patient specimens was 
obtained from the provisional national ethical review board of the Ministry of Health 
Benin, registered under the N° IRB00006860. Written informed consent from the 
patients or from the guardians of the patients was obtained before surgical 
specimens were used for reconfirmation of clinical diagnosis and detailed 
immunohistological analysis. 
 
Study participants 
12 patients aged between five and 70 years (median age 12 years) reporting 
between April 16 and August 15 2009 with laboratory reconfirmed BU plaque lesions 
at the Centre de Depistage et de Traitement de l’Ulcere de Buruli d’Allada in Benin 
were included in the study (Table 1). Most (9/12) lesions were located at the upper 
(4/12) or lower (5/12) extremities. The diameter of the lesions was between four and 
15 cm. All patients were coming from the highly BU endemic Ze commune in the 
Department Atlantique of Benin. The gender distribution was nine males and three 
females. Clinical diagnosis was reconfirmed by positive results in at least two of the 
three laboratory tests (IS2404 PCR, detection of acid fast bacilli (AFBs) on 
microscopy and histopathology) performed. All patients completed the WHO 
recommended combination dual chemotherapy with oral rifampicin (10 mg/kg/day) 
and i. m. streptomycin (15 mg/kg/day) for 56 days. All patients were tested negative 
for HIV. 
 
Histopathological analysis 
Punch biopsies were taken for histopathological analyses prior to start of 
chemotherapy on day -2 to day 0 (T1). Of these 12 T1 samples, one was not suitable 
for immunohistochemical analysis. A second punch biopsy taken 26 to 48 days after 
start of chemotherapy (T2) became available from 11/12 patients. According to the 
judgment of the responsible clinician, based on the evolution of the lesions including 
remaining induration and increasing lesion surface area, nine patients received 
adjunct surgical treatment seven to 39 days after completion of chemotherapy and 
had skin grafting five to 14 days after excision. Samples from seven of the nine 
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excised lesions became available for histopathological analysis. In the case of the 
two other patients that received surgery, a third punch biopsy was taken and 
analyzed prior to surgical excision. Tissue samples were fixed in 4% neutral-buffered 
paraformaldehyde for 24h and subsequently transferred to 70% ethanol for transport. 
Biopsies were dehydrated, embedded in paraffin, cut into 5 mm thin sections and 
retrieved on glass slides. After dewaxing and rehydration, sections were stained with 
haematoxylin/eosin (HE) and Ziehl-Neelsen (ZN) staining of AFBs was performed. 
Immunohistochemistry was performed with antibodies against Elastase 
(polymorphonuclear neutrophils [PMNs]; Dako clone NP57), CD3 (T lymphocytes; 
Dako clone F7.2.38), CD8 (cytotoxic T lymphocytes; Serotec clone 4B11), CD4 
(helper T lymphocytes; Dako clone 4B12), CD68 (macrophages/monocytes; Dako 
clone KP1), Ki67 (proliferation marker; Dako polyclonal rabbit serum) and CD20 (B 
lymphocytes; Novocastra clone7D1). Staining was performed using Vector NovaRED 
and haematoxylin as a counterstain. 
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Results  
 
Clinical response to antibiotic treatment 
Included in this study were twelve BU patients (Tab. 1) with single new laboratory-
reconfirmed plaque lesions reporting between April 16 and August 15, 2009 at the 
Centre de Depistage et de Traitement de l’Ulcere de Buruli d’Allada in Benin. All 
patients received the WHO recommended dual chemotherapy with rifampicin and 
streptomycin for 56 days [7]. Seven out of 12 lesions ulcerated during chemotherapy 
(Fig. 1C, E, F). Six of these patients received surgical treatment to remove necrotic 
tissue (Fig. 1E, F). Based on clinical judgment, tissue was also excised from the 
lesions of another three patients, which had at this stage not yet developed 
ulceration, but an induration (Fig 1D). Three patients healed without surgical 
intervention (Fig. 1A-C), one of them had developed a small ulceration during 
chemotherapy (Fig. 1C) which needed no further intervention.  
For patients who received surgical treatment, excisions were performed 7 to 39 days 
(average 19 days) after completion of chemotherapy. Skin grafting followed 5 to 14 
days (average 8 days) after excision and patients were discharged from hospital 16 
to 100 days (average 36 days) after skin grafting. The time interval between start of 
antibiotic treatment till discharge from hospital was between 55 to 179 days (average 
103 days) for the 12 patients (Tab.1). Depending on the location of the lesion this 
period was prolonged by a phase of physiotherapy (Tab. 1). 
 
Histopathological features of untreated plaque lesions 
For histopathological characterization of the untreated plaque lesions, punch biopsies 
were taken before start of antibiotic treatment. Certain features, depicted in Fig. 2, 
were found in all samples analyzed. The dermis presented with relatively intact 
collagen with minor infiltrations around vessels and glands (Fig. 2A, C), reflecting the 
pre-ulcerative nature of the plaque lesions. Most strikingly, the subcutis was in all 
patients extensively necrotic and oedematous (Fig. 2A). Additional features typical for 
an untreated BU lesion, like fat cell ghosts (Fig. 2D) and minimal infiltration limited to 
the surrounding of a few remaining partially intact blood vessels (Fig. 2E), were 
always present. Immunohistochemical staining revealed N-elastase positive 
neutrophilic debris (Fig. 2F) reflecting an early wave of neutrophilic infiltration. In 
addition, only few intact neutrophils (Fig. 2G) and CD68 positive macrophages (Fig. 
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2H) were found. Tissue of only two patients contained also a few intact CD3 positive 
T-cells in the dermal tissue (data not shown).  
Acid fast bacilli (AFB) were found in only 7/31 (23%) of the tissue samples analyzed 
altogether. This reflects the focal distribution of the mycobacteria and the extension 
of tissue destruction, attributable to the diffusion of mycolactone, into tissue areas 
with low mycobacterial burden [16]. Fig. 2B depicts an example, where a 
mycobacterial focus was sampled. Here a band of extracellular AFBs was found in a 
deep layer of the necrotic subcutis. 
 
Persistence of necrotic areas with limited infiltration in the course of antibiotic 
treatment 
Punch biopsies taken between 26 and 48 days after start of antibiotic treatment 
typically consisted still primarily of large oedematous necrotic areas with fat cell 
ghosts (Fig. 3A/B). Overall, infiltration was much less pronounced than typically 
found in ulcerative lesions at this time point of antibiotic treatment [17]. 9/11 patients 
presented with a mild infiltration consisting of very few N-elastase positive neutrophils 
(Fig. 3D), more CD68 positive macrophages (Fig. 3E) and CD3 positive T-cells (Fig. 
3F). These infiltrates were scattered throughout the dermis and extended only in 3/11 
samples into the large necrotic areas. Structured infiltrates typically found in healing 
BU lesions [14], were rare: granuloma formation (Fig. 3H) was found in 2/11 
samples, CD20 positive B-cell clusters (Fig. 3G) and giant cells (Fig. 3I) in 3/11 
biopsies. AFBs were found in 4/11 samples; they were primarily intracellular or had a 
‘beaded’ appearance (Fig. 3C).  
 
Features of tissue excised after completion of antibiotic treatment 
While lesions of three of the enrolled patients healed without adjunct treatment, the 
responsible clinician decided to support wound healing by surgical excision of 
affected tissue in 9/12 patients. All nine excisions were performed after completion of 
antibiotic treatment, 56 to 94 days after start of chemotherapy. While six of the nine 
tissue samples were excised from lesions, which had spontaneously ulcerated during 
antibiotic treatment, the other three were excised from non-ulcerated lesions showing 
no adequate clinical improvement.  
All nine excisions consisted to a large extent of necrotic and oedematous tissue with 
fat cell ghosts (Fig. 4A). In the case of the three patients which had still non-
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ulcerative lesions at the time of excision, the dermis presented with necrosis and 
infiltration, indicative for progression towards ulceration (Fig. 4C). Most (7/9) samples 
showed massive infiltration of the subcutis (Fig. 4B) often with a clear border 
between intact leucocytes, mainly CD14 positive macrophages/monocytes (Fig. 
4D1), and the still necrotic areas containing N-elastase positive neutrophilic debris 
(Fig. 4D2). Infiltrates were mainly composed of CD68 positive macrophages (Fig. 4E) 
and CD3 positive T cells (Fig. 4F) with a higher proportion of CD8 positive (Fig. 4G) 
than CD4 positive (Fig. 4H) T-cells. In addition CD68 positive langhans and foreign 
body giant cells (Fig. 4I), granulomas and small CD20 positive B-cell clusters (Fig. 
4J) were found. Some areas were strongly infiltrated with N-elastase positive 
neutrophils (Fig. 4K). Angiogenesis inside the necrotic and hypoxic tissue was 
observed in 5/9 patients (data not shown). Small numbers of intra- and extracellular 
AFB with a beaded appearance were found in the specimens of 2/9 patients (Fig. 
4L).  
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Discussion 
 
BU plaque lesions are defined as firm, painless, elevated and well demarcated lesion 
with more than 2 cm in diameter [18]. Our histopathological analysis of the tissue 
specimen from plaque lesions reconfirmed earlier quantitative RT-PCR analyses [16], 
demonstrating a focal distribution of the mycobacteria and a mycolactone-mediated 
extension of tissue destruction to tissue areas with low mycobacterial burden. Our 
studies provided no evidence for survival of mycobacterial clusters after 
chemotherapy. The few AFBs found after chemotherapy had beaded appearance 
and were largely phagocytosed [17] and all tissues turned culture negative during 
treatment. Interestingly, in those punch biopsies of untreated BU lesions, where a 
mycobacterial focus was sampled, mycobacteria were typically found as a band of 
extracellular AFBs in a deep layer - several mm below the epidermis- of the necrotic 
subcutis (Fig 2B). This might explain why in cases, with clinical features consistent 
with BU, microscopic results are frequently and PCR results are occasionally 
negative. Especially when collecting diagnostic specimens from non-ulcerative 
lesions by fine needle aspiration, also deep layers should be sampled to increase 
chances to reach these bacteria. Focal distribution of M. ulcerans and related lack of 
AFB in some of the tissue samples reflects a major limitation of histopathological 
analyses using punch biopsies. While findings at a particular location of the lesion 
may not be representative for the entire lesion, many major histopathological features 
described here were very consistently found in all samples analyzed. 
 
Also earlier studies [14] demonstrating a reversal of local immune suppression during 
chemotherapy were confirmed. This process starts with a diffuse chronic infiltration, 
primarily by macrophages and T cells. While neutrophils play only a minor role in this 
process, N-elastase positive debris in the necrotic areas are indicative for a wave of 
neutrophil invasion during the early phase of BU pathogenesis. It has been shown 
[14] that after an initial phase of diffuse infiltration development of structured 
leukocyte aggregates, such as B cell clusters and granulomas usually are observed. 
While the development of such highly organized ectopic lymphoid tissue was also 
observed in the case of plaque lesions, this was confined to the margins of the 
necrotic areas. Large regions showing massive coagulative necrosis without 
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significant infiltration were still found in the surgical specimens excised 7 – 39 days 
after completion of chemotherapy. 
 
Infiltration and angiogenesis in the affected tissue during and after chemotherapy 
promotes the resorption of tissue debris. Initial inflammatory responses may be 
associated with paradoxical reactions, before converging into a phase of wound 
healing. In two of the 12 patients enrolled, this process of resorption of necrotic tissue 
was efficient enough to permit healing without ulceration. However, in most cases the 
necrotic areas of plaque lesions seemed to be too extensive to permit complete 
resorption without ulceration. In general, our histopathological analysis of plaque 
lesions revealed a much larger and deeper destruction of the subcutaneous tissue 
than expected. Spontaneous ulceration during antibiotic treatment was observed in 
7/12 patients and tissue samples from three other non-ulcerated patients showed 
gradual degeneration of the dermis, indicative for a progression to ulceration. While 
ulceration result in the loss of necrotic tissue, our analysis of tissues surgically 
excised 7 – 39 days after completion of chemotherapy from lesions that 
spontaneously ulcerated during chemotherapy, revealed incomplete loss of necrotic 
tissue. These findings support the decision of the responsible clinician to support 
wound healing by débridement of the margins of the ulcers. It is well documented 
that wound débridement i.e. the removal of materials incompatible with healing, can 
substantially accelerate the complex wound healing process [19-21]. Even if 
superinfections are controlled with antibiotics, chronic wounds can be caught in a 
chronic inflammatory phase and débridement is then required to convert the chronic 
wound bed into an acute wound and mediate healing through the stages of 
inflammation, proliferation and maturation [20]. This may also apply for BU lesions 
which show massive infiltration during antibiotic treatment and may subsequently be 
arrested in a chronic stage without the chance of proper healing. In patients with 
severe and extensive lesions an early decision for wound débridement may therefore 
reduce hospital stays to less than 100 days.  
 
In the present study the time span between start of treatment and discharge from the 
hospital was 55 - 61 days for the three patients, which did not require an excision. 
For those three patients, which showed no spontaneous ulceration, but were 
surgically treated to remove necrotic tissue this time span was 90 – 95 days. 
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Degeneration of the dermis of the excised lesions harbouring large areas of necrotic 
tissue indicated that these patients would have developed ulceration at a later stage, 
leading to a severely delayed subsequent start of the healing process. Those six 
patients who showed spontaneous ulceration during chemotherapy and received 
later wound débridement, stayed for 108 – 179 days in the hospital. Surgical 
treatment was performed 7 – 39 days after completion of chemotherapy and skin 
grafting 5 – 7 days after excision. Five of these six patients were discharged from 
hospital 27 – 38 days after skin grafting, only in one case this time period was much 
longer (99d) due to secondary infection and delayed wound healing. While bacteria 
are present on basically every open wound, secondary infections above a critical 
bacterial load (>105 organisms per gram of tissue) may lead to an arrest of the wound 
healing process [22-24]. 
 
Taken together our analysis indicates that due to massive coagulative necrosis only 
a minority of BU plaque lesions may heal without spontaneous ulceration. It appears 
advisable to consider débridement of ulcers that have developed in the course of 
chemotherapy in order to remove necrotic tissue and to favour wound healing. The 
effect of adjunct surgical treatment should therefore be formally tested in a clinical 
trial setting to support development of differentiated guidelines for BU wound 
management. 
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Table 
 
Table 1: Characteristics of the 12 Buruli ulcer plaque patients 
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Figures 
 
 
Figure 1: Presentation of BU lesions before and during therapy  
Representatives of the different patient groups are depicted. A, B: Patients with 
lesions that did not ulcerate and which did not require a surgical intervention. C: 
Patient with a lesion that ulcerated during treatment but did not require a surgical 
intervention. D: Patient with a lesion that did not ulcerate but was excised; E, F: 
Patients with lesions that ulcerated during treatment and needed surgical excisions. 
A: Patient 1; day -1, before start of treatment, punch hole visible. B: Patient 2; day 0, 
at the start of treatment, punch hole visible. C: Patient 3; C1: day -2 before start of 
treatment; C2: day 50 after start of treatment; C3: day 300 after end of treatment. D: 
Patient 5; D1: day -8 before start of treatment; D2: day 10 after end of antibiotic 
treatment; D3: day 17 after end of antibiotic treatment; D4: day 35 after end of 
antibiotic treatment. E: Patient 10; E1: day -1 before start of treatment. E2: day 89 
after start of treatment. E3: day 39 after end of antibiotic treatment. E4: day 75 after 
end of antibiotic treatment. F: Patient 12; F1: day 0, at start of treatment; F2: day 26 
after start of treatment; F3: day 54 after start of treatment; F4: day 39 after end of 
antibiotic treatment. F5: day 72 after end of antibiotic treatment. 
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Figure 2: Characteristic histopathological features of tissue samples taken 
before start of antibiotic treatment 
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Histological sections were stained either with Haematoxylin-Eosin (HE) (A, C-E), 
Ziehl-Neelsen (counterstain methylenblue) (ZN) (B) or with antibodies against cell 
surface or cytoplasmic markers (counterstain haematoxylin) (F-H). A: Punch biopsy 
with large necrotic areas, fat cell ghosts and oedema but relatively intact epidermis 
and dermis. B: a band of extracellular AFBs is present in a deep layer of the necrotic 
subcutis. C: epidermis and dermis. D: necrotic region with fat cell ghosts. E: few 
infiltrating cells around a blood vessel. F: N-elastase staining revealed the presence 
of neutrophilic debris inside the necrotic regions. G: few intact neutrophils and H: 
CD68 positive infiltrating macrophages were found.  
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Figure 3: Characteristic histopathological features of tissue samples taken 26-
34 days after start of antibiotic treatment 
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Histological sections were stained either with Haematoxylin-Eosin (HE) (A, B, H), 
Ziehl-Neelsen (counterstain methylenblue) (ZN) (C) or with antibodies against cell 
surface or cytoplasmic markers (counterstain haematoxylin) (D-G, I). A: Punch biopsy 
with large necrotic areas, fat cell ghosts and oedema but relatively intact epidermis 
and dermis. B: Higher magnification of necrotic tissue with large numbers of fat cell 
ghosts. C: Small numbers of intra and extracellular beaded AFB. D: N-elastase 
positive intact neutrophils were rare. E: More intact CD68 positive macrophages and 
F: CD3 positive T-cells were observed in the dermal tissue. Additionally, small CD20 
positive B-cell cluster (G), few granulomas (H) and langhans giant cells (I) were 
found in only few of the samples.  
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Figure 4: Characteristic histopathological features of tissue surgically excised 
to support wound healing 
Histological sections were stained either with Haematoxylin-Eosin (HE) (A-C), Ziehl-
Neelsen (counterstain methylenblue) (ZN) (L) or with antibodies against cell surface 
or cytoplasmic markers (counterstain haematoxylin) (D-K). A: Overview over an 
excised tissue specimen still harbouring large necrotic areas with fat cell ghosts and 
oedema. B: Overview over an excised tissue specimen presenting with mixed 
infiltration in the former necrotic region. C: Necrosis and oedema of the dermis of an 
excised non-ulcerative lesion. D: CD14 (D1) and N-elastase (D2) staining revealing a 
clear border between infiltration with intact CD14 positive macrophages (D1) and 
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neutrophilic debris inside the necrotic area (D2). Infiltrated tissue areas contained 
large numbers of CD68 positive macrophages (E) and large numbers of CD3 positive 
cells (F). These belonged mainly of the CD8 (G) and not of the CD4 (H) subset. 
Langhans and foreign body giant cells (I) and B-cell cluster (J) were present in the 
majority of the samples. Accumulations of N-elastase positive cells (K) were 
occasionally found. AFB were rare, had a beaded appearance and intracellular 
location (L). 
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Abstract 
 
Background: The neglected tropical disease Buruli ulcer (BU) caused by 
Mycobacterium ulcerans is an infection of the subcutaneous tissue leading to chronic 
ulcerative skin lesions. Histopathological features are progressive tissue necrosis, 
extracellular clusters of acid fast bacilli (AFB) and poor inflammatory responses at 
the site of infection. After the recommended eight weeks standard treatment with 
rifampicin and streptomycin, a reversal of the local immunosuppression caused by 
the macrolide toxin mycolactone of M. ulcerans is observed.  
 
Methodology/ Principal findings: We have conducted a detailed histopathological 
and immunohistochemical analysis of tissue specimens from two patients developing 
multiple new skin lesions 12 to 409 days after completion of antibiotic treatment. 
Lesions exhibited characteristic histopathological hallmarks of Buruli ulcer and AFB 
with degenerated appearance were found in several of them. However, other than in 
active disease, lesions contained massive leukocyte infiltrates including large B-cell 
clusters, as typically found in cured lesions. 
 
Conclusion/ Significance: Our histopathological findings demonstrate that the skin 
lesions emerging several months after completion of antibiotic treatment were 
associated with M. ulcerans infection. During antibiotic therapy of Buruli ulcer 
development of new skin lesions may be caused by immune response-mediated 
paradoxical reactions. These seem to be triggered by mycobacterial antigens and 
immunostimulators released from clinically unrecognized bacterial foci. However, in 
particular the lesions that appeared more than one year after completion of antibiotic 
treatment may have been associated with new infection foci resolved by immune 
responses primed by the successful treatment of the initial lesion.  
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Author Summary 
 
Buruli ulcer (BU) is a chronic necrotizing skin disease presenting with extensive 
tissue destruction and local immunosuppression. Standard treatment recommended 
by the WHO includes 8 weeks of rifampicin/streptomycin and, if necessary, wound 
débridement and skin grafting. In some patients satellite lesions develop close to the 
primary lesion or occasionally also at distant sites during effective antibiotic treatment 
of the primary lesion. We performed a detailed analysis of tissue specimen from 
lesions that emerged in two BU patients from Benin 12 to 409 days after completion 
of chemotherapy. Histopathology revealed features of tissue destruction typically 
seen in BU and degenerated acid-fast bacilli. In addition, lesions contained organized 
immune infiltrates typically found in successfully treated BU lesions. Secondary 
lesions emerging many months after completion of chemotherapy may have been 
caused by immune response-mediated paradoxical reactions. The late onset may 
however also indicate that they were associated with new infection foci 
spontaneously resolved by adaptive immune responses primed by antibiotic 
treatment of the primary lesions. 
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Introduction 
 
Buruli ulcer (BU) is a chronic necrotizing infection of subcutaneous tissue caused by 
Mycobacterium ulcerans [1-4]. BU seems to start usually as a movable subcutaneous 
nodule or papule and may later progress to a plaque or oedema. After destruction of 
subcutaneous tissue, the skin may break down centrally leading to the development 
of largely painless necrotic skin ulcers with characteristic undermined edges. These 
may progress to large necrotic lesions. M. ulcerans is unique among mycobacterial 
pathogens in that it resides in advanced lesions mainly extracellular. A 
histopathological hallmark of progressing BU is a poor local inflammatory response in 
the presence of clusters of extracellular acid-fast bacilli surrounded by areas of 
necrosis [5-7]. M. ulcerans produces a toxin with a polyketide-derived macrolide 
structure, named mycolactone, which plays a central role in tissue destruction and 
local immunosuppression. Observations both in cell culture and infection models 
indicate that cells infiltrating BU lesions are killed due to the cytotoxic and apoptosis 
inducing activity of mycolactone [7-10]. While M. ulcerans may be captured by 
phagocytes during initial stages of infection, it appears to persist only transiently 
inside these host cells [11,12]. After killing of the phagocytes, extracellular growth 
leads to the development of extracellular mycolactone-producing bacterial foci in 
areas of coagulating necrosis. Thermosensitivity of M. ulcerans seems to favour 
development of skin lesions of the limbs [13-15] .  
 
Clinical diagnosis of BU can be confirmed by insertion sequence 2404 (IS2404) PCR 
[16-18], microscopic detection of acid-fast bacilli (AFB), culture of M. ulcerans [19] 
and histopathological examination of lesions [6,20-22]. While surgery has traditionally 
been the only recommended treatment for BU [23,24], WHO recommends currently 
as a first-line treatment a combination therapy with rifampicin and streptomycin (R/S) 
for eight weeks for all forms of the active disease [25,26]. After a pilot study 
assessing treatment of BU with R/S [25], a case-series in Benin showed that of 224 
patients 215 were successfully treated [27], with 47% of them receiving antibiotics 
only. More recently, studies by Nienhuis et al., Kibadi et al. and Sarfo et al. [28-30] 
reconfirmed efficacy of R/S treatment. However, débridement, surgery and skin 
grafting may be used as an adjunct to the antimicrobial therapy, mainly to remove 
necrotic tissue, cover skin defects and correct deformities.  
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Reported rates of recurrence after surgical treatment alone range between 6% and 
47% because even wide surgical excision of lesions may not remove all bacilli [31-
34]. Recurrences may be caused by small numbers of M. ulcerans that have spread 
to healthy tissue surrounding the primary lesion [5]. Also lymphohematogenous 
spread of the mycobacteria may occur, since subsets of BU patients develop multiple 
skin lesions or metastatic osteomyelitis [35-39]. Although clinical trials indicate that 
some bacilli may survive the recommended eight week course of antibiotic treatment 
[28,30], recurrence rates after R/S treatment are as low as 1-2% [27,29].  
 
In active BU disease, a protective cloud of mycolactone around the mycobacterial 
clusters is thought to both destroy infiltrating leukocytes and hinder them from 
passing pro-inflammatory signals to other cells. It is most likely, but still remains to be 
formally proven, that mycolactone production is reduced or abolished early after the 
onset of R/S chemotherapy due to impairment of mycolactone synthesis, bacterial 
growth arrest and/or bacterial cell death, reflected by ‘beaded’ appearance of AFBs 
(MT Ruf; unpublished results). Declining toxin levels allow leukocytes to reach the 
extracellular mycobacteria, leading to their phagocytosis and destruction [40]. 
Chronic leukocyte infiltration cumulates in the development of ectopic lymphoid 
structures [20]. After eight weeks of R/S chemotherapy, antigen presenting cells as 
well as B and T lymphocyte foci are found in large numbers inside the BU lesions 
[20] indicating that antigen recognition and processing is leading to active M. 
ulcerans specific immune responses. Vigorous local immune responses during R/S 
treatment may lead in some of the patients to the development of clinical 
deteriorations, ‘paradoxical reactions’ [41]. For this study we conducted detailed 
immunohistochemical analyses of secondary lesions which had occurred at extended 
periods of time after effective R/S treatment at different body sites.  
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Materials and Methods 
 
Ethics statement 
Ethical approval for analyzing patient specimens was obtained from the ethical 
review board of the Ministry of Health of Benin. Written informed consent from the 
guardians of the patients was obtained before surgical specimens were used for 
reconfirmation of BU as well as a detailed immunohistological analysis. 
 
Study participants 
Both patients, two six year old boys, included in this study were laboratory-confirmed 
BU cases with one primary lesion. Both received a combination of rifampicin 
(10mg/kg body weight) and streptomycin (15mg/kg body weight) administered daily 
over 8 weeks at the Centre de Diagnostic et de Traitement de l’Ulcère de Buruli 
(CDTUB) in Pobè, Benin according to the WHO recommendations. Both patients 
developed several new lesions at different parts of the body, 12 - 409 days after 
completion of antibiotic treatment. These lesions were removed by limited excision 
and no additional antibiotic treatment was administered. Excised tissue from a 
number of these new lesions became available for histopathological analysis (Table 
1). Both patients were tested negative for HIV, shistosomiasis, hepatitis B and 
syphilis. Blood values tested and the nutritional status was within the limits typically 
found in children in rural Africa. Only patient 2 presented with a BCG scar.  
 
Histopathological analysis 
Tissue specimens analyzed are listed in Table 1. Samples were fixed in 4% neutral-
buffered paraformaldehyde for 24 h and subsequently transferred to 70% ethanol for 
storage and transport. Afterwards biopsies were dehydrated, embedded in paraffin, 
and cut into 5 µm thin sections. After deparaffinization and rehydration sections were 
either directly stained with haematoxylin/eosin (HE) or Ziehl-Neelsen/methylenblue 
(ZN) according to WHO standard protocols [42] or further processed for 
immunohistochemistry (IHC). For IHC antigen retrieval was performed according to 
standard protocols either with citrate buffer, EDTA buffer or by enzymatic trypsin 
digestion (Dako® Education guide: Immunohistochemical Staining methods). 
Afterwards endogenous peroxidase was inactivated with 0.3% H202 for 20min and 
prevention of unspecific binding was achieved by incubation with blocking serum 
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matching the secondary antibody host. Primary antibodies specific for N-Elastase 
(polymorphonuclear neutrophils [PMNs]; Dako clone NP57), CD3 (T-lymphocytes; 
Dako clone F7.2.38), CD8 (CD8+ T-lymphocytes; Serotec clone 4B11), CD14 
(Monocytes/macrophages; Novocastra clone 7) and CD20 (B-lymphocytes; 
Novocastra clone7D1) were appropriately diluted in phosphate buffered saline (PBS) 
containing 0.1% Tween-20 and added to the slides for 1 h at room temperature or 
over night at 4°C. After incubation with a matching biotin-conjugated secondary 
antibody staining was performed using the Vector NovaRED system. Haematoxylin 
was used as a counter stain. 
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Results 
 
Clinical presentation of BU patients developing secondary skin lesions after 
completion of antibiotic treatment 
In the present report we describe clinical and histopathological observations in two 
BU patients that have developed series of new skin lesions (Table 1) after effective 
anti-mycobacterial chemotherapy.  
 
Patient 1, a six year old boy, presented at the Centre de Diagnostic et de Traitement 
de l’Ulcère de Buruli (CDTUB) in Pobè, Benin with a 15x15cm ulcerated plaque 
lesion at the right forearm and elbow with undermined edges characteristic for BU 
(Figure 1A). First BU symptoms had been noticed eight month before and the lesion 
had been treated afterwards with traditional medication. After admission to the 
hospital clinical diagnosis was confirmed by a positive IS2404 PCR result of a fine 
needle aspirate, whereas culture was negative. As recommended in the WHO 
guidance on the role of specific antibiotics in the management of BU [26] the patient 
received for 8 weeks daily oral rifampicin (10mg/kg body weight) and intramuscular 
streptomycin (15mg/kg body weight). 37 and 65 days after start of this standard R/S 
chemotherapy wound débridement was performed, 18 days after the last excision 
skin grafting was done and 83 days after grafting the primary lesion had healed.  
75 days after completion of chemotherapy a first new ulceration 0,5x0,5 cm (ulcer 1) 
in the axilla of the right arm emerged. After performing some débridement, this lesion 
had healed 35 days later and the patient was discharged from hospital. 275 days 
after completion of chemotherapy the patient was readmitted with a non ulcerated 
fluctuant nodule 1,5x1,5 cm (nodule 1) on the back (Figure 1B), which was excised 
with primary skin closure one day later. 409 days after completion of chemotherapy 
two more lesions developed, a 1,5x1,5 cm nodule (nodule 2) on the thorax (Figure 
1C) and an ulcerated plaque 3x3cm on the right shoulder (ulcer 2) (Figure 1D). Both 
lesions were excised two days after admission. From both lesions specimen taken 
were IS2404 PCR as well as AFB positive, whereas culture was negative. 28 days 
after the surgical intervention, the patient was discharged from hospital. No further 
relapses were observed after 10 months of follow-up (February 2011). 
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Patient 2, also a six year old boy, presented at the CDTUB with a 20x15cm ulcerated 
lesion on the interior side of his right upper leg and knee. Undermined edges as well 
as ‘cotton wool’ appearance of necrotic tissue at the center of the lesion were 
characteristic for BU [42]. Clinical diagnosis was confirmed by positive IS2404 PCR 
results and microscopic detection of AFB in swab samples. Surgical débridement 
was performed 29 days after start of standard R/S chemotherapy followed 10 days 
later by skin grafting. Twelve days after completion of antibiotic treatment, a nodule 
(nodule 1) 2x2 cm; had emerged about 5 cm proximal of the border of the primary 
lesion at the upper right leg and was excised 7 days later. The initial lesion as well as 
the lesion at the excision site had healed 39 days after completion of the antibiotic 
treatment (i. e 57 days after skin grafting) and the patient was discharged from 
hospital. 
One week after discharge (46 days after completion of antibiotic treatment) the 
patient was readmitted with a second nodule (1,5x1,5 cm) located at the lower right 
leg about 15 cm distal of the border of the primary lesion. Again eight days later (54 
days after completion of antibiotic treatment) a third nodule (nodule 3) (3x2 cm) had 
emerged at the upper right leg located 5cm proximal of the initial wound. These two 
nodules were excised 93 days after completion of the antibiotic therapy. While AFB 
staining, as well as IS2404 PCR confirmed the presence of M. ulcerans, both 
nodules were culture negative.  
After surgical excision and healing of the satellite lesions the patient was discharged, 
but re-admitted 176 days after completion of antibiotic treatment with a fourth nodule 
(nodule 4)  2x2cm on the right foot. A minimal surgical intervention was performed 
and the patient was discharged 10 days later and no further relapses were observed 
after 10 months of follow-up (February 2011).  
 
Histopathological features of excised secondary lesions 
Histopathological and immunohistochemical analyses were performed with nodule 1, 
nodule 2 and ulcer 2 from patient 1, and nodule 2 and 3 of patient 2 (Table 1). These 
lesions appeared 275 to 409 days and 46 to 54 days, respectively, after completion 
of chemotherapy. Analysis yielded comparable results for all specimens analyzed. 
Typical data are shown below.  
Features characteristic for BU pathology, such as fat cell ghosts, necrotic soft tissue, 
haemorrhages, and epidermal hyperplasia were present in all specimens analyzed. 
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As shown in Figure 2A, necrotic areas were massively infiltrated with leucocytes, a 
feature, which is characteristic for successfully treated lesions [20].  
Immunohistochemical analysis revealed mixed cellular infiltrations (Region 1) 
composed of large numbers of CD14 positive macrophages/monocytes (Figure 2B) 
and CD3 positive T-cells (Figure 2C). In contrast, intact N-elastase positive 
neutrophils were rare (Figure 2D). As described previously [20], some areas, such as 
the AFB containing region 2 in Figure 2A contained N-elastase positive debris 
(Figure 2E), which appears to represent remains of an early wave of neutrophilic 
infiltration. ZN staining revealed AFBs and globi like structures in the necrotic areas 
in the tissue from nodule 1 of patient 1 and in nodules 2 and 3 of patient 2 (Figure 2F, 
G). AFBs had a ‘beaded’ appearance (Figure 2G), which has been shown to be an 
indicator for loss of viability in the case of M. leprae [43]. 
Clusters of CD20 positive B-cells, another hallmark of ectopic lymphoid tissue 
developing in BU lesions after successful treatment [20], were also found in the 
tissue specimens analyzed. These clusters varied in size ranging from very large 
accumulations forming a band throughout the whole tissue (Figure 3A) to small 
dense B cell accumulations (Figure 3B) surrounded by CD14 positive 
macrophages/monocytes (Figure 3C) and few interspersed CD3 positive T-cells 
(Figure 3D), mostly CD8 negative (Figure 3E), mainly at the border of the dense B-
cell cluster. Higher magnifications confirmed the dense packaging of B-cells (Figure 
3F) and more dispersed distribution of other leucocytes (Figure 3G-H). 
 
In some parts of the lesions small uninfiltrated necrotic areas surrounded by belts of 
leucocytes still remained. Immunohistochemical analyses gave indications for 
sequential infiltration of these areas by different types of leucocytes (Figure 4). 
Necrotic areas were surrounded by an inner dense belt of CD14 positive 
macrophages/monocytes (Figure 4A), which thus seem to constitute the first line of 
infiltration after decline of cytotoxic mycolactone levels. While a belt containing large 
numbers of CD3 positive T-cells representing a second line of infiltration were found 
in direct neighbourhood to the macrophages (Figure 4B), intact N-elastase positive 
neutrophils (Figure 4C) and CD20 positive B-cells (Figure 4D) were comparatively 
rare in these settings. However a strong staining of N-elastase positive neutrophilic 
debris was observed inside the necrotic areas (Figure 4C). Higher magnification 
revealed no intact cells in this location (Figure 4C insert).  
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Discussion 
 
In this report we describe the development of series of new skin lesions in two BU 
patients 12 – 409 days after completion of antibiotic treatment. The newly emerging 
nodules and ulcerations were located either at some distance from the initial lesion at 
the same extremity or at other body locations. Detection of M. ulcerans DNA by 
IS2404 PCR, microscopic detection of AFBs and the presence of histopathological 
features characteristic for BU demonstrated that the new lesions were associated 
with M. ulcerans infection. Degenerated appearance of the AFBs and the presence of 
massive immune cell infiltrates in most parts of the lesions were on the other hand 
characteristic for treated BU lesions [20].  
 
Detailed immunohistochemical analyses showed that residual necrotic areas were 
surrounded by an outer belt of T-lymphocytes and an inner belt of 
macrophages/monocytes with appendices reaching into the necrotic tissue. These 
belts of intact leucocytes seem to reflect ongoing efforts of the immune system to 
resolve the necrotic areas. In contrast, remains of neutrophils found inside the 
necrotic areas seem to be leftovers of early acute neutrophilic infiltration waves. 
These are also observed in early phases of M. ulcerans infection in experimentally 
infected mice (MT Ruf et al., unpublished results). Apart from these residual necrotic 
regions, the destroyed adipose and dermal connective tissue layers showed 
angiogenesis and contained abundant leukocyte infiltrates. It is thought that such 
chronic infiltrates can only develop once the concentration of the cytopathic M. 
ulcerans macrolide toxin mycolactone has diminished [20,44]. Imbedded in the 
diffuse infiltrates, more structured leukocyte accumulations, such as B-cell clusters 
indicative for humoral immune responses [45-47] and first granulomas were found. In 
BU granulomas may function primarily as a place for antigen presentation and 
adaptive immune response, rather than for sequestration of the mycobacteria [20].  
 
Recently O’Brien et al have described the occurrence of paradoxical reaction in two 
Australian BU patients during R/S treatment of BU [41]. After a first clinical 
improvement worsening of the clinical appearance occurred. For one patient 
incomplete excised wound margins showed paradoxical reaction whereas for the 
other patient a more distant secondary lesion opened, before end of treatment was 
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reached. Worsening of lesions motivated a change in the treatment regimen and 
additional surgery. After detailed evaluation, data have been interpreted as immune-
mediated reactions rather than treatment failures, as it has been shown that antibiotic 
therapy for M. ulcerans leads to a reversal of local immunosuppression [20,41,48]. 
The observed vigorous local immune responses are most likely caused by bacterial 
antigens and immunostimulators released from the killed mycobacteria. Similar 
paradoxical reactions have been well described for M. tuberculosis, M. leprae and in 
particular in immunocompromised HIV patients who commence HAART [49-52]. In 
tuberculosis an elevation of the TNF‐α level, stimulated by lipoarabinomanan and 
other lipopolysaccharides present in the cell wall, has been postulated as an initial 
step in the development of paradoxical reaction [53,54]. Limited surgical excision 
may help to resolve paradoxical reactions by reducing the burden of mycobacterial 
antigens and in some clinical settings corticosteroids have been used for down 
regulation of immune responses [55-58]. 
 
In the case of the two patients described here, new lesions developed at prolonged 
periods of time after completion of antibiotic treatment. These lesions may represent 
secondary M. ulcerans infection foci that were already present without clinical signs 
and symptoms during antibiotic treatment and development of new lesions may be 
the consequence of delayed paradoxical reactions. However, in particular the lesions 
that appeared more than one year after completion of antibiotic treatment may also 
have been associated with new infection foci caused by new M. ulcerans infections 
or by mycobacteria that had survived the eight week course of R/S treatment [28,29]. 
These may have been resolved by immune responses primed by the successful 
treatment of the primary lesion. If this is the case, detailed analysis of immune 
responses in more patients developing such secondary lesions may provide 
important insights into immune protection against M. ulcerans and support vaccine 
design [59]. 
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Table 
 
Table 1: Features of skin lesions that emerged after completion of antibiotic 
treatment. Lesions from which tissue samples became available for histopathological 
analysis are written in bold letters. 
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Figures 
 
 
 
 
Figure 1: Clinical presentation of lesions (Patient 1) 
A: Initial ulcerated lesion at the right arm, reaching from the elbow to the forearm. B: 
Nodule1 appearing on the back, 275 days after end of antibiotic treatment. Both, 
nodule 2 on the thorax (C) and an ulcerated plaque on the right shoulder (D) had 
appeared 409 days after completion of antibiotic treatment. 
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Figure 2: Histopathological presentation of secondary lesions  
Histological sections (nodule 2 of patient 2) were stained either with Ziehl-Neelsen 
(counterstain methylenblue; A, F, G) or with antibodies against cell surface or 
cytoplasmic markers (counterstain haematoxylin; B-E). A: Overview over excised 
tissue specimen revealing typical BU pathology features like fat cell ghosts, necrosis, 
epidermal hyperplasia and AFB (region 2) as well as a strong mixed infiltration 
typically observed in successfully treated BU lesions (region 1). B: CD14 staining of 
macrophages/monocytes; C: CD3 staining of T-cells; D: Elastase staining of 
neutrophils.  In the necrotic region 2 large numbers of elastase-positive neutrophilic 
debris (E) and small clumps of AFB (F) with a beaded appearance (G) were 
observed. 
Chapter 5. Chemotherapy of Buruli ulcer 
 
89
 
 
Figure 3: Presence of B-cell clusters in the secondary lesions 
A: Band of CD20 positive B-cells in sections of ulcer 2 of patient 1. B-E: serial 
sections of nodule 3 of patient 2 with a small dense cluster of CD20 positive B-cells 
(B) surrounded by CD14 positive macrophages/monocytes (C) and few interspersed 
CD3 positive T-cells (D) from which the majority was CD8 negative (E). Higher 
magnification (F-I) revealed a very dense package of the B-cells.  
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Figure 4: Bands of leucocytes surrounding an uninfiltrated necrotic area 
Serial sections of nodule 2 of patient 1 with a necrotic area surrounded by a belt of 
CD14 positive monocytes/macrophages (A) and a more external second belt of CD3 
positive T-cells (B). The necrotic core contained N-elastase positive neutrophilic 
debris (C), but no intact neutrophils (D insert). Clusters of CD20 positive B-cells were 
found away from the necrotic core (D). 
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Abstract 
 
Mycobacterium ulcerans infection is responsible for severe skin lesions in sub-
Saharan Africa. We enrolled 30 Beninese patients with Buruli ulcers in a pilot study to 
evaluate efficacy of an oral chemotherapy using rifampicin plus clarithromycin 
during an 8-week period. The treatment was well tolerated, and all patients were 
healed by 12 months after initiation of therapy without relapse. 
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Introduction 
 
Mycobacterium ulcerans is the causative agent of Buruli ulcer, an emerging tropical 
disease marked by devastating skin lesions [1]. Buruli ulcer affects mainly children in 
rural areas, where access to health care is often delayed and where lengthy hospital 
stays are problematic. Until recently, surgery was the only treatment for Buruli ulcer. 
Significant progress has been made in the past 5 years with the demonstration of the 
efficacy of rifampicin plus streptomycin (R + S) chemotherapy [2]. Its routine 
implementation has dramatically improved healing while reducing the frequency of 
relapses [3]. However, streptomycin is an injectable drug, and the lack of an 
efficacious oral treatment remains one of the main obstacles to decentralizing care at 
local level.  
A recently published randomized controlled trial from Ghana showed no significant 
difference in the proportion of patients who achieved cure after receiving the World 
Health Organization (WHO)–recommended 8-week course of R + S chemotherapy, 
compared with the proportion who achieved cure after receiving a treatment 
consisting of 4 weeks of R + S followed by 4 weeks of rifampicin + clarithromycin 
(R + C) [4].  
This study represents a significant step to improve Buruli ulcer treatment. Indeed, 
clarithromycin is orally administered and is better tolerated than streptomycin, which 
requires daily injections and is associated with adverse events, such as vestibular 
toxicity (which occurs in 0.5%–5% of patients) and nephrotoxicity (which occurs in 
5%–10%) [5]. A clarithromycin-based oral treatment would be more easily 
administered, better accepted by patients, and contribute to limiting the number of 
injections in the developing world [6]. Implementation of an oral R + C 
chemotherapy is supported by recent evidence of its bactericidal activity in vivo [7, 8] 
and by several clinical successes [9, 10].  
Here, we report a pilot study involving 30 patients with Buruli ulcer disease treated 
using an oral combination of rifampicin and clarithromycin over an 8-week period. All 
patients were successfully healed, and no adverse event was observed.  
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Materials and Methods 
 
This study was realized at the Centre de Diagnostic et de Traitement de l'Ulcère de 
Buruli (CDTUB) in Pobè, Benin. Eligible patients had laboratory-confirmed cases of 
Buruli ulcer, were at least 5 years of age, presented with lesions ≤10 cm in diameter 
that had appeared within the past 6 months, agreed to be hospitalized during 
treatment, and were likely to be followed up for 18 months (i.e., had stable 
habitation). Written informed consent was obtained from the patient and from the 
patient’s parent or guardian if the patient was under 18 years of age.  
Noninclusion criteria were lesions >10 cm in diameter, multiple lesions, lesions 
located over a joint, history of treatment with antimycobacterial drugs, receipt of 
macrolide or quinolone antibiotics during the previous month, allergy to rifampicin or 
clarithromycin, pregnancy, or human immunodeficiency virus infection. All 
nonincluded patients were treated according to WHO guidelines.  
The primary end point was defined as healing of the wound at 12 months, without 
recurrence 18 months after initiation of chemotherapy. Patients were treated using an 
oral combination of rifampicin (10 mg/kg) and clarithromycin (12 mg/kg) administered 
simultaneously, once daily, over 8 weeks.  
During treatment, patients were hospitalized and attended daily by nursing staff, who 
dispensed chemotherapy with a fatty snack and monitored patients for adverse 
effects during a 1-h period after treatment intake. Clarithromycin was administered as 
250-mg tablets completed with syrup to achieve exact dose. Nursing staff cleansed 
the wound using physiological solution and renewed the wound dressing using 
simple sterile dressings. Every week, patients were examined by a doctor, who also 
collected samples at week 4, 6, and 8 if the lesion had not healed, using swabs or 
aspiration. These samples were sent for M. ulcerans culture and polymerase chain 
reaction (PCR) analysis. After the wound closed, patients were discharged from the 
hospital and were followed-up every 3 months up to 18 months after starting 
treatment.  
Limited surgery was defined as curettage of the lesion or a minor excision to remove 
excess granulation tissue and to debride ulcer margins. Extensive surgery was 
defined as major excision followed by skin-grafting. Surgery was undertaken if: (1) no 
improvement or an aggravation of the lesion characteristics was observed at week 4 
of chemotherapy or after, (2) induration persisted 12 weeks after initiation of 
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chemotherapy, (3) the lesion started bleeding at any time, or (4) the lesion showed 
signs of improper scaring and risks of functional incapacities at any time. Excised 
tissue was sent for histological analysis, as well as M. ulcerans culture and PCR.  
All biological samples were collected and handled identically according to WHO 
guidelines. Blinded analysis of samples was performed at the laboratory in Angers, 
France, along with routine microbiological analyses for the CDTUB.  
Ethical approval for this study was given by the Ministry of Health in Benin. Technical 
approval was given by the WHO Buruli ulcer working group on chemotherapy.  
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Results 
 
Patients were enrolled consecutively from December 2007 through February 2009. 
Included patients represented one-third of eligible patients who received a diagnosis 
during this period. The main reason for nonparticipation was refusal of 
hospitalization. Twelve of the patients were male, and 18 were female; 11 were >15 
years of age. Nine patients presented with nonulcerative lesions, and 21 presented 
with ulcerative lesions. Buruli ulcer diagnosis was confirmed by PCR for all patients, 
and 13 patients (43%) had a positive culture result at enrolment.  
Treatment was well tolerated, and no adverse events were reported. All patients had 
reached 18 months of follow-up by September 2010.  
All 30 patients were successfully treated, with complete re-epithelialization of wounds 
12 months after treatment initiation, and no patient experienced relapse during 
follow-up. The median duration of healing was 104 days (range, 30–212 days; see 
Table 1 and supplementary Table 1 for individual data).  
Microbiological follow-up was performed at week 4, 6, and 8 on lesions that remained 
open. Culture results became negative for all sampled patients except 1 after 4 
weeks; no culture was positive after 6 weeks. PCR follow-up of lesions that remained 
open showed that negative PCR results were rarely obtained before scarring 
(supplementary Table 2).  
Among those 30 patients, 15 (50%) healed after chemotherapy without any additional 
intervention (Table 1), and 11 (37%) of the patients underwent limited surgical 
procedures, such as curettage (n = 9) or excision (n = 2). These procedures were 
mainly undertaken without suspicion of failure to promote a faster and more regular 
scaring of lesions presenting excessive granulation or risks of functional incapacities.  
Four patients, 6–8 years of age, underwent extensive surgical excision followed by 
skin grafting. Three patients presented with category 2 lesions that were large for 
their body size and either worsened or showed no improvement (supplementary 
Table 1). One patient who had previously healed without surgery experienced trauma 
at the site of the scar and required secondary extensive surgery.  
As observed in our routine experience of R + S chemotherapy [3], R + C 
chemotherapy was also sufficient to cure most (8 of 10) patients with category 1 
ulcerative lesions and to cure 5 of 11 patients who presented with larger ulcerative 
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lesions. A majority of nonulcerative lesions (7 of 9) required additional surgical 
procedures.  
Tissue specimens were collected from the 15 patients who underwent surgery. Of 14 
samples analyzed in culture, none was positive for M. ulcerans. However, 13 patients 
had a positive PCR result, suggesting persistence of mycobacterial material, as 
described by others [2].  
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Discussion 
 
In this pilot study, 30 patients with confirmed Buruli ulcer disease were successfully 
healed using R+C chemotherapy. Microbiological results indicate that persistence of 
viable mycobacteria was unlikely, even when extensive surgery was required. 
Histological analysis supports this point, showing that 10 of 11 samples analyzed 
presented evidence of massive inflammatory infiltration. Local inflammatory reactions 
and the development of ectopic lymphoid tissue have been observed in Buruli ulcer 
lesions during healing while receiving chemotherapy [11, 12]. This most likely results 
from mycobacterial antigens and immunostimulators released during chemotherapy. 
In our experience, as confirmed by others [13], this reaction is associated with good 
response to treatment and occurs irrespective of the chemotherapy used (A.C., 
unpublished data).  
We advocate that additional chemotherapy efficacy studies should rely on an 
improved definition of treatment failure that includes microbiological evidence of 
viable, treatment-resistant mycobacteria and histological assessment of inflammatory 
reaction. Clinical criteria do not provide a clear rule to discriminate between patients 
who experience chemotherapy failure and patients who successfully clear the 
infection but require surgery to expedite the healing process.  
In the Ghanaian trial, treatment failure was defined according to clinical criteria, such 
as lesion size progression or the need for extensive surgery, for all but one of the 
patients who experienced treatment failure [4]. The subjective component of such 
clinical criteria makes it difficult to compare results across different studies. In our 
study, 3 patients required extensive surgery, but none presented persistence of 
viable mycobacteria.  
Positive cultures were obtained in Ghana after treatment completion in 5 patients 
who belonged to the 4 weeks of R + S followed by 4 weeks of R + C arm [4]. This 
result is difficult to interpret without information on drug resistance or possible re-
infections. In our study, viable mycobacteria were not observed after 6 weeks of 
treatment. We hypothesize that our higher dosage of clarithromycin was more 
efficient at clearing the infection, without causing more adverse effects.  
In conclusion, this study provides compelling evidence to support a future 
randomized controlled trial that compares the standard regimen (8 weeks of R + S) 
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with the complete oral regimen (8 weeks of R + C). Proving the efficacy of the 
R + C combination could lead to a simpler, less invasive, and less painful treatment 
that is easier to implement at the local level. Surgery is likely to remain necessary for 
severe lesions, but a large proportion of patients can be cured through oral 
chemotherapy alone, which is a great boon to the rural communities most affected by 
Buruli ulcer.  
 
 
Acknowledgements 
 
We thank the patients who participated in this study and their families and 
communities, as well as M. Vray, A. Fontanet, and S. Dalglish, for critical reading and 
helpful discussions while writing this article.  
Financial support. Fondation Raoul Follereau and Institut National de la Santé et de 
la recherché Médicale (Inserm).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. Oral treatment for M.ulcerans 
 
106
Table 
 
Table 1: Outcome and Additional Care received in 30 Patients with Buruli Ulcer 
Disease Treated with Oral Rifampicin plus Clarithromycin (R + C) Chemotherapy 
over an 8-Week Period 
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Abstract 
 
The highly immunogenic mycobacterial proteins ESAT-6, CFP-10, and HspX 
represent potential target antigens for the development of subunit vaccines and 
immunodiagnostic tests. Recently, the complete genome sequence revealed the 
absence of these coding sequences in Mycobacterium ulcerans, the causative agent 
of the emerging human disease Buruli ulcer. Genome reduction and the acquisition 
of a cytopathic and immunosuppressive macrolide toxin plasmid are regarded as 
crucial for the emergence of this pathogen from its environmental progenitor, 
Mycobacterium marinum. Earlier, we have shown the evolution of M. ulcerans into 
two distinct lineages. Here, we show that while the genome of M. marinum M 
contains two copies of the esxB-esxA gene cluster at different loci (designated 
MURD4 and MURD152), both copies are deleted from the genome of M. ulcerans 
strains belonging to the classical lineage. Members of the ancestral lineage instead 
retained some but disrupted most functional MURD4 or MURD152 copies, either by 
newly identified genomic insertion-deletion events or by conversions of functional 
genes to pseudogenes via point mutations. Thus, the esxA (ESAT-6), esxB (CFP-
10), and hspX genes are located in hot-spot regions for genomic variation where 
functional disruption seems to be favoured by selection pressure. Our detailed 
genomic analyses have identified a variety of independent genomic changes that 
have led to the loss of expression of functional ESAT-6, CFP-10, and HspX proteins. 
Loss of these immunodominant proteins helps the bacteria bypass the host's 
immunological response and may represent part of an ongoing adaptation of M. 
ulcerans to survival in host environments that are screened by immunological 
defence mechanisms. 
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Introduction 
 
The emerging pathogen Mycobacterium ulcerans is the causative agent of Buruli 
ulcer, a mycobacterial disease of skin and soft tissue with the potential to leave 
sufferers scarred and disabled. While it is endemic in more than 30 countries (26), 
the major disease burden falls on children living in poor rural communities of West 
Africa. Buruli ulcer is prevalent in areas neighbouring rivers, slow-flowing waters, and 
swamps, but the exact mode of transmission has remained elusive. This is partly 
attributable to a clonal population structure and an associated lack of high-resolution 
genetic fingerprinting methods for microepidemiologic studies. 
M. ulcerans seems to have recently evolved via lateral gene transfer and reductive 
evolution from the fish disease-causing environmental species Mycobacterium 
marinum (40, 43). Particularly, it has acquired the virulence plasmid, pMUM001, 
encoding the genes for the synthesis of the macrolide toxin, mycolactone. This toxin 
has cytopathic and immunomodulatory properties and plays a decisive role in 
producing an extracellular infection after an initial phase within macrophages (4, 41, 
42, 47). In addition, M. ulcerans has undergone extensive gene loss due to DNA 
deletions, DNA rearrangements, and pseudogene formation, which apparently drives 
its evolution toward a niche-adapted specialist (27, 34, 39). Previous findings suggest 
that M. ulcerans lineages from different geographic areas reveal variations in 
virulence (27, 32; also F. Portaels, unpublished data). 
The ESX-1 secretion system is required for the virulence of Mycobacterium 
tuberculosis and related pathogenic mycobacteria. It comprises the 6-kDa early 
secretory antigenic target protein (ESAT-6) and the 10-kDa culture filtrate protein 
(CFP-10), which are among the strongest T-cell response elicitors in tuberculosis 
patients (7, 8). The genes encoding these proteins are localized on the region of 
difference 1 (RD1) locus, which is intact in virulent members of the M. tuberculosis 
complex but absent from the attenuated vaccine strain Mycobacterium bovis BCG 
(ΔRD1BCG) (21, 29). Similarly, the vole bacillus, Mycobacterium microti, was found to 
have a natural deletion (ΔRD1microti) overlapping the deletion ΔRD1BCG (6, 18). The 
so-called extended RD1 encompasses most of the genes that form the ESX-1 
secretion apparatus (7, 16, 17) or are crucial for both ESAT-6/CFP-10 secretion and 
virulence (7, 17, 19, 31). This secretion apparatus enhances virulence in M. 
tuberculosis and M. marinum infection by secretion of effector proteins into the 
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cytosol of infected macrophages (37), prevention of phagolysosomal maturation (28, 
45), and cytolytic activity (24). On the other hand, infected individuals develop strong 
T-cell responses against these proteins, which seem to be relevant for immune 
protection (8). The 16-kDa heat shock protein HspX, or α-crystallin-like protein Acr, a 
dominant protein expressed during static growth in M. tuberculosis, is required for 
mycobacterial persistence within the macrophage. HspX is yet another potent 
immune response elicitor and suitable for detecting M. tuberculosis infection (14, 15, 
20, 25, 35, 49). 
In mycobacterial disease control, highly antigenic proteins serve both as targets for 
diagnostic tests and as candidate proteins for vaccine development (1, 8, 30). While 
being present in the sequenced M. marinum strain M (http://www.sanger.ac.uk/cgi-
bin/BLAST/submitblast/m_marinum), genes encoding ESAT-6, CFP-10, and HspX 
are absent from the genome of the sequenced Ghanaian M. ulcerans strain Agy99 
(http://genopole.pasteur.fr/Mulc/BuruList.html). However, earlier data showed that 
some M. ulcerans isolates and other related mycolactone-producing mycobacteria 
harbour at least segments of these genes (32, 48). Recently, we have identified two 
distinct genetic lineages of M. ulcerans, with representatives of the ancestral lineage 
being phylogenetically closer to its progenitor, M. marinum, than members of the M. 
ulcerans classical lineage (27). Here, we have analyzed a worldwide collection of M. 
ulcerans strains belonging to these two lineages for the presence of esxA, esxB, and 
hspX and their surrounding genomic regions. 
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Materials and Methods 
 
Mycobacterial strains and genomic DNA extraction.  
M. marinum strain M was used for interspecies comparison. A worldwide strain 
collection of M. ulcerans had been used earlier for investigation of genomic strain 
variations (34). Although several attempts to differentiate these strains achieved only 
low resolution (2, 3, 11, 22, 23, 38, 44), this collection of patient isolates was shown 
to be divided in two lineages displaying major genomic differences (27). In this study, 
we used M. ulcerans clinical isolates of both lineages as follows. For the classical 
lineage, the following strains were used: Ghana Agy99, Ghana ITM (Institute of 
Tropical Medicine, Antwerp, Belgium) 970321, Ghana ITM 970359, Ghana ITM 
970483, Ivory Coast ITM 940662, Ivory Coast ITM 940815, Ivory Coast ITM 940511, 
Benin ITM 970111, Benin ITM 940886, Benin ITM 940512, Benin ITM 970104, 
Democratic Republic of Congo (DRC) ITM 5150, DRC ITM 5151, DRC ITM 5155, 
Togo ITM 970680, Angola ITM 960657, Angola ITM 960658, Papua New Guinea 
(PNG) ITM 941331, PNG ITM 9537, Malaysia ITM 941328, Australia ITM 941324, 
Australia ITM 941325, Australia ITM 941327, Australia ITM 9549, Australia ITM 9550, 
Australia ITM 8849, Australia ITM 940339, Australia ITM 5142, and Australia ITM 
5147. For the ancestral lineage, the following strains were used: China ITM 980912, 
Japan ITM 8756, French Guiana ITM 7922, Surinam ITM 842, and Mexico ITM 5143. 
The presence of the specific PCR products obtained with primer pairs CH5/CH4 and 
CH3/CH4 (that exclude each other by design) (see Fig. 1) occurred concomitantly in 
strains DRC ITM 5151 and PNG ITM 941331. Since also variable-number tandem 
repeat typing analysis indicated that these strains are impure, we excluded these 
strains from further analysis. 
Bacterial pellets of about 60 mg (wet weight) were heat inactivated for 1 h at 95°C in 
500 μl of extraction buffer (50 mM Tris-HCl, 25 mM EDTA, 5% monosodium 
glutamate) and sequentially treated with 17 M lysozyme (for 2 h at 37°C) and 0.3 M 
proteinase K in proteinase K buffer (1 mM Tris-HCl, 5 mM EDTA, 0.05% sodium 
dodecyl sulfate, pH 7.8; overnight at 45°C). After digestion, the samples were 
subjected to bead-beater treatment (7 min at 3,000 rpm; Mikro-Dismembrator; B. 
Braun Biotech International, Melsungen, Germany) with 300 μl of 0.1-mm zirconia 
beads (BioSpec Products, Bartlesville, OK). DNA was extracted from the 
supernatants by phenol-chloroform (Fluka, Buchs, Switzerland) extraction and 
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subjected to ethanol precipitation. DNA concentration was measured by determining 
the optical density at 260 nm (GeneQuant spectrophotometer; Pharmacia Biotech, 
Cambridge, United Kingdom). 
 
DNA methods.  
PCR was performed using FirePol 10× BD buffer and 0.5 μl of FirePol Taq 
polymerase (Solis BioDyne, Tartu, Estonia), 2.5 ng of genomic DNA or the equivalent 
volume of nuclease-free water as a negative control, a 0.6 μM concentration of each 
forward and reverse primer, 1.7 mM MgCl2, and a 0.3 mM concentration of each 
deoxynucleoside triphosphate in a total volume of 30 μl. PCRs were run in a 
GeneAmp PCR system 9700 PCR machine. The thermal profile for PCR 
amplification of M. ulcerans genomic DNA included an initial denaturation step of 95 
to 98°C for 5 min, followed by 32 cycles of 95°C for 20 s, annealing at 58 to 65°C for 
20 s, and elongation at 72°C for 30 s up to 4 min. The PCRs were finalized by an 
extension step at 72°C for 10 min. For experiments with more than 30 samples, Hot 
Star Taq (Qiagen AG, Hombrechtikon, Switzerland) was used according to the 
manufacturer's protocol. In order to retrieve PCR products that were subsequently 
subjected to sequencing, iProof high-fidelity DNA polymerase (Bio-Rad Laboratories, 
Hercules, CA) was used. PCR products were analyzed on 1 to 2% agarose gels by 
gel electrophoresis using ethidium bromide staining and the AlphaImager illuminator 
and AlphaImager software (Alpha Innotech, San Leandro, CA). Primers as 
summarized in Table 1 were designed using the Primer3 program 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). PCR fragments produced 
for analysis of unknown genomic sequences were purified using a NucleoSpin 
purification kit (Macherey-Nagel GmbH & Co. KG, Düren, Germany) and subjected to 
direct sequencing or cloned using a TOPO TA cloning kit (Invitrogen Corp., Carlsbad, 
CA), transformed into JM109 (Sigma Aldrich, Buchs, Switzerland) bacterial cells, and 
sequenced after DNA preparation (Miniprep Kit; Sigma Aldrich, Buchs, Switzerland). 
Variable-number tandem repeat typing analysis undertaken for confirmation of strain 
identities was performed according to the method of Stragier et al. (44). Sequencing 
was performed using a BigDye kit and an ABI Prism 310 genetic sequence analyzer 
(Perkin-Elmer, Waltham, MA). All gene sequences were reproduced and subjected to 
alignment and comparison with an ABI Prism Autoassembler, version 1.4.0 (Perkin-
Elmer, Waltham, MA). 
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Data analyses and bioinformatics.  
Retrieved sequences were compared to the BuruList (http://genopole.pasteur.fr/Mulc 
/BuruList.html) and the M. marinum (http://www.sanger.ac.uk/cgi-bin/BLAST/   
submitblast/m_marinum) BLAST servers and analyzed using the Sequence 
Manipulation Suite (http://bioinformatics.org/sms/index.html), the sequence alignment 
tool BLAST 2 sequences (http://www.ncbi.nlm.nih.gov/BLAST/bl2seq/wblast2.cgi), 
the multiple sequence alignment website Multalin (http://bioinfo.genopole-
toulouse.prd.fr/multalin/multalin.html), and the Artemis software program, release 9 
(The Wellcome Trust Sanger Institute, Hinxton, United Kingdom) (36). The 
sequences for M. tuberculosis were retrieved from the following Web page: 
http://www.sanger.ac.uk/Projects/M_tuberculosis. Linear genomic comparison was 
performed using the Artemis comparison tool software, release 6 (9). 
 
Nucleotide sequence accession numbers.  
The sequences of the indicated genes from M. ulcerans strains have been deposited 
in the GenBank database (http://www.ncbi.nlm.nih.gov/GenBank/index.html) under 
the following accession numbers (the associated protein is shown in parentheses): 
for hspX (HspX), accession numbers EU257156, EU257157, EU257158, EU257159, 
and EU257160; for esxA (ESAT-6), accession numbers EU257151, EU257152, 
EU257153, EU257154, and EU257155; and for esxB (CFP-10), accession numbers 
EU257146, EU257147, EU257148, EU257149, and EU257150. Accession numbers 
correspond to genes from the Japan 8756, China 980912, Surinam 842, French 
Guiana 9722, and Mexico 5143 strains, in respective order. Note that the annotated 
hspX gene in M. ulcerans Agy99 is an orthologue of M. tuberculosis htpX and that 
the M. tuberculosis hspX orthologue is not present in strain Agy99. 
 
 
 
 
 
 
 
 
Chapter 7. Loss of immunogenic proteins in M.ulcerans 
 
116
Results 
 
Presence of esxB-esxA in M. ulcerans strains of the ancestral lineage.  
Blast searches of the partially annotated genome of M. marinum M 
(http://www.sanger.ac.uk/cgi-bin/BLAST/submitblast/m_marinum) showed that this 
strain contains two copies of the esxB-esxA (CFP-10-ESAT-6) gene cluster. Both 
copies are deleted from the genome of the African M. ulcerans isolate Agy99 (43). 
The corresponding two RDs between the genome sequences of the two 
mycobacterial species have been designated MURD152 (M. marinum genome 
position 6489253 to 6592034) and MURD4 (M. marinum genome position 218302 to 
230285) (43). 
Compared to M. marinum M, the M. ulcerans Agy99 genome has a 2.8-kb deletion in 
MURD152, which is associated with a large inversion at the 5′ end of the deletion 
(Fig. 1A). To test whether all M. ulcerans lineages share this genome constellation in 
MURD152, we screened a comprehensive M. ulcerans strain collection of worldwide 
origin by PCR analysis using a primer pair (CH3 and CH4) that yields a PCR product 
of 162 bp only when MURD152 is deleted and flanked by the inverted sequence (Fig. 
1A and B). Whereas members of the ancestral lineage (strains from Asia, South 
America, and Mexico) were negative, members of the classical lineage (strains from 
Africa, Papua New Guinea, Malaysia, and Australia) were positive, except for strain 
Australia 9549, which has a larger deletion in this region (see below). Likewise, a 
PCR using a primer pair (CH8 and CH9) specific for the sequence constellation of 
strain Agy99 in MURD4 revealed a PCR product of 1,712 bp only for representatives 
of the classical and not for members of the ancestral lineage (Fig. 1B), demonstrating 
genomic diversity between the two M. ulcerans lineages in this locus. 
A PCR with primers (CH1 and CH2) corresponding to the 5′ end of the esxB coding 
sequence and the 3′ end of the esxA coding sequence (Fig. 1A) yielded a PCR 
product of the expected size of 610 bp with genomic DNA from the M. marinum 
control and in all M. ulcerans strains belonging to the ancestral lineage (Fig. 2). 
Primers corresponding to the flanking regions of either the MURD4- or the 
MURD152-associated esxB-esxA gene cassette were used to determine the 
localization of this cluster in the genomes of these M. ulcerans strains (Fig. 2). 
Results indicated that esxB-esxA of the Asian and South American strains is located 
in MURD152, whereas in the Mexican strain the gene cluster is located in MURD4 
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(Fig. 2). These localizations were verified by PCR analyses extending several 
kilobases further into the flanking regions. While in the Asian and South American 
haplotypes the respective M. marinum MURD152 genome constellations were found, 
the cluster was flanked in the case of the Mexican haplotype by the MURD4-
associated sequences of M. marinum. 
 
Unique deletions in MURD152 in strains 5143 from Mexico and 9549 from 
Australia.  
While MURD152 esxB-esxA is deleted from Mexican strain 5143 (Fig. 2), no PCR 
product specific for the MURD152 constellation of the strains belonging to the 
classical lineage was obtained with primers CH3 and CH4 (Fig. 1B), giving evidence 
for a larger deletion. A PCR analysis with primers corresponding to different positions 
of the genomic sequences flanking MURD152 demonstrated that the Mexico 5143 
strain has a deletion (Fig. 3, ΔRD13A) that is replaced by an IS2404 element. This 
insertion-deletion (indel) event can have occurred either from an M. marinum M-like 
genome constellation or from an M. ulcerans Agy99-like constellation (loss of 41.8 kb 
or of 8 kb, respectively). The DNA sequences flanking ΔRD13A in the Mexican strain 
have a slightly higher identity to the corresponding sequence stretches of M. ulcerans 
Agy99 than to those of M. marinum M (98% versus 94% over 986 bp). 
Failure to obtain a PCR product with both the CH1/CH2 and the CH3/CH4 PCR 
primers for the Australian strain 9549 (Fig. 1) provided evidence for yet another 
deletion type within the MURD152 region. PCR analysis using primers located in the 
sequences flanking the corresponding region in the M. ulcerans Agy99 genome led 
to the characterization of a deletion of 13,662 bp including an IS2404 element on 
each of the ends of the deleted DNA segment (Fig. 3, ΔRD13B). The deleted DNA 
stretch was, in strain Australia 9549, replaced by an IS2404 element that, according 
to sequence analysis, differed from both versions of IS2404 in Agy99 that were 
deleted in the ΔRD13B deletions. 
 
Sequence variation in ESAT-6 and CFP-10.  
PCR products obtained with primers corresponding to MURD locus-specific flanking 
regions and comprising the respective esxB-esxA clusters (Fig. 2) were sequenced. 
Deduced amino acid sequences of all versions of M. ulcerans ESAT-6 and CFP-10 
encoded in MURD4 (Mexico 5143) or MURD152 (South American and Asian strains) 
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were compared with the M. marinum M sequences in the two loci (Fig. 4; see also 
the supplemental material). As expected, the translated ESAT-6 amino acid 
sequence of the Mexican strain clustered to and was identical with the MURD4-
associated M. marinum M sequence (Fig. 4B). While the four MURD152-associated 
M. ulcerans ESAT-6 sequences of the Asian and the South American strains were 
identical to each other, their amino acid sequences differed at six positions from the 
MURD152-associated M. marinum sequence but only at two positions from the 
MURD4-associated M. marinum sequence (Fig. 4B). At the nucleotide level, the esxA 
genes of the Asian and South American strains appear as hybrids composed of an 
M. marinum MURD4 sequence stretch at the 5′ end and a MURD152 stretch at the 3′ 
end. 
The two M. marinum esxB genes differed only at three nucleotide positions at the 5′ 
end (Fig. 4A), encoding CFP-10 proteins with identical deduced amino acid 
sequences (Fig. 4B). The esxB gene of the Mexican strain differed at four positions 
from the M. marinum M MURD4 locus but at only one position from the MURD152 
locus. While the esxB gene sequences of the South American M. ulcerans strains 
were identical to the MURD152-associated sequence, a frameshift mutation has 
converted esxB of the Asian strains to a pseudogene (Fig. 4B). 
 
Lack of the immunodominant HspX/Acr protein in the classical lineage of M. 
ulcerans.  
Next, we screened the worldwide M. ulcerans strain collection for the presence of the 
coding sequence (CDS) encoding the immunogenic protein HspX (Acr) located in 
MURD92 (M. marinum genome position 4271366 to 4313737) (43). Using primers 
(CH14 and CH15) corresponding to the hspX flanking regions, a PCR product of 791 
bp comprising the complete hspX gene was obtained for all members of the ancestral 
lineage but for none of the strains belonging to the classical lineage (not shown). 
Instead, amplification of a 469-bp PCR product (primers CH16 and CH17) obtained 
with a complementary PCR again demonstrated the presence of the Agy99 genome 
constellation (related to the MURD92 deletion) in all members of the classical 
lineage. While strains coming from the same geographical area had identical gene 
sequences, Asian and South American sequences differed slightly from each other 
and from the M. marinum sequence (Fig. 5A; see also the supplemental material). In 
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the case of the Mexican strain, nucleotide insertions resulted in a frameshift mutation 
leading to a truncated translation product (Fig. 5B). 
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Discussion 
 
The M. tuberculosis proteins ESAT-6, CFP-10, and HspX are strong T- and B-cell 
immunogens. This makes them suitable targets for immunodiagnostic tests (7, 8, 14, 
15, 20) and potentially also for subunit vaccine development (1, 30, 35). These 
approaches cannot be duplicated for Buruli ulcer, since these proteins are not 
expressed by classical-lineage M. ulcerans strains that are found in areas of 
endemicity in Africa and Australia and are responsible for the vast majority of clinical 
cases worldwide. 
The genome of the M. marinum strain M harbours two esxB-esxA gene clusters at 
distant chromosomal locations, one in MURD4 and the other in MURD152. Such 
duplications are common for proteins of the Esx protein family (46). In this report we 
demonstrate that all analyzed M. ulcerans strains belonging to the ancestral lineage 
have lost only one copy of the esxB-esxA cassette: the Asian and South American 
strains have lost the MURD4 copy and the Mexican strain has lost the MURD152 
copy. Furthermore, a frameshift mutation has converted the remaining esxB gene of 
the Asian strains to a pseudogene. The basis for the high degree of identity of the N-
terminal esxA nucleotide sequence located in the MURD152 locus in the South 
American and Asian haplotypes with the M. marinum MURD4 sequence is unclear, 
but the finding implies a history of homologous recombination between the two 
copies of the esxB and esxA genes before loss of the MURD4 region. Members of 
the classical lineage have lost both copies, probably in a bottleneck situation that 
forged this lineage. 
Since MURD152, MURD92, and MURD4 show genomic differences not only 
between M. marinum and M. ulcerans but also within M. ulcerans strains, we 
designated these RDs RD13, RD14, and RD15, respectively, in continuation of the 
previously assigned RDs within the species M. ulcerans (34). A detailed alignment of 
the chromosomal organization in RD13, which corresponds to RD1 in M. 
tuberculosis, is shown in Fig. 3. These RDs represent hot spots of genetic variation 
potentially suitable for performing genetic fingerprinting of M. ulcerans. 
In addition to the previously identified five M. ulcerans indel haplotypes (27, 34), 
strain Australia 9549 was identified as representing a sixth indel haplotype, which is 
defined by ΔRD13B. 
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In MURD152 alone, at least three different deletion events are responsible for the 
indel diversity within M. ulcerans (Table 2). When this region was analyzed for 
variations among a collection of mycolactone-producing mycobacteria, an unclear 
situation was suggested for a Mexican strain (48). Here, we show that the deletion of 
8 kb replaced by an IS2404 element (ΔRD13A) in the Mexican strain (or 41.8 kb with 
respect to the M. marinum backbone) differs from the MURD152 deletion in Agy99. 
This deletion is independent of yet another extended deletion of 13.7 kb (ΔRD13B) in 
this genomic region in the Australia 9549 strain. The latter deletion is also replaced 
by an IS2404 element and displays a second, large sequence polymorphism within 
Australian isolates in addition to the previously described RD3 (27, 34). It will be 
worth investigating the distribution of this indel polymorphism within a collection of 
Australian M. ulcerans isolates using the primer pair combination CH10/CH11, 
demonstrating the presence of the ΔRD13B deletion, and both CH10/CH12 and 
CH13/CH11, displaying positive results for strains with the sequence configuration of 
Agy99 (Fig. 3). 
The described deletions also encompass CDSs surrounding the esxA, esxB, and 
hspX genes, indicating loss or modification of molecular apparatuses or pathways. 
First, PE35, essential for secretion (7), was lost in both MURD152 and ΔRD13A and 
is also commonly deleted in ΔRD1BCG and ΔRD1microti (Fig. 3). Second, many of the 
genes of the ESX-1 secretion system (the genes Rv3866/MMAR_5441 through 
Rv3881/MMAR_5457/espB, corresponding to the extended RD1 region) are equally 
affected by deletions ΔRD13A and/or MURD151 through MURD153, namely, the 
AAA protein family members Rv3868/MMAR_5443, Rv3871/MMAR_5446, and 
Rv3877/MMAR_5452 (7, 17, 19). Members of the classical lineage omit an 
MMAR_5457 orthologue in MURD153, which was recently described as a secreted 
product and renamed espB (31). Also in MURD92, hspX was jointly deleted with the 
co-regulated Rv2032/nitroreductase gene (33). 
As for ESAT-6 and CFP-10, we also found for HspX different genetic mechanisms 
that have led to loss of expression, comprising both deletions of genomic sequences 
and single-base differences (Table 2). Many of the sequence variations across the M. 
ulcerans haplotypes that led to the loss (of function) of these highly immunogenic 
proteins appear to have emerged independently of each other. This may indicate a 
counterselection for expression of these proteins. HspX seems to be a negative 
growth regulator involved in hypoxic shift-down to promote the non-replicating 
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persistence of M. tuberculosis (15, 20, 25). Both ESAT-6 and CFP-10 were shown to 
be virulence factors of M. tuberculosis, and their loss reduces infectivity due to the 
dysfunction of the ESX-1 secretion apparatus (5, 10, 12, 13). The mycolactone-
producing and largely extracellular M. ulcerans has a profoundly different survival 
strategy in mammalian hosts than the intracellular M. tuberculosis; therefore, it is 
most likely that the pathogenicity of M. ulcerans for mammalian hosts is due to other 
virulence factors. Thus, our data suggest that functional disruption or complete loss 
of major targets of the immune response may confer a selective advantage to this 
emerging pathogen. Still, it is currently unclear whether pathogenicity for mammalian 
hosts, i.e., shedding into the environment from chronic wounds, contributes 
significantly to the survival of the species M. ulcerans. However, the observed loss of 
expression of highly immunogenic proteins caused by a variety of genomic changes 
may represent an indication that immune selection plays a role in the adaptation of 
M. ulcerans to a more stable environment. 
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Tables 
 
Table 1: Primers used in this study and description of respective PCR products 
All primers are listed in 5’-3’ orientation. 
 
 
 
 
 
 
 
 
Table 2: Genomic deletions and amino acid changes in CDSs of immunogenic 
proteins 
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Figures 
 
 
 
Figure 1: Confirmation of the MURD-specific deletions affecting esxB (CFP-10) and 
esxA (ESAT-6) in an M. ulcerans worldwide strain collection. (A) Schematic view of 
an alignment of M. marinum M and M. ulcerans Agy99 genomic sequences displayed 
by the Artemis comparison tool (9). Regions of conformity are shown in parallel gray 
plains, an inverted DNA segment is depicted as an inverted surface, and white areas 
represent unique sequences like MURD152, which is present only in M. marinum M 
and is deleted from M. ulcerans Agy99. Indicated are the genes esxB and esxA and 
the PCR primers (CH1 through CH4) used for this experiment. (B) PCR products of 
162 bp or 1,712 bp proved the MURD152 deletion of 2.8 kb and the MURD4 deletion 
of 12 kb, respectively. 
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Figure 2: Localization of the two esxB-esxA clusters in the genomes of strains of the 
M. ulcerans ancestral lineage. Positions of the corresponding primers are indicated 
for the PCR product of the esxB-esxA cluster, where CH1 and CH2 correspond to 
sequences within the CDSs of both locations, and of the slightly larger PCR products 
amplified with flanking primers specific for either MURD152 or MURD4 (Table 1). 
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Figure 3: Chromosomal organization of CDSs in RD13 including deletional variations 
between M. ulcerans and other mycobacteria. Gene names are indicated for M. 
tuberculosis 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=genomeprj&cmd=Retrieve&dopt=Overv
iew&list_uids=224), M. marinum (http://www.sanger.ac.uk/Projects/M_marinum/), and 
M. ulcerans (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=genomeprj&cmd=Show 
DetailView&TermToSearch=16230), and orthologous genes are aligned. RD13 of M. 
ulcerans corresponds to RD1 in M. tuberculosis. Deletions in M. bovis BCG, M. 
microti, and various M. ulcerans strains are indicated by solid bars as marked 
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Figure 4: Nucleotide variations (A) and amino acid sequence alignments (B) in esxB 
and esxA CDSs and their gene products (CFP-10 and ESAT-6, respectively).  
Position 1 of the nucleotide alignment reflects the start of the gene esxB. For the 
DNA sequences, only differing nucleotides are shown (positions as indicated). For 
whole-sequence alignments, see the supplemental material. Orthologous sequences 
of M. tuberculosis H37Rv and M. bovis AF2122/97 are included in the amino acid 
alignments. 
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Figure 5: Nucleotide variations (A) and amino acid sequence alignments (B) in the 
hspX CDS and its gene product. Position 1 of the nucleotide alignment reflects the 
start of the gene. For the DNA sequences, only differing nucleotides are shown 
(positions as indicated). For whole-sequence alignments see the supplemental 
material. Orthologous sequences of M. tuberculosis H37Rv and M. bovis AF2122/97 
are included in the amino acid alignments. 
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Abstract 
 
Genomic studies on pathogenic and environmental mycobacteria are of growing 
interest for understanding of their evolution, distribution, adaptation, and host-
pathogen interaction. Since most mycobacteria are slow growers, material from in 
vitro cultures is usually scarce. The robust mycobacterial cell wall hinders both 
experimental cell lysis and efficient DNA extraction. Here, we compare elements of 
several DNA preparation protocols and describe a method that is economical and 
practical and reliably yields large amounts—usually 10-fold increased compared to 
earlier protocols—of highly pure genomic DNA for sophisticated downstream 
applications. This method was optimized for cultures of a variety of pathogenic and 
environmental mycobacterial species and proven to be suitable for direct 
mycobacterial DNA extraction from infected insect specimens. 
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Introduction 
 
Mycobacterial diseases are a major health concern for humans (i.e., Mycobacterium 
tuberculosis, M. leprae, M. ulcerans, M. avium, and M. paratuberculosis) (4, 13, 18, 
29, 30), livestock (M. bovis and M. avium subsp. paratuberculosis) (1, 3), fisheries 
(M. marinum) (25), and wildlife (M. avium, M. pinnipedii, M. microti, M. caprae, and 
other species) (13, 20). Efficient methods for DNA preparation are required both for 
the identification and genotyping of such pathogens and for population genomics, 
which is developing into an important tool to study bacterial evolution, virulence, and 
epidemiology. 
Extraction of mycobacterial genomic DNA is especially demanding since (i) many 
mycobacterial species are among the most extreme slow growers, accounting for 
small amounts of starting material, and (ii) a robust and waxy cell wall renders 
mycobacteria difficult to lyse. Published protocols for mycobacterial DNA 
preparations and commercially available extraction kits are mainly designed for the 
isolation of small amounts of genomic material suitable for conventional PCR 
application (2, 7, 9, 11, 14, 15, 23, 24, 27, 28, 33), such as for testing of potentially 
contaminated milk (6, 8, 17). However, such DNA quantities and qualities are usually 
not sufficient for more sophisticated molecular analyses. 
M. ulcerans, the causative agent of the devastating human skin disease Buruli ulcer, 
is one of the slowest growers among mycobacterial species, and the development of 
molecular tools is crucial for studying its transmission and microepidemiology. The 
objective of this study was to develop an optimized extraction protocol for DNA of 
both high quantity and quality from scarce material of in vitro-cultivated M. ulcerans 
disease isolates. We compared elements of several protocols and developed a DNA 
preparation method that is optimized in each individual step and thus ready to use for 
virtually all mycobacterial species to yield a maximum of pure genetic material. In 
addition, we applied the established method to cultures of a variety of pathogenic and 
environmental mycobacterial species and tested it by isolating DNA from insects 
experimentally infected with M. ulcerans. 
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Materials and Methods 
 
Mycobacterial strains and preparation of mycobacterial cell suspensions.  
The strains used for this investigation and their origins are as follows: M. ulcerans 
Agy99, Malaysia 1615, and Japan 753 (21); Ghana IFIK1066089, Ghana Nm50/04, 
Ghana Nm51/04, Ghana Nm53/04, Ghana Nm74/02, Ghana Nm97/02, Ghana 
Nm98/02, Ghana Nm103/02, and Mexico IFIK 973880 (this study); Ghana Nm18/02, 
Ghana Nm21/02, Ghana Nm31/04, Ghana Nm38/02, and Ghana Nm59/02 (10); and 
Japan ITM 8756, French Guiana ITM 7922, and Surinam ITM 842 (22); M. marinum 
M, ATCC 927, CC240299, and DL240490 and M. pseudoshottsii L15 (21); M. liflandii 
XT128 (32); M. tuberculosis Pasteur 14001.0001 (5); and M. bovis BCG ATCC35734 
(5). Mycobacteria were obtained from cultures as described earlier (19, 31), 
resuspended in phosphate-buffered saline (PBS; pH 7.4), and heat inactivated at 
95°C for 60 min. Note that pathogenic mycobacteria need to be processed under 
appropriate biosafety containment. To avoid cross-contamination, 1.5-ml screw-cap 
tubes were used. Samples were centrifuged for 5 min at 2,500 × g to remove residual 
PBS. 
 
Extraction of mycobacterial DNA from pellets.  
Mycobacterial pellets were resuspended in 300 μl of lysis buffer A, B, or C (buffer A 
contained 5% monosodium glutamate, 50 mM Tris [pH 8.5], and 25 mM EDTA; buffer 
B contained 15% sucrose, 50 mM Tris [pH 8.5], and 50 mM EDTA; and buffer C 
contained 4 M guanidine isothiocyanate [GITC] and 50 mM Tris [pH 7.2]) and then 
incubated with different amounts of lysozyme. After incubation at 37°C for 1 h, 
sodium dodecyl sulfate (SDS) and proteinase K (PK) were added at different end 
concentrations and the mixture was further incubated at 37°C for 1 h, followed by 
enzyme inactivation at 70°C for 5 min. Some pellets were preincubated with 
chloroform-methanol (MeOH) at a 2:1 ratio for delipidation. Various matrix materials 
(200 μl of 0.1-mm zirconia beads [BioSpec Products, Bartlesville, OK] or 0.5-mm or 
1.4-mm ceramic or glass beads [Bertin Technologies, Montigny-le-Bretonneux, 
France]) were used, and samples were homogenized with a mechanical bead beater 
device, the Mikro-Dismembrator S (B. Braun Biotech International, Melsungen, 
Germany) for 2 to 7 min at 2,000 to 3,000 rpm or the Precellys 24 (Bertin 
Technologies, Montigny-le-Bretonneux, France) at conditions ranging from 2 × 40 s 
Chapter 8. Optimized method for mycobacterial DNA preparation 
 
139
at 5,000 rpm to 3 × 30 s at 6,800 rpm. Supernatants were transferred to new 1.5-ml 
reaction tubes and subjected to phenol-chloroform (Fluka, Buchs, Switzerland) 
extraction and chloroform purification (Fluka, Buchs, Switzerland). For this, addition 
of 500 μl of phenol-chloroform or chloroform was followed by a vortexing step and 
centrifugation at room temperature for 5 min at 4,000 rpm. After isopropanol or 
ethanol (EtOH) precipitation at −70°C for >30 min, DNA pellets were resuspended in 
100 μl nuclease-free water. Alternatively, mycobacterial purification kits (Promega 
Wizard [Promega AG, Dübendorf, Switzerland], Sigma GeneElute [Sigma-Aldrich, 
Buchs, Switzerland], and the BD GeneOhm lysis kit [Becton Dickinson Biosciences, 
Allschwil, Switzerland]) were used according to the manufacturers’ protocols, without 
or in combination with mechanical treatment. 
For further purification and quality control, extracted DNA was freed from residual 
RNA by incubation with 1.5 mg/ml RNase A (Fermentas, St. Leon-Rot, Germany) for 
2 min at 37°C and purified from degradation products, residual solvent, and protein 
contaminants with the QIAmp DNA purification MiniKit (Qiagen AG, Hombrechtikon, 
Switzerland) according to the manufacturers’ protocols. For genome sequencing 
applications, DNA was concentrated with a Concentrator 5301 (Vaudaux-Eppendorf 
AG, Basel, Switzerland). 
 
Experimental infection of aquatic insects and DNA extraction.  
Wild-caught insects belonging to the family Naucoridae (Naucoris cimicoides) were 
collected from swamps in western France. They were housed in an aquarium—filled 
with water of their natural environment—at 28°C and a photoperiod of 12 h each light 
and dark without any feeding for 7 days. These insects were then fed with a 15- to 
20-day-old grub of Phormia terrae novae (Verminière de l'Ouest, Tremblay, France) 
that was infected by inoculation with 106 CFU of M. ulcerans in a volume of 30 μl with 
a 25-gauge needle. Alternatively, Naucoris insects were directly inoculated in the 
coelomic cavity with 106 CFU of M. ulcerans in a volume of 30 μl with a 25-gauge 
needle (16). Insects were sacrificed with 70% cold EtOH, transferred to a 1.5-ml 
screw-cap tube, and processed for DNA extraction as described for mycobacterial 
pellets. 
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DNA quantification, amplification, and gel electrophoresis.  
DNA concentration was determined with the NanoDrop Spectrophotometer ND-1000 
(NanoDrop, Wilmington, DE) by measuring the absorption at 260 nm, and the 
decontamination of DNA from solvents and proteins was estimated by measuring the 
absorption at 230 and 280 nm, respectively. Purity and fragmentation of the extracted 
genomic DNA were assessed by 1% agarose gel electrophoresis. Detection limits of 
purified genomic materials were assayed by PCR with primers targeting unique 
regions in the mycobacterial genomes (primers MK810 
[TCTGTCAAGACAAGCCGATG], MK811 [GACTCGTGGTGATCGAGGAT], MK60 
[ATCGTTTAGCGCATCGATCT], MK61 [CACAGGTCGACCCCAACTAC], MK63 
[GTCGATGATCGCCTGTGGT], and MK35 [GTCGGCATCTTGTTGCTCA]). The 
presence of M. ulcerans in environmental insect specimens was tested with primers 
MU5 and MU6 (26) for detection of IS2404 and MK289 
(GTCGTAGATGTGGGCGAAA) and MK263 (GGTGCGGTTCCATTGAGA) for 
detection of IS2606. Primers were designed with the Primer3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). PCR was performed with 
FirePol 10× buffer and 0.5 μl FirePolTaq polymerase (Solis BioDyne, Tartu, Estonia), 
10 ng genomic DNA, 0.6 μM each forward and reverse primer, 1.5 mM MgCl2, and 
0.4 mM each deoxynucleoside triphosphate in a total volume of 30 μl. PCRs were run 
in a GeneAmp PCR System 9700 PCR machine (Perkin-Elmer, Schwerzenbach, 
Switzerland). The thermal profile for PCR amplification of M. ulcerans genomic DNA 
included an initial denaturation step of 95°C for 5 min, followed by 32 cycles of 95°C 
for 20 s, annealing at 58°C for 30 s, and elongation at 72°C for 45 s up to 2 min 20 s. 
The PCR was finalized by an extension step at 72°C for 10 min, followed by the 
analysis of the PCR products on 1% agarose gels by gel electrophoresis with 
ethidium bromide staining and the AlphaImager illuminator (Alpha Innotech, San 
Leandro, CA). 
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Results and Discussion 
 
Our first aim was to reduce the DNA extraction volume to 1.5-ml centrifugation tubes 
to facilitate rapid processing of large numbers of samples, in comparison to the 
commonly used volumes of 10 to 50 ml (2, 24). Extraction of DNA from samples with 
a wet weight of up to 20 mg in a volume of 1.5 ml turned out to be highly economical 
with respect to time and reagent consumption, while the use of more starting material 
did not result in a proportional increase in the amount of extracted DNA (Table 1). 
Next, we adopted and evaluated elements of several protocols of mycobacterial DNA 
extraction (2, 9, 15, 23, 24) for a comprehensive method optimization (Table 1). It 
was reported earlier that removal of lipids and lipid-like surface proteins by 
chloroform-MeOH treatment preceding cell lysis improved DNA purity, especially of 
large-size DNA (2, 9, 12). We confirmed this but also experienced substantial loss of 
genomic material. In contrast to an earlier study (15), the type of lysis buffer used 
had no marked influence on the DNA yield. Likewise, changes in lysozyme and PK 
concentrations made no significant differences. However, we found that an increase 
in the concentration of SDS resulted in increasing DNA yields. A commercially 
available kit designed to chemically lyse mycobacteria for PCR purposes yielded only 
small amounts of DNA suitable for PCR. In contrast, high-velocity mechanical 
treatment turned out to be very efficient in cell wall disruption, as already reported in 
several studies (2, 17, 33). When comparing matrix materials for bead beater 
treatment, good results were obtained with both zirconia and glass beads and cell 
solubilization was best when using beads of small diameter. The DNA yields tended 
to be higher when using harsh conditions, i.e., highest speed conditions and 
homogenization times of the respective device (Table 1) (17). However, since high-
velocity treatment jeopardizes shearing of DNA (2, 33), we recommend the 
performance of quality control by agarose gel electrophoresis after purification. 
Figure 1 shows that a combination of mechanical disruption and chemical 
solubilization of the waxy lipid and mycolic acid-containing cell wall renders the 
mycobacteria accessible for enzymatic lysis. Incubation with 4% SDS followed by 
mechanical disruption, a combination that was (to our knowledge) not used in any 
previous protocol, was here found to be essential for a high DNA yield (sample D). All 
protocols lacking one of these two treatments yielded strikingly smaller amounts of 
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DNA (samples B and C, respectively). When both steps were omitted, no DNA was 
extracted at all (sample A). 
For purification, the properties of DNA binding to silica in the presence of chaotropic 
salts are generally used to circumvent the use of phenol-chloroform. However, silica-
based commercial purification kits reached neither our elevated quantity nor quality 
requirements, even when applied after mechanical solubilization (Table 1; Fig. 1, 
samples G and H). Thus, although column use facilitates handling, we decided to use 
conventional phenol-chloroform extraction. Two steps of phenol-chloroform extraction 
were found to be crucial for removing protein and lipid contaminations from the 
genomic DNA, and an additional purification step with only chloroform helped in 
removing residual phenol (Table 1). A second round of this three-step phenol-
chloroform extraction after EtOH precipitation led to enhanced DNA purity but 
reduced the overall yield (Fig. 1, sample E). Although the highest DNA yield and 
purity were represented by sample F (Fig. 1), where DNA was precipitated with 
isopropanol instead of EtOH, this protocol resulted, in most cases, in a yellowish, 
slimy pellet that was difficult to resuspend and thus prone to material loss during 
handling. In conclusion, when a maximum of extracted genetic material is required, 
the protocol described for sample D should be applied, which had a 260/280-nm ratio 
(∼1.6) sufficient for most downstream applications. When a higher purity of DNA is 
required, a protocol including chloroform-MeOH pretreatment and/or a second round 
of phenol-chloroform extraction and EtOH precipitation is indicated, although it is 
associated with lower yields. 
From these results, we derived an improved standard protocol (Table 2) that involves 
(i) the use of 20 mg (wet weight) of pellets; (ii) pretreatment with 10 mg/ml lysozyme, 
200 μg/ml PK, and 4% SDS; (iii) mechanical disruption with 0.1-mm zirconia beads; 
(iv) two phenol-chloroform extractions, followed by chloroform purification; and (v) 
EtOH precipitation with two EtOH washing steps, followed by resuspension of the 
DNA pellet in 100 μl of nuclease-free water. 
We applied the established DNA extraction method to cell pellets of a panel of M. 
ulcerans strains and other mycobacterial species including M. marinum, M. 
pseudoshottsii, M. liflandii, M. tuberculosis, and M. bovis BCG (Table 3). A mean 
yield of 713 ng genomic DNA per mg (wet weight) cells with a 260/280-nm ratio of 
1.58 (standard deviation, 0.09) was obtained. This represents a 10- to 20-fold 
increase in DNA yield in our experiments compared to previous protocols, elements 
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of which we combined for optimization. We performed detailed quality control for 
DNA extractions from two strains, M. ulcerans Agy99 and Japan ITM 8756, 
representing the two distinct lineages of M. ulcerans (Fig. 2). Genomic DNA yields 
from 20-mg (wet weight) cell pellets were sufficient in quantity (typically, >5 μg; Fig. 
2) and quality for whole-genome microarray hybridization and whole-genome 
sequencing analyses. Single-copy gene sequences of >2 kb could be easily amplified 
by PCR with 10 ng as the template (Fig. 2). Subsequent RNase treatment and 
genomic DNA column purification decontaminated the samples from RNA and small 
DNA fragments resulting from shearing of genomic DNA (Fig. 2). 
In addition, we applied the optimized DNA extraction method to aquatic insects 
experimentally infected with M. ulcerans. Genomic DNA was sufficient in quantity and 
purity to specifically detect M. ulcerans in infected insects (Table 4), showing that the 
established method is suitable for direct processing of environmental samples. 
In conclusion, we envision this protocol to facilitate the investigation of pathogenic 
and nonpathogenic mycobacteria sampled from both infected tissue and the 
environment. In combining and optimizing crucial elements of established DNA 
extraction methods, our ready-to-use protocol meets the challenging characteristics 
of slow growth and distinct cell wall composition of mycobacteria and greatly 
enhances both the yield and the purity of mycobacterial DNA preparations. 
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Tables 
 
 
Table 1: Comparative advantages and/or disadvantages of various elements of DNA 
extraction protocolsa 
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Table 2: Optimized protocol for preparation of mycobacterial DNA 
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Table 3: DNA yields from a variety of mycobacterial speciesa 
 
 
 
 
 
Table 4: Detection of M. ulcerans genomic DNA after extraction from infected aquatic 
insectsa 
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Figures 
 
 
 
Figure 1: DNA yields (bars) and purity (line) achieved when testing different 
combinations of DNA extraction, purification, and precipitation procedures. Twenty-
milligram (wet weight) pellets of M. ulcerans strain IFIK1066089 were used. 
(Superscript 1) SDS was applied to a final concentration of 4%. (Superscript 2) 
Mechanical disruption was performed with a Precellys 24 homogenizer at 6,800 rpm 
for 3 × 30 s with glass beads. (Superscript 3) Second round, after EtOH precipitation, 
of three-step phenol-chloroform (Phe-Chl) extraction. (Superscript 4) Promega 
Wizard. (Superscript 5) Sigma GeneElute. For details, see Materials and Methods. 
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Figure 2: Quality control of DNA preparations from two M. ulcerans strains (Agy99 
and Japan ITM 8756 [Jp8756]) by agarose gel electrophoresis. Shown are ethidium 
bromide stainings of isolated genomic DNA, four PCR products thereof, and RNase-
treated and column-purified aliquots (right panel). Primer pair MK810/MK811 was 
designed to yield PCR product sizes specific for either Agy99 (2 kb) or Jp8756 (0.3 
kb). Primer pairs MK60/MK61, MK60/MK63, and MK60/MK35 were designed to yield 
identical PCR products in both strains with increasing sizes (0.17, 1.2, and 2.15 kb, 
respectively). 
 
 
 
 
Chapter 8. Optimized method for mycobacterial DNA preparation 
 
149
References 
 
1.  Ayele, W. Y., S. D. Neill, J. Zinsstag, M. G. Weiss, and I. Pavlik. 2004. Bovine 
tuberculosis: an old disease but a new threat to Africa. Int J Tuberc. Lung Dis. 8:924-
937. 
2.  Belisle, J. T. and M. G. Sonnenberg. 1998. Isolation of genomic DNA from 
mycobacteria. Methods Mol. Biol 101:31-44. 
3.  Chacon, O., L. E. Bermudez, and R. G. Barletta. 2004. Johne's disease, inflammatory 
bowel disease, and Mycobacterium paratuberculosis. Annu. Rev. Microbiol. 58:329-363. 
4.  Cole, S. T., K. Eiglmeier, J. Parkhill, K. D. James, N. R. Thomson, P. R. Wheeler, N. 
Honore, T. Garnier, C. Churcher, D. Harris, K. Mungall, D. Basham, D. Brown, T. 
Chillingworth, R. Connor, R. M. Davies, K. Devlin, S. Duthoy, T. Feltwell, A. Fraser, 
N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, C. Lacroix, J. Maclean, S. Moule, L. 
Murphy, K. Oliver, M. A. Quail, M. A. Rajandream, K. M. Rutherford, S. Rutter, K. 
Seeger, S. Simon, M. Simmonds, J. Skelton, R. Squares, S. Squares, K. Stevens, 
K. Taylor, S. Whitehead, J. R. Woodward, and B. G. Barrell. 2001. Massive gene 
decay in the leprosy bacillus. Nature 409:1007-1011. 
5.  Diaz, D., H. Dobeli, D. Yeboah-Manu, E. Mensah-Quainoo, A. Friedlein, N. Soder, 
S. Rondini, T. Bodmer, and G. Pluschke. 2006. Use of the immunodominant 18-
kiloDalton small heat shock protein as a serological marker for exposure to 
Mycobacterium ulcerans. Clin. Vaccine Immunol. 13:1314-1321. 
6.  Donaghy, J. A., M. T. Rowe, J. L. Rademaker, P. Hammer, L. Herman, J. De, V, B. 
Blanchard, K. Duhem, and E. Vindel. 2008. An inter-laboratory ring trial for the 
detection and isolation of Mycobacterium avium subsp. paratuberculosis from raw milk 
artificially contaminated with naturally infected faeces. Food Microbiol. 25:128-135. 
7.  Fyfe, J. A., C. J. Lavender, P. D. Johnson, M. Globan, A. Sievers, J. Azuolas, and 
T. P. Stinear. 2007. Development and application of two multiplex real-time PCR 
assays for the detection of Mycobacterium ulcerans in clinical and environmental 
samples. Appl. Environ. Microbiol. 73:4733-4740. 
8.  Gao, A., L. Mutharia, M. Raymond, and J. Odumeru. 2007. Improved template DNA 
preparation procedure for detection of Mycobacterium avium subsp. paratuberculosis in 
milk by PCR. J Microbiol. Methods 69:417-420. 
9.  Hilty, M., D. Yeboah-Manu, D. Boakye, E. Mensah-Quainoo, S. Rondini, E. 
Schelling, D. Ofori-Adjei, F. Portaels, J. Zinsstag, and G. Pluschke. 2006. Genetic 
Diversity in Mycobacterium ulcerans Isolates from Ghana Revealed by a Newly 
Identified Locus Containing a Variable Number of Tandem Repeats. J Bacteriol. 
188:1462-1465. 
10.  Honore-Bouakline, S., J. P. Vincensini, V. Giacuzzo, P. H. Lagrange, and J. L. 
Herrmann. 2003. Rapid diagnosis of extrapulmonary tuberculosis by PCR: impact of 
sample preparation and DNA extraction. J Clin. Microbiol. 41:2323-2329. 
11.  Imai, T., K. Ohta, H. Kigawa, H. Kanoh, T. Taniguchi, and J. Tobari. 1994. 
Preparation of high-molecular-weight DNA: application to mycobacterial cells. Anal. 
Biochem. 222:479-482. 
Chapter 8. Optimized method for mycobacterial DNA preparation 
 
150
12.  Katoch, V. M. 2004. Infections due to non-tuberculous mycobacteria (NTM). Indian J 
Med. Res. 120:290-304. 
13.  Khan, I. U. and J. S. Yadav. 2004. Development of a single-tube, cell lysis-based, 
genus-specific PCR method for rapid identification of mycobacteria: optimization of cell 
lysis, PCR primers and conditions, and restriction pattern analysis. J Clin. Microbiol. 
42:453-457. 
14.  Kotlowski, R., A. Martin, A. Ablordey, K. Chemlal, P. A. Fonteyne, and F. Portaels. 
2004. One-tube cell lysis and DNA extraction procedure for PCR-based detection of 
Mycobacterium ulcerans in aquatic insects, molluscs and fish. J. Med. Microbiol. 
53:927-933. 
15.  Marsollier, L., R. Robert, J. Aubry, J. P. Saint Andre, H. Kouakou, P. Legras, A. L. 
Manceau, C. Mahaza, and B. Carbonnelle. 2002. Aquatic insects as a vector for 
Mycobacterium ulcerans. Appl. Environ. Microbiol. 68:4623-4628. 
16.  Merchand, J. A., I. Estrada-Garcia, M. J. Colston, and R. A. Cox. 1996. A novel 
method for the isolation of mycobacterial DNA. FEMS Microbiol. Lett. 135:71-77. 
17.  Odumeru, J., A. Gao, S. Chen, M. Raymond, and L. Mutharia. 2001. Use of the bead 
beater for preparation of Mycobacterium paratuberculosis template DNA in milk. Can. J 
Vet. Res. 65:201-205. 
18.  Onyebujoh, P. and G. A. Rook. 2004. Tuberculosis. Nat. Rev. Microbiol. 2:930-932. 
19.  Palomino, J. C. and F. Portaels. 1998. Effects of decontamination methods and 
culture conditions on viability of Mycobacterium ulcerans in the BACTEC system. J Clin. 
Microbiol. 36:402-408. 
20.  Petrini, B. 2006. Non-tuberculous mycobacterial infections. Scand. J Infect. Dis. 
38:246-255. 
21.  Ranger, B. S., E. A. Mahrous, L. Mosi, S. Adusumilli, R. E. Lee, A. Colorni, M. 
Rhodes, and P. L. Small. 2006. Globally distributed mycobacterial fish pathogens 
produce a novel plasmid-encoded toxic macrolide, mycolactone f. Infect. Immun. 
74:6037-6045. 
22.  Rondini, S., M. Käser, T. Stinear, M. Tessier, C. Mangold, G. Dernick, M. Naegeli, 
F. Portaels, U. Certa, and G. Pluschke. 2007. Ongoing genome reduction in 
Mycobacterium ulcerans. Emerg. Infect. Dis. 13:1008-1015. 
23.  Rondini, S., E. Mensah-Quainoo, H. Troll, T. Bodmer, and G. Pluschke. 2003. 
Development and application of real-time PCR assay for quantification of 
Mycobacterium ulcerans DNA. J. Clin. Microbiol. 41:4231-4237. 
24.  Ross, B. C., K. Raios, K. Jackson, and B. Dwyer. 1992. Molecular cloning of a highly 
repeated DNA element from Mycobacterium tuberculosis and its use as an 
epidemiological tool. J Clin. Microbiol. 30:942-946. 
25.  Stamm, L. M. and E. J. Brown. 2004. Mycobacterium marinum: the generalization and 
specialization of a pathogenic mycobacterium. Microbes. Infect. 6:1418-1428. 
26.  Stinear, T., B. C. Ross, J. K. Davies, L. Marino, R. M. Robins-Browne, F. 
Oppedisano, A. Sievers, and P. D. Johnson. 1999. Identification and characterization 
Chapter 8. Optimized method for mycobacterial DNA preparation 
 
151
of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium 
ulcerans by PCR. J. Clin. Microbiol. 37:1018-1023. 
27.  Sweeney, R. W., R. H. Whitlock, and S. C. McAdams. 2006. Comparison of three 
DNA preparation methods for real-time polymerase chain reaction confirmation of 
Mycobacterium avium subsp. paratuberculosis growth in an automated broth culture 
system. J Vet. Diagn. Invest 18:587-590. 
28.  Thomson, L. M., H. Traore, H. Yesilkaya, C. Doig, H. Steingrimsdottir, L. Garcia, 
and K. J. Forbes. 2005. An extremely rapid and simple DNA-release method for 
detection of M. tuberculosis from clinical specimens. J Microbiol. Methods 63:95-98. 
29.  Turenne, C. Y., R. Wallace, Jr., and M. A. Behr. 2007. Mycobacterium avium in the 
postgenomic era. Clin. Microbiol. Rev. 20:205-229. 
30.  Wansbrough-Jones, M. and R. Phillips. 2005. Buruli ulcer. BMJ 330:1402-1403. 
31.  Yeboah-Manu, D., T. Bodmer, E. Mensah-Quainoo, S. Owusu, D. Ofori-Adjei, and 
G. Pluschke. 2004. Evaluation of decontamination methods and growth media for 
primary isolation of Mycobacterium ulcerans from surgical specimens. J. Clin. Microbiol. 
42:5875-5876. 
32.  Yip, M. J., J. L. Porter, J. A. Fyfe, C. J. Lavender, F. Portaels, M. Rhodes, H. Kator, 
A. Colorni, G. A. Jenkin, and T. Stinear. 3007. Evolution of Mycobacterium ulcerans 
and other mycolactone-producing mycobacteria from a common Mycobacterium 
marinum progenitor. J Bacteriol. 189:2021-2029. 
33.  Zhang, Z. Q. and M. Ishaque. 1997. Evaluation of methods for isolation of DNA from 
slowly and rapidly growing mycobacteria. Int J Lepr. Other Mycobact. Dis. 65:469-476. 
  
 
 
 
 
Chapter 9. Genetic fine-typing of M.ulcerans 
 
153
 
Chapter 9. Genetic fine-typing of M.ulcerans 
Chapter 9 
 
 
 
Single nucleotide polymorphism typing of Mycobacterium 
ulcerans reveals focal transmission of Buruli ulcer in a 
highly endemic region of Ghana 
 
 
Katharina Röltgen1,2, Weihong Qi1,2, Marie-Thérèse Ruf1,2, Ernestina Mensah-
Quainoo3, Sacha J. Pidot4, Torsten Seemann5, Timothy P. Stinear4, Michael 
Käser1,2,, Dorothy Yeboah-Manu6, Gerd Pluschke1,2 
 
 
1Swiss Tropical and Public Health Institute, Molecular Immunology, Basel, 
Switzerland 
2University of Basel, Basel, Switzerland 
3Ghana Health Service, Ministry of Health, Tema, Ghana 
4Department of Microbiology, Monash University, Clayton, Victoria, Australia, 
5Victorian Bioinformatics Consortium, Monash University, Clayton, Victoria, Australia, 
6Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, 
Ghana 
 
 
 
 
This article has been published in: 
PLOS Neglected Tropical diseases 
 
Chapter 9. Genetic fine-typing of M.ulcerans 
 
154
Abstract 
 
Buruli ulcer (BU) is an emerging necrotizing disease of the skin and subcutaneous 
tissue caused by Mycobacterium ulcerans. While proximity to stagnant or slow 
flowing water bodies is a risk factor for acquiring BU, the epidemiology and mode of 
M. ulcerans transmission is poorly understood. Here we have used high-throughput 
DNA sequencing and comparisons of the genomes of seven M. ulcerans isolates that 
appeared monomorphic by existing typing methods. We identified a limited number of 
single nucleotide polymorphisms (SNPs) and developed a real-time PCR SNP typing 
method based on these differences. We then investigated clinical isolates of M. 
ulcerans on which we had detailed information concerning patient location and time 
of diagnosis. Within the Densu river basin of Ghana we observed dominance of one 
clonal complex and local clustering of some of the variants belonging to this complex. 
These results reveal focal transmission and demonstrate that micro-epidemiological 
analysis by SNP typing has great potential to help us understand how M. ulcerans is 
transmitted.  
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Author Summary 
 
Mycobacterium ulcerans causes a destructive skin disease known as Buruli ulcer 
(BU), which has been reported from more than 30 tropical or subtropical countries, 
with the highest prevalence in Western Africa. Due to the striking genetic 
monomorphism of African M. ulcerans populations, conventional genetic 
fingerprinting methods have largely failed to differentiate isolates coming from the 
same BU endemic area.  
Here we report a highly discriminatory fingerprinting method for M. ulcerans using a 
single nucleotide polymorphism-based genetic fine-typing technique. This method 
has enabled us for the first time to identify different M. ulcerans haplotypes within a 
BU endemic area. Linking the origins of M. ulcerans strains with the patients` 
residences unveiled the clustering of unique M. ulcerans haplotypes within the Densu 
river basin of Ghana. Results show, that haplotypes do not spread within a short time 
over the entire BU endemic region, but rather form independent focal transmission 
clusters. 
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Introduction 
 
Infection with Mycobacterium ulcerans causes a chronic, necrotizing disease of the 
skin and the subcutaneous adipose tissue commonly known as Buruli ulcer [1]. This 
serious infectious disease remains a major health problem in many parts of the 
world, but in particular, in Western and Central Africa [2]. In spite of considerable 
research efforts made during the past few years transmission and environmental 
reservoirs of M. ulcerans are still incompletely characterized [1]. Endemic foci are 
usually linked to wetlands and riverine areas, which has lead to the assumption that 
M. ulcerans is an environmental mycobacterium and that micro-traumata of the skin 
may initiate infection [3]. However, isolation of the slow growing M. ulcerans from an 
environmental source has been achieved only once so far, from an aquatic insect [4]. 
PCR screening of environmental samples for the presence of IS2404 has implicated 
insects such as biting aquatic hemiptera and mosquitoes in the transmission of M. 
ulcerans [5-7], but their positivity for M. ulcerans DNA in polymerase chain reaction 
(PCR) tests may be only an indicator for the presence of M. ulcerans or other 
genetically closely related mycobacteria in the environment. Although BU is known to 
develop in all age groups with a nearly equal gender distribution, children 15 years of 
age or younger make up at least 50% of all cases in Africa [8]. Occasional clustering 
of cases within families may reflect a common source of infection or increased 
genetic susceptibility to infection rather than human-to-human transmission. 
Seroepidemiological studies have indicated that infection with M. ulcerans may lead 
to disease only in a minority of exposed individuals [9]. 
Many genetic fingerprinting methods have been applied for M. ulcerans, including 
IS2404, IS2606 and IS2426 PCR [10,11], amplified fragment length polymorphism 
analysis (AFLP) [12], IS2404 restriction fragment length polymorphism analysis 
(RFLP) [13,14], multi-locus sequence typing (MLST) [15-17], variable-number 
tandem repeat analysis (VNTR) [18-21], IS2404-Mtb2 PCR [22], and large sequence 
polymorphisms [23]. Among these, AFLP [12] and VNTR typing [19,21] were the only 
methods to reveal any genetic diversity among African strains.   
MLST, which has now been developed for more than 50 microbial taxa [24], revealed 
extremely low levels of polymorphisms in several protein coding genes of African M. 
ulcerans strains [16,17]. Analyses of the population structure of bacterial pathogens 
such as M. tuberculosis [25], Yersinia pestis [26] or Salmonella enterica Typhi [27] 
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have shown that single nucleotide polymorphism (SNP) typing is the most suitable 
fine-typing method for genetically monomorphic species [24]. This prompted us to 
develop a SNP typing method for M. ulcerans strains from a BU endemic area of 
Ghana. We selected two Ghanaian patient isolates representing two different 
Ghanaian VNTR types [19] for genome re-sequencing and compared obtained 
sequences with the published genome sequence of the reference strain Agy99 [28]. 
Whole genome comparison between these three strains detected 173 SNPs in total 
[29], which were used for the establishment of amplification refractory mutation 
system (ARMS) real-time PCRs using hairpin-shaped primers [30]. Typing of 74 
strains isolated from patients living in the BU endemic Densu river basin at 65 SNP 
loci revealed the presence of five haplotypes in addition to the Agy99 reference 
haplotype. Sequencing of 4 additional strains chosen on the basis of detected 
haplotypes enabled further differentiation of isolates. Location of the homes of 
patients from whom the strains were isolated facilitated a phylogeographic analysis of 
haplotype distribution.  
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Materials and Methods 
 
Ethics statement  
In the present study, M. ulcerans isolates were obtained from BU diagnostic samples. 
Data were analyzed anonymously and bacterial isolates delinked from the patients 
from whom they originated. Ethical approval to use the diagnostic specimens for 
immunological and microbiological research was obtained from the ethical review 
board of the Noguchi Memorial Institute for Medical Research, University of Ghana, 
Legon, Ghana. Written informed consent was provided by all patients for standard 
surgical treatment and anesthesia. In addition the ethical review board requested 
written informed consent for taking blood samples for immunological research on a 
special consent form, but not for potential later investigations of bacterial isolates 
generated during standard diagnostic procedures.  
 
Mycobacterial strains and genomic DNA extraction 
A total of 74 M. ulcerans patient isolates from a BU endemic area located in the Ga 
West, Ga East and Akuapim South Districts were included in the SNP typing 
analysis. Patients were aged 2 - 75 years, while 71% of the patients were younger 
than 15 years. In addition, M. ulcerans patient isolates from the Ashanti Region 
(Amansie West District) of Ghana and from other West-African countries (Ivory 
Coast, Togo, Benin, Democratic Republic of Congo and Angola) were enclosed for 
further SNP typing analyses (Table 1). The complete Agy99 genome sequence 
published in 2007 [28] and re-sequenced genomes of isolates NM20/02, NM31/04 
[29], NM14/01, NM43/02, NM49/02 and NM54/02 were used as reference 
sequences. The genomes of strains NM14/01, NM43/02, NM49/02 and NM54/02 
were analyzed at Monash University using an Illumina GAIIx Genome Analyzer. A 
100x coverage per genome was obtained on average. The Short Read Mapping 
Package (SHRiMP) software was used for aligning the genomic reads against the 
target Agy99 genome. For SNP identification the Nesoni software was used. 
Genomic DNA was isolated by cell wall disruption and phenol-chloroform extraction 
as described previously [31].  
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SNP typing 
Real-time PCR hairpin primer (HP) assays [30] were used to detect SNPs in the 74 
Ghanaian M. ulcerans strains. Real-time PCR was performed using Power SYBR 
green 1x PCR Master Mix (Applied Biosystems), 5 ng genomic DNA and 0.3 µM 
forward and reverse primers each in a total volume of 25 µl. Reactions were carried 
out in a Step One Plus Real-time PCR system (Applied Biosystems) with a 96-well 
block. Thermal conditions were as follows and as described previously [30]: stage 1, 
95°C for 10 min, 70°C for 30 s; stage 2, 72°C for 30 s, 95°C for 20 s, 69°C for 30 s, 
lowering one degree in the last step for every cycle during 10 cycles; stage 3, 72°C 
for 30 s, 95°C for 20 s, and 60°C for 30 s, repeated 40 times; Melt curve stage, 95°C 
for 15 s, 60°C for 1 min, 95°C for 15 s. Data were collected in the last step of stage 3 
and after the Melt curve stage for analysis with the Step One Software version 2.0 
(Applied Biosystems). SNPs were detected by ARMS assays and for each assay two 
PCRs with two sets of PCR primers were performed in parallel. Each PCR reaction 
contains SNP-specific primers, which are designed to be either fully complementary 
to the DNA template or mismatched at the 3`end nucleotide. As reactions with totally 
complementary primers have a more rapid developing fluorescence curve and an 
earlier cycle-threshold, differences between the two reactions allow the detection of 
SNPs.   
The hairpin-shaped primers were designed as described previously [30]. In the first 
step linear primers were designed with Primer3 [32] to produce short amplicons (30 
to 90 bp) and to anneal between 60 and 65°C. A tail was added to the 5' end of the 
SNP-detecting primer in order to produce a stem with the 3' end of the primer. The 
stem was designed with mfold software (http://www.bioinfo.rpi.edu /applications/ 
mfold/old/dna/) to have a melting temperature of 67 to 70°C with a free energy of 
between -0.5 and -2.0. Primers are provided in Table S1.  
 
Validation of SNP typing assays 
Assays were validated on the published genome Agy99 as well as the reference 
strains NM20/02, NM31/04, NM14/01, NM43/02, NM49/02 and NM54/02 to confirm 
the presence of each allele and to verify the performance of SNP assays. Assays 
with genomic DNA samples from clinical isolates were considered reliable only if the 
cycle thresholds generated in the paired wells differed by three or more cycles and if 
the melting curves of paired wells were coherent. ARMS assays with low 
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discriminatory power were not included into the standard set of 65 SNP typing 
assays. Sanger DNA sequencing of PCR products was used to validate a selected 
subset of SNPs. Primers used for PCR and sequencing were designed using Primer3 
[32] software. PCR was performed using FirePol 10x buffer and 0.5 µl FirePolTaq-
Polymerase (Solis BioDyne), 5 ng genomic DNA, 0.72 µM forward and reverse 
primers each, 2mM MgCl2 and 0.4 mM dNTPs (Sigma) in a total volume of 25 µl. 
PCR reactions were carried out in a Gene Amp PCR System 9700 PCR machine 
(Applied Biosystems). Thermal conditions for PCR amplification of M. ulcerans 
genomic DNA were as follows: initial denaturation step, 94°C for 5 min; 32 cycles: 
94°C for 30 s (denaturation), 60°C for 30 s (annealing), 72°C for 1 min (elongation); 
final extension step, 72°C for 10 min. PCR products were analyzed on 1% agarose 
gels. PCR products were purified using the Nucleo Spin Extract II Kit (Macherey-
Nagel). Sequencing of purified PCR products was done by Macrogen (World 
Meridian Venture Center, Seoul/Korea). Sequencing was conducted by the Sanger 
method using BigDyeTM terminator cycling conditions using the Automatic Sequencer 
3730xl (Applied Biosystems).  
Several random SNP loci were validated by Sanger sequencing in order to verify the 
ARMS approach for a differentiation of M. ulcerans isolates. Additionally, validation of 
pivotal SNPs loci revealing different haplotypes within the endemic area around the 
Ga District as well as differences between Amansie West District strains and isolates 
from other African countries was carried out. 100% of 36 randomly chosen SNP loci 
tested in reference strains Agy99, Nm20/02 and Nm31/04 were reconfirmed by 
Sanger sequencing. 100% of 70 significant SNP loci dividing Ga District strains into 5 
haplotypes other than Agy99 and distinguishing Amansie West District as well as 
African strains were likewise verified by Sanger sequencing. In contrast, four real-
time PCR typing results, which were validated because of unique allele occurrences 
in certain Ga District isolates diverged from reconfirmatory Sanger sequencing 
analysis. Subsequent repetition of real-time PCRs in duplicates revised the initial 
real-time PCR analyses and confirmed Sanger sequencing results.    
 
Phylogenetic analysis 
MEGA software version 4.1 (beta) [33] was used to reconstruct the neighbor-joining 
tree based on SNP typing data (Phylogeny Test and options: Bootstrap 1000 
replicates; Gaps/Missing Data: Complete Deletion; Codon Positions: 
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1st+2nd+3rd+Noncoding; Model: Nucleotide, Number of differences; Substitutions to 
include: Transitions + Transversions; Pattern among lineages: Same = 
Homogeneous; Rates among sites: Uniform rates). 
We created a map of West Africa by using the map creator tool of Epi Info version 
3.5.1 in order to illustrate detected SNP patterns in different African countries. 
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Results 
 
Development of ARMS SNP typing assays 
Recently we have compared 454 and Illumina genome sequencing data of M. 
ulcerans patient isolates NM20/02 and NM31/04 originating from two different BU 
endemic areas of Ghana with the published genome sequence of the Ghanaian 
strain Agy99 [29]. Based on the identification of 173 SNPs we have developed 
medium-throughput ARMS-based real-time PCR SNP assays with hairpin-shaped 
(HP) primers. Initial ARMS assays were successful for 108 of 173 detected SNP loci 
at predefined optimal conditions. We were able to discriminate alleles under a single 
standard condition at 73/108 (67.6%) SNP loci. This is close to the success rate of 
72.4% reported by Hazbon and Alland for their first round of HP-assay design [30]. 
Real-time PCR analysis revealed sequencing errors in the Agy99 reference 
sequence at eight of these loci, which were thus not suitable for further typing 
analyses. Redesign of the 100 initially failed assays and ongoing whole-genome 
sequencing of additional isolates will increase the pool of discriminatory SNP assays 
for future analyses of the population structure of African M. ulcerans. Developed SNP 
assays were used to type a collection of strains from two different BU endemic areas 
of Ghana and other African countries (Figure 1).  
 
Different clonal complexes of M. ulcerans dominate in the BU endemic regions 
of Africa    
SNP typing of three strains from the Amansie West District of Ghana including the 
sequenced Amansie West reference strain NM31/04 revealed differences at 24 of the 
65 SNP loci analyzed (37%) between these isolates (Figure 1B). In comparison to 
Agy99 differences at 29, 27 and 5 loci were found. A neighbor-joining tree analysis 
sub-grouped haplotypes from the two different BU endemic areas of Ghana into two 
clades (Figure 2). Clade 1 comprises strains isolated between 2001 and 2007 in the 
Densu river basin, which could be differentiated into 6 haplotypes (Figure 1A).  All 
Amansie West District isolates are sub-grouped together with the 1999 isolate Agy99 
into clade 2 (Figure 2).    
Typing of patient isolates from other BU endemic African countries at the 65 SNP loci 
yielded 2 of 15 strains with patterns similar to haplotypes found in Ghana (Figure 1A 
and B). The only strain available from Togo had a haplotype which differed at only 
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one locus from haplotype 6 found in the Densu river basin. One of the two analyzed 
strains from the Ivory Coast had a haplotype similar to the haplotypes of strains from 
the Amansie West District of Ghana. The other isolate from the Ivory Coast as well 
as all seven analyzed strains from Benin, three strains from the Democratic Republic 
of Congo (DRC) and two strains from Angola shared a distinct SNP pattern when 
compared to the Ghanaian isolates (Figure 1A and B). Thus, SNP typing results of 
clinical isolates from Ghana and isolates from other African countries revealed a 
neighbor-joining tree with 3 main branches. The strain from Togo is sub-grouped 
together with haplotypes 2-6 into clade 1, while strain 1 from the Ivory Coast is 
classed with Amansie West District isolates and Agy99 into clade 2. The other 13 
West-African strains are sub-grouped into clade 3 (Figure 2). 
 
SNP typing of M. ulcerans patient isolates from a BU endemic area of Ghana 
identifies ten haplotypes belonging to a dominating clonal complex  
Using the 65 established ARMS assays we SNP-typed 74 M. ulcerans patient 
isolates collected between 2001 and 2007 from the BU endemic Densu river basin of 
Ghana, from which the sequenced strains Agy99 and NM20/02 originated. Within this 
group of 74 strains of common geographical origin, differences at 14 of the 65 SNP 
loci tested (22%) were observed (Figure 1A). Altogether five haplotypes (designated 
haplotypes 2-6) other than the Agy99 associated haplotype 1 could be distinguished. 
Haplotypes 2 - 6 differed at 41, 43, 47, 48 and 55 of the 65 analyzed SNP loci from 
haplotype 1 (strain Agy99), respectively.  
Based on detected haplotypes we re-sequenced 4 representative strains NM14/01 
(haplotype 5), NM43/02 (haplotype 3), NM49/02 (haplotype 6) and NM54/02 
(haplotype 4) in order to further differentiate strains from the same haplotype. We 
detected new unique SNPs in NM43/02 (26 SNPs), NM54/02 (11 SNPs), NM14/01 (9 
SNPs) and NM49/02 (4 SNPs) and established 24 new assays, which enabled a 
segregation of each haplotype into two haplotypes (Figure S1). A phylogenetic tree 
for haplotypes 1-10 is shown in Figure 3. 
 
Temporal and spatial distribution of haplotypes 
In contrast to the generally rarer haplotypes 2-4; 6-8 and 10, haplotypes 5 and 9 
were found within each time interval (one year) from 06/2001 to 06/2006 (data not 
shown). Haplotypes 1 and 2 were not found again in the whole strain collection. 
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Possible explanations include the actual absence of these haplotypes from the 
residual clonal M. ulcerans complex in the Densu river basin as well as phylogenetic 
or sampling bias.  
For a phylogeographic analysis the homes of patients from whom the strains were 
isolated were marked in a map, depicting the distribution of haplotypes (Figure 4). 
Haplotypes 4, 6, 7, 9 and 10 appear to be unevenly distributed; i.e. they were found 
only in certain parts of the BU endemic area. Haplotype 10 was even found only 
within one small village. In contrast, the most prevalent haplotype (haplotype 5) co-
localized with all other haplotypes. Interestingly, two M. ulcerans isolates of identical 
haplotype (haplotype 4) were isolated from two patients coming from the same 
household, suggesting a common source of infection.  
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Discussion 
 
Previous investigations on the genetic diversity of M. ulcerans by comparative 
genomic hybridization analysis enabled differentiation of a world-wide collection of 
strains into two main lineages and six continental haplotypes [34]. However, 
phylogeographic and transmission pathway analysis requires high-resolution fine 
typing of strains from the same BU endemic region. This has been accomplished so 
far only for a few M. ulcerans populations and at low resolution. VNTR analysis of a 
Ghanaian strain collection based on the polymorphic loci ST1 and MIRU1 revealed 
the presence of three distinct allele combinations (BD/B, C/BAA and BD/BAA) in 
Ghana. All isolates from the Buruli ulcer endemic Densu river basin tested, except for 
Agy99, displayed combination BD/B [19]. Our recent genome re-sequencing analysis 
[29] compared the two Ghanaian VNTR type reference strains NM20/02 (BD/B) and 
NM31/04 (C/BAA) to Agy99 (BD/BAA) with the goal of detecting single nucleotide 
polymorphisms suitable for development of a fine-typing method. By selection of 
isolates with the three prevalent VNTR types in Ghana we expected to capture as 
much of the genetic variation present in the Ghanaian M. ulcerans population as 
possible. Our assumption was reinforced by re-sequencing four M. ulcerans strains 
initially grouped into haplotypes 3-6. Only 16 additional SNPs could be detected by 
comparison of the four strains to reference strain Agy99, while 50 unique SNPs could 
be identified by comparing the four strains among themselves. We anticipated that 
detected SNPs will provide the first useful genetic markers for phylogeographic and 
transmission pathway analyses at least in the Densu river basin and other BU 
endemic areas of Ghana.  
 
We have identified 10 different haplotypes in a relatively small BU endemic area 
within the Densu river basin. Haplotypes 1-10 are descendants of a founder 
haplotype that has spread over the district; the most common haplotype 5 may 
represent this founder haplotype. Analysis of this spatial distribution of haplotypes 
indicates that emerging new haplotypes do not readily spread over the entire 
endemic area, but form focal transmission clusters. 
 
Our data are comparable to studies of other genetically monomorphic organisms like 
Salmonella typhi, which report multiple strain types circulating within a specific 
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location [35-37]. Comparison of typing results in strains from two geographically 
separate BU endemic areas in the Densu river basin and the Amansie West Districts 
of Ghana uncovered a total of 61 differing alleles at 65 SNP loci. Within each of the 
two endemic areas SNP variation was significantly smaller (14 and 24 differences, 
respectively) than the overall variation between the two endemic areas. These results 
indicate the dominance of two different clonal complexes in the two separate 
Ghanaian BU endemic areas. SNP typing of two strains from Ghanaian neighboring 
countries showed similar SNP patterns when compared to AW District isolates (strain 
1 from the Ivory Coast) or Ga District haplotypes (strain from Togo). Typing of 13 
strains collected in additional African countries (Benin, DRC, Angola, strain 2 from 
the Ivory Coast) revealed a completely new SNP pattern compared to all other 
isolates. On the basis of typing with the Ghanaian set of SNPs these 13 strains could 
not be distinguished among each other and were thus clustered together into a clade. 
This clustering may however represent a phylogenetic discovery bias, i.e grouping of 
actually diverse strains leading to a so called “branch collapse”. Future addition of 
SNP loci identified by genome re-sequencing of a comprehensive pan-African 
selection of M. ulcerans isolates will lead to a further subdivision and differentiation of 
African strains. Phylogenetic discovery bias is implicit to SNP typing and will continue 
to exist as long as not every single sample will be sequenced. It will become smaller 
though with every additional re-sequenced genome. SNP typing based on a wider 
range of SNPs may therefore yield evidence for genetic divergence of strains from 
Benin, DRC, and strain two from the Ivory Coast. Hence, phylogeographic analyses 
in other African BU endemic areas will require whole genome comparison of strains 
from that area to develop a local set of informative SNPs. This is supported by our 
recent identification of seven insertion sequence element-related SNP types within 
Africa [38].  
 
M. ulcerans has evolved from the aquatic environmental M. marinum and seems to 
have adapted to a more stable ecological niche [28]. Gain of the immunosuppressive 
toxin mycolactone is accompanied by loss of highly immunogenic proteins [39], 
suggesting an adaptation to survival in host environments that are screened by 
immunological defense mechanisms. Serological analyses have indicated that many 
individuals living in BU endemic areas are exposed to M. ulcerans, whereas relatively 
few develop clinical disease [9]. There is no published evidence for direct person to 
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person transmission of M. ulcerans. Based on numerous reports demonstrating an 
association of BU with slow flowing or stagnant water bodies, it is therefore 
commonly assumed that infection takes place through trauma of the skin or insect 
bites via an environmental reservoir in the aquatic ecosystems. Both biotic 
components, such as biofilms and aquatic invertebrate species are being considered 
as potential vectors and/or reservoirs [5,6,40-42]. Recent findings in south-eastern 
Australia have implicated mammals as environmental reservoir (Fyfe et al., 
submitted) and mosquitoes as vectors of M. ulcerans [43,44]. While large numbers of 
possums in a BU-endemic area of Australia are infected with M. ulcerans, a similar 
mammalian reservoir has not been identified in BU endemic regions of Africa. If such 
a reservoir plays a role in transmission, spread of M. ulcerans from chronic, ulcerated 
lesions to insect vectors or another currently unknown environmental reservoir 
should be considered. Subsequent infection of individuals living in the same 
settlements may be responsible for the focal transmission patterns, such as of 
haplotype 10, which was found only within one small village.  
The Densu river basin represents one of the coastal drainage systems of Ghana. Its 
water is collected in the Weija Lake, which developed after construction of a dam at 
the river’s mouth in the 1970s. If M. ulcerans bacteria would be carried freely by the 
flow of water of the Densu river and its tributaries, haplotypes present in upper parts 
of the river system should be represented in the lower parts. However, among patient 
isolates coming from the lower part of the basin close to the Weija Lake the rare 
haplotypes 4 and 7 dominated. M. ulcerans bacteria that are swept downstream in 
the river water thus do not seem to play a major role in transmission.  
Results of this retrospective pilot study indicate that future longitudinal micro-
epidemiological studies involving SNP typing of isolates may give deeper insight into 
transmission pathways and relevant reservoirs of M. ulcerans. 
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 Table 
 
Table 1. M. ulcerans strains included in the analysis 
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Figures 
 
 
 
Figure 1. SNP typing analysis of African M. ulcerans isolates. 
A M. ulcerans isolates from the Densu river basin of Ghana were analyzed at 65 
SNP loci (Primer IDs) by real-time PCRs. Base exchanges relative to the reference 
sequence of strain Agy99 were registered as 1 (grey). Allele matches with Agy99 
were recorded as 0 (white). 5 haplotypes in addition to haplotype 1 (Agy99) could be 
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distinguished on the basis of 14 SNP loci. B SNP typing results of strains from a 
second BU endemic area of Ghana as well as from additional African countries 
carried out with the set of SNP assays developed by whole genome sequencing of 
Ghanaian isolates. AW: Amansie West; Ga: strains from the Densu river basin; IC: 
Ivory Coast; T: Togo; B: Benin; C: Democratic Republic of Congo; A: Angola. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 9. Genetic fine-typing of M.ulcerans 
 
172
 
 
Figure 2. Geographical distribution of African M. ulcerans clades.  
Map of West-Africa, showing the distribution and SNP haplotypes of three African M. 
ulcerans clades. Clade 1: yellow; clade 2: green; clade 3: blue. AW: Amansie West; 
Ga: strains from the Densu river basin; IC: Ivory Coast; T: Togo; B: Benin; C: 
Democratic Republic of Congo; A: Angola. A neighbor-joining tree shows sub-
grouping of detected haplotypes from the Densu river basin together with the only 
strain from Togo into clade 1, strains from AW together with strain Agy99 and strain 1 
from the Ivory Coast into clade 2 and all other strains from additional African 
countries into clade 3 (scale: number of differences at the SNP loci tested). 
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Figure 3. Neighbor-joining tree of 75 Ghanaian M. ulcerans isolates. 
75 M. ulcerans isolates were aligned based on their SNP type (scale: number of 
differences at the SNP loci tested). HT = haplotype. 
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Figure 4. Geographical distribution of M. ulcerans haplotypes.  
Map of the Densu river basin, showing the homes of patients from whom the strains 
have been isolated between 2001 and 2006 (colored dots). Haplotypes 2 (black), 3 
(white), 4 (yellow), 6 (purple), 7 (dark blue), 8 (light blue), 9 (dark green), 10 (light 
green) are unevenly distributed, whereas haplotype 5 (red) co-localizes with all other 
haplotypes. The background map was created using elevation data from the Shuttle 
Radar Topography Mission (SRTM). Water bodies were classified using optical data 
from Landsat ETM and radar data from TerraSAR-XReferences. 
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10.1 General remarks 
 
BU was first detected in Uganda 1897, but only after the first international 
Conference on “BU Control and Research” in 1998 in Yamoussoukro the disease 
gained significant public attention. BU causes, particularly in poor West African 
countries a substantial public health burden. It is assumed that all neglected tropical 
diseases (NTDs) together produce a burden of disease that may be equivalent to up 
to one-half of the sub-Saharan’s malaria disease burden and more than double the 
one caused by tuberculosis in Africa 1,2. Since the Yamoussoukro conference many 
research efforts were undertaken and important insights into the nature of BU have 
been gained. However there are still many unsolved questions and problems 
especially in the field of transmission, diagnosis and treatment.  
 
Improved case detection systems, a greater awareness of the disease in the 
population of endemic countries and the availability of an effective therapy might 
have contributed to the fact that case rates in some BU endemic areas seem to 
decrease. However, WHO estimates that still every year more than 5000 people 
worldwide are newly diagnosed with BU and the disease stays a major health 
problem 3,4. 
 
Within the framework of the present thesis, histopathological analysis of tissue 
samples from BU patients and from experimentally infected mice allowed us to gain 
new insights into the pathogenesis of the disease, histopathological changes during 
treatment and causes for paradoxical reactions during and after chemotherapy. 
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10.2 Diagnosis of Buruli ulcer and monitoring of treatment success 
 
In remote rural areas, diagnosis of BU is mostly based on clinical grounds although 
the disease can be confused with other skin diseases 5,6. It is known that experienced 
health care physicians can reliably recognize, in particular advanced, BU lesions.  
Nevertheless, a fast and easy laboratory diagnostic test would be very helpful for the 
correct diagnosis of pre-ulcerative lesions. Several methods for laboratory 
confirmation are currently available, of which most are only feasible in sophisticated 
labs. The only laboratory method suitable for rural health centers is microscopy, 
analyzing exudate smears of ulcerative lesions or fine-needle aspirations (FNA) of 
pre-ulcerative lesions for the presence of AFB 7-9. However the sensitivity of this 
method is low, recognizing less then 50% of the BU cases 6. Reference laboratories 
which are capable of performing other tests, like histopathology, cultivation of 
samples or IS2404 PCR confirmation are rare in the BU endemic African countries10. 
Cultivation is a very time-consuming technique often revealing false negative results 
because cultures are overgrown by other fast growing organisms or viable bacteria 
are absent in swab exudates. However, for genomic analysis (Chapter 7, Chapter 9) 
or phenotypic resistance testing cultivated bacteria are required. PCR detection of M. 
ulcerans DNA has a very high sensitivity, but is in turn prone for contamination and 
expensive lab equipment is needed 10,11. Diagnosis by histopathological examination 
can be reliable if tissue specimens are taken carefully from the right place and 
analyzed by a trained person (Chapter 4, Chapter 5) 6,12-14.  
To monitor treatment success all these methods do not allow to differentiate between 
viable and dead bacteria. In our mouse study we could still observe AFB 12 weeks 
after start of chemotherapy in the histopathological samples, although CFU counts 
were already negative for a long time. Furthermore human BU lesions remain IS2404 
PCR positive for a long time after completion of antimycobacterial treatment 
(unpublished results). Detection of AFB or DNA thus cannot be used to determine the 
activity of the infection. Currently, the most reliable method to determine viability of 
the M. ulcerans bacteria is in vitro cultivation. New methods to overcome this lack are 
under evaluation. One possibility would be the detection of mycolactone in tissue. It 
is assumed that the level of mycolactone is declining very fast after killing of the 
bacteria and therefore this parameter would probably represent a good surrogate 
marker to determine viability and to monitor the efficacy of antibiotic or heat therapy. 
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Currently several groups are working on the development of a mass spectrometry 
method to detect and quantify mycolactone in tissue and wound exudates. It has 
been shown that it is possible to extract detectable amounts of mycolactone from 
tissue and from circulating blood monocytes 15.  
The thin-layer chromatography (TLC) method was improved and adapted by Kishi 
and Spangenberg to detect mycolactone in the acetone soluble lipid fraction. 
Although this method is cheap and easy to handle sensitivity has to be improved in 
order to directly detect mycolactone in human tissue 16,17. Another option, 
independent of mycolactone, could be the detection of mycobacterial RNA inside 
tissue samples as it is used in leprosy and tuberculosis 18,19. For RNA detection as 
well as mass spectrometry expensive lab equipment is needed making it impossible 
to perform these assays in remote rural areas. A modification of the Quantigene RNA 
ELISA method could represent a format that is adaptable to the field.  
Another approach for the development of a point-of-care diagnostic test could be the 
development of an easy to handle serological test format, such as a dip-stick, which 
can be used on spot and gives a fast and reliable result 20,21. First antigens were 
already evaluated, in particular the 18KD small heat-shock protein from M. ulcerans. 
Unfortunately, not only patients but also healthy household contacts and people living 
in endemic areas showed reactivity 22. Another group used M. ulcerans specific 
proteins identified by comparative genomics which are useful to determine exposure 
to M. ulcerans and for sero-epidemilogical studies 23.  
During our histopathological analysis of mouse and human tissue samples infected 
with M. ulcerans (Chapter 3, Chapter 4, Chapter 5), we observed bacteria with an 
incomplete ZN staining, the so-called beading. This phenomenon was discovered in 
M.leprae and is due to a decomposition of the mycobacterial cell wall 24,25. In M. 
ulcerans infected mice we observed already one week after commencement of 
antibiotic treatment a change of the ZN staining and the occurrence of beading 
(Chapter 3). Beading correlated with the inability to cultivate the bacteria. At close 
examination, the same phenomenon was observed in tissue from treated BU patients 
(Chapter 4, Chapter 5). This led us to the assumption that also in BU beading of 
bacteria is a marker for non - viability and can be used to estimate treatment success 
or the probability of relapse.  
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10.3 Treatment of BU 
 
Until 2004, the only recommended treatment for M. ulcerans was the extensive 
surgical excision of the ulcerated tissue down to the deep fascia and into the healthy 
margins of the lesion, followed by skin grafting. In a high percentage of patients the 
removal of mycobacteria was incomplete and recurrences appeared in up to 47% of 
the cases 26-29. Tissue that appeared macroscopically healthy frequently harbored M. 
ulcerans bacteria able to form new infection foci 30.  
Studies with antibiotics in mice showed no benefit until the combination of rifampicin 
and amikacin was used and showed bactericidal effectivity against M. ulcerans 31-34. 
Following these results, a small clinical trial with pre-ulcerative lesions in Ghana 
using the combination of rifampicin and streptomycin, reported efficacy of this 
combination and led in 2004 to the provisional WHO recommendations to treat BU 
patients with a combination of rifampicin and streptomycin for 8 weeks 35-37. Although 
this treatment is effective and recurrence rates are below 2%, it is associated with 
several problems 37,38. First of all, rifampicin is a frontline drug in the treatment of M. 
tuberculosis and the 8 weeks treatment for BU may be associated with the risk to 
develop resistant tuberculosis strains in patients with a BU/TB co infection. Beside 
this there are several other complications linked to the antibiotic treatment. O’Brien 
reported for the first time the occurrence of paradoxical reactions in BU patients 
receiving antibiotic therapy 39. These reactions have similarities to the immune 
reconstitution inflammatory syndrome (IRIS) in HIV/M .tuberculosis co-infected 
patients who commence anti-retroviral therapy 40-42.  
A worsening of the wound during treatment is frequently observed 37,43 leading to the 
question whether a prolonged antibiotic therapy or a change in the treatment regimen 
is necessary. Careful retrospective evaluation revealed that worsening of the lesion 
was not due to a treatment failure but rather a strong immune response towards 
mycobacterial antigens still present inside the tissue 39,44.  
During our studies we examined two patients who developed secondary lesions 
(Chapter 5) during or after successful initial antibiotic treatment at various body sites, 
at some distance to the initial lesion. Secondary lesions should not be confused with 
untreated patients presenting before commencement of treatment with multiple 
lesions, the so called metastatic, BU disease 45. In earlier times, secondary lesions 
were thought to be due to a new infection or relapse and additional treatment would 
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be necessary. Our histopathological analysis identified secondary lesions as an 
inactive BU lesion with typical histopathological hallmarks observed after antibiotic 
therapy (granulomas, B-cell cluster) 46. This suggests that no additional antibiotic 
therapy is necessary but minimal surgical excision might be beneficial.  
Plaques are the most problematic pre-ulcerative stages to treat, due to the frequently 
observed occurrence of ulceration during antibiotic therapy. The results we obtained 
revealed large necrotic areas still present after completion of standard antibiotic 
therapy. No indications for treatment failure were observed in ulcerating lesions. 
However the immune system was not capable to clear large necrotic tissue areas 
entirely, leading to an opening of the wounds. Plaque patients which received 
surgical wound débridement showed a faster improvement and a shorter hospital 
stay. Wound cleaning and the transition from a chronic wound into an acute wound 
has been shown beneficial in several other diseases (venous ulcer, diabetic ulcer) 
and to favor the healing process 47-49. This might not be only true for plaque lesions 
but for all larger BU wounds with a delayed and slow healing.  
For clinical decision making it is thus important to differentiate immune-mediated 
paradoxical reactions from relapses or new infections. 
The possibility to discriminate closely related strains by genetic fingerprinting 
(Chapter 9) may help to differentiate between re-infection and relapse 50. 
A fully oral treatment would simplify chemotherapy and adverse side effects would be 
minimized if streptomycin could be omitted. A first clinical trial with 30 patients from 
Benin (Chapter 6) showed that treatment efficacy with the combination of 
rifampicin/clarithromycin is comparable to that with rifampicin/streptomycin and no 
differences in the histopathological changes during treatment could be observed 44,51.  
Another promising treatment alternative is the thermotherapy which is based on the 
finding that M. ulcerans grows best at a temperature of 30°C and is killed at higher 
temperatures 52. This property was already used in a first thermotherapy study in the 
seventies 53. Recently Junghanss et al published a proof of principle trial in which a 
phase change material to produce heat was used and six BU patients were 
successfully cured 54. Currently a large trial to evaluate safety, applicability and 
effectiveness of thermotherapy is ongoing and first results will be available 2012. 
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10.4 Immune response 
 
Early histopathological examinations of BU lesions revealed a complete absence of 
infiltration and the presence of large necrotic areas. Destroyed fat tissue with the 
presence of fat cell ghosts and foci of extracellular bacterial clusters were identified 
as histopathological hallmarks of BU 55. Our studies in mice showed that one week 
after inoculation a strong neutrophilic infiltration could be observed which later on 
changed to a more macrophage- dominated response followed by the formation of 
the typical necrotic areas (Chapter 3). Although human lesions of these early stages 
are not available for analysis we found in more advanced lesions neutrophilic debris 
to be present inside the necrotic core, most likely the remains of an early wave of 
infiltration (Chapter 5). The proportion of individuals that can clear a M. ulcerans 
infection before clinical signs and symptoms emerge is not known. However, 
serological studies with M. ulcerans antigens revealed a high number of sero-positive 
but healthy people in BU endemic areas 22.  
After commencement of antibiotic therapy the histopathological appearance changes 
dramatically 46,56. We observed a strong influx of immune cells into the lesion, 
especially the formation of a rim of macrophages around the necrotic areas (Chapter 
5), the formation of granulomas as well as of B-cell cluster (Chapter 4, Chapter 5).  
Whether HIV infection increases the risk to develop BU is not well investigated. Co-
infections of BU/HIV have been reported with severe BU clinical presentation 57,58. A 
case–control study comparing HIV-1/HIV-2 sero-prevalence in BU patients from 
Benin suggests that HIV sero-positivity increases the risk for BU. Another study 
showed that BU is more aggressive and osteomyelitis is more common in HIV 
positive patients 57,58 We are planning a systematic histopathological study with 
HIV/BU co-infected patients in order to characterize if immune and treatment 
responses are comparable to non-HIV patients. Due to the reduction in CD4 T- cell 
counts the immune response and the histopathological presentation might be altered 
compared to non-HIV patients.  
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10.5 Genetic fingerprinting and Transmission 
 
The full genome of the Ghanaian M. ulcerans strain Agy99 was published in 2007 59 
by the group of Tim Stinear. Compared to M. marinum, M. ulcerans lost over 1.1 Mb 
of DNA caused by deletions and acquired the virulence plasmid pMU001. Comprised 
in the deleted genes were many virulence factors and immunodominant antigens 
compared with its progenitors M. marinum and M. tuberculosis. EsxA and EsxB are 
both important virulence factors in M. tuberculosis and we could show that both are 
deleted in strains belonging to the classical lineage of M. ulcerans (African and 
Australian strains). In strains of the ancestral lineage loss-of-function mutations and 
partial deletions were observed (Chapter 7). This suggests that the loss provides a 
selective advantage 59,60.  
Due to the monomorphic population structure of M. ulcerans, belonging to the 
classical lineage, typing by conventional methods (MLST, VNTR) resulted only in a 
low resolution 61-63. During our studies Ghanaian strains from the same geographical 
region were compared and a fine-typing method based on single-nucleotide 
polymorphisms (SNPs) was established 50 (Chapter 9). With this method it was for 
the first time possible to distinguish clinical isolates from one BU endemic region. 
Dominance of one clonal complex and local clustering of some of the variants 
belonging to this complex was observed 50. This method might help to answer some 
of the open questions concerning transmission. By genetic comparison of clinical 
isolates with environmental samples from soil, insects and water it might be possible 
to follow and elucidate the mode of transmission and the reservoir. Additionally, 
genetic fingerprinting should help to differentiate between relapse (same strain) and 
new infection (different strain) (Chapter 5). If more than one family member is 
suffering from BU a fine typing method would reveal if the same strain causes the 
disease in all members. Finally, in patients with multiple lesions one could investigate 
if all lesions are caused by the same strain which may have spread via lymphatics 
and blood to distant sites (Chapter 5). The drawback of this method is that for each 
region a unique set of SNPs has to be defined and evaluated. In the near future 
whole genome comparison of large strain collections will be the method of choice. 
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10.6 Vaccine development and disease control 
 
Although an effective antibiotic therapy to cure BU is available, it is tedious, 
expensive, requires injections and treatment failures are observed. Prevention of the 
disease by avoiding risks for infection is very difficult because the mode of 
transmission is not clear and people may get in touch with reservoirs of the pathogen 
during their daily live while fishing, farming and washing 64,65. Therefore, the 
availability of a vaccine for prevention would be highly desirable. 
 
Whether a protective immune response against M. ulcerans can develop is so far not 
known but several indications support this hypothesis: 
1. Serological studies revealed that household contacts show an immune response 
against mycobacterial antigens without signs of the disease 22. Whether sero-positive 
individuals are protected against future infections has not been evaluated and it is 
unclear if this immune response was primed by M. ulcerans or by an infection with 
other cross- reactive environmental mycobacteria.  
2. Limited BCG vaccination effectivity against M. ulcerans disease was shown in 
several trials with a protection for up to six month and reduced risk of developing 
severe BU form, including osteomyelitis 66-68. Additionally, mouse studies with BCG 
showed a delayed onset of the disease in BCG vaccinated animals. However 
variable results were obtained when using different M. ulcerans isolates and different 
mouse strains 69. 
3. Our in depth analysis of secondary lesions emerging after chemotherapy (Chapter 
5) or thermotherapy (unpublished results) suggest that a priming of the immune 
system occurs during initial treatment, leading to the ability to resolve bacterial foci 
formed either by newly infecting bacteria or by spreading of bacteria which survived 
the initial treatment (Chapter 5). 
4. Positive cultures after 8 weeks of RIF/STR treatment were observed in several 
clinical trials as well as in our mouse study (Chapter 3). Surprisingly, lesions resolved 
without prolongation of the antibiotic therapy indicating development of an immune 
response to M. ulcerans which was sufficient to contain the infection70.  
The polyketide toxin mycolactone would be an obvious candidate for a vaccine but 
no natural immune response against it has been observed. Carrier conjugates of this 
macrolide showed no strong immunogenicity in mice 71 and so far only one 
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monoclonal antibody against mycolactone was generated (JP Dangy, unpublished 
results). 
Research efforts have recently been started (BuruliVac Project) to develop either a 
live attenuated or a subunit vaccine against M. ulcerans. Subunit vaccines, based on 
recombinant proteins or plasmid DNA represent a safe strategy in contrast to live 
attenuated vaccines. For protein subunit vaccines protective antigens as well as a 
suitable adjuvant system are required. For pre-clinical development a mouse 
infection model is available. 
Irrespective of these research efforts it is extremely important to strengthen access to 
health care in the affected remote communities. Additionally, implementation of 
surveillance activities and sensibilization of the population to recognize BU at a very 
early stage are needed in order to reduce the morbidity and sequelae of the disease. 
Access to physiotherapy for the prevention of disability and rehabilitation is another 
important element 3. 
In many rural areas people still believe in witchcraft as the cause of the disease and 
prefer to seek care at traditional healers which delays start of antibiotic treatment. 
Cost of treatment, duration of admission and the distance between the hospital and 
the homes of patients also influence the health seeking behaviour 72. To overcome 
these problems patients should be aware of the symptoms, know what causes the 
disease and their confidence in a successful and helpful treatment should be 
strengthened. A decentralisation of health care and regular visits of health workers to 
remote rural areas may help to fulfil these goals and this will hopefully lead to an 
earlier diagnosis and treatment in most of the BU patients. 
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10.7 Conclusions 
 
In this thesis the histopathological analysis and evaluation of M. ulcerans infected 
tissue samples is described. The results contribute to our understanding of the 
pathology and treatment associated changes of M. ulcerans. The most important 
scientific findings are: 
 
1. The BU mouse footpad model was used to study in detail the early 
pathogenesis and the effects of antibiotic treatment. Histopathology revealed 
that early infiltrate, mainly composed of neutrophils and macrophages emerge 
early after inoculation. In contrast B-cell cluster and T-cells are found much 
later in the course of chemotherapy. Granuloma formation as usually observed 
in antibiotic- treated human patients was not seen in mice. Beading of AFB 
was found to a marker of loss of viability in M. ulcerans.  
 
2. The histopathological analysis of plaque lesions, which tend to ulcerate during 
antibiotic treatment, revealed large necrotic areas still present after 8 weeks of 
standard antibiotic therapy. Limited surgical excision may lead to a faster 
healing and shorter hospital stays.  
 
3. Analysis of secondary BU lesions, which occurred up to 14 month after 
completion of antibiotic treatment, revealed typical signs of inactive BU 
lesions. These lesions may be caused by an immune- driven paradoxical 
reaction against mycobacterial antigens released from bacilli killed by the 
primary chemotherapy. Alternatively they may be secondary infection foci 
controlled by immune responses, primed during initial treatment. Additional 
antibiotic treatment is obviously not necessary. 
 
4. A purely oral treatment with a combination of rifampicin and clarithromycin 
showed a very good effectivity. Histopathological changes were comparable to 
these observed in RIF/STR treated patients. 
 
5. Genetic analysis revealed that the two copies of the esxB-esxA gene cluster 
found in M. marinum M are deleted from the genome of M. ulcerans strains 
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belonging to the classical lineage. Loss of expression of highly immunogenic 
proteins is an indication that M. ulcerans is adapting to a more stable 
environment that is screened by an immune system. 
 
6. A DNA extraction protocol for M. ulcerans was developed which greatly 
enhanced both the yield and the purity of isolated DNA.  
 
7. The development of a real-time PCR method based on the analysis of SNPs 
(single-nucleotide-polymorphisms) represented a milestone in genetic typing 
of M. ulcerans.  
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